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A B S T R A C T
Since the early 1990s, hallucinogenic drugs, such as psilocybin, have been increasingly
used to investigate the neuronal basis of altered states of consciousness and psychosis.
Furthermore, renewed interest has emerged in using these drugs as an adjunct to
psychotherapy. Nevertheless, the therapeutic and experimental use of these substances
is still controversial due to fears of potential harm. Although the experience of many in-
vestigators suggests that potential risks are minimal when these drugs are administered
in a carefully monitored clinical or research environment, the subjective tolerability of
these drugs under these conditions has not yet been evaluated in large samples. The
revival of hallucinogen research during the past 20 years has also greatly increased the
need for well-validated instruments assessing the the acute subjective effects of these
drugs. Although Adolf Dittrich’s questionnaires for the assessment of altered states
of consciousness (ASCs) were frequently used for this purpose, especially in Europe,
the factorial structure of these questionnaires is not clearly established because previ-
ous psychometric investigations have serious methodological limitations. Finally, the
effects of hallucinogens are believed to be critically dependent on non-pharmacological
variables (e.g., the user’s personality, current mood state and environment), but few
empirical studies have investigated several of these predictor variables at a time. Thus,
little is known about the order of importance of these variables.
To solve these problems, three empirical studies were conducted, all of which were
based on pooled data from Prof. Vollenweider’s research group at the University
Hospital of Psychiatry in Zurich. Vollenweider’s group was one on the first to restart
human hallucinogen research in the early 1990s and since then has collected an amount
of data that is unrivaled in the world.
In the first study, acute, subacute, and long-term subjective effects of psilocybin were
investigated by analyzing the pooled data of eight double-blind placebo-controlled
experimental studies. The sample included 110 healthy subjects who had received 1-4
oral doses of psilocybin in a dose range of 45-315 μg/kg body weight. It was found
that the effects of psilocybin were generally well tolerated. Most subjects described
the experience as pleasurable, enriching, and non-threatening. Strong anxiety and/or
dysphoria occurred only in the two highest dose conditions in a relatively small
proportion of subjects and in all cases resolved by providing emotional support and
without pharmacological intervention. Complaints 24 h after drug intake were mild and
mostly included headache and fatigue. Furthermore, follow-up interviews conducted
8-16 months after the psilocybin sessions indicated that all of the subjects were healthy
and that none of them had experienced any of the most feared negative consequences
of hallucinogen exposure, that is, flashbacks, prolonged psychosis, or subsequent drug
abuse.
The second study critically examined the psychometric properties of the altered
states of consciousness rating scale OAV in a sample of psilocybin (n = 327), ketamine
(n = 162), and MDMA (n = 102) induced ASCs. The factorial structure was analyzed
by using exploratory factor analysis (EFA), hierarchical item clustering (ICLUST) and
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various techniques of structural equation modeling (SEM), including confirmatory factor
analysis (CFA), exploratory structural equation modeling (ESEM) and multiple indicators
and multiple causes (MIMIC) modeling. The results indicated that the originally proposed
factorial structure did not fit the data well. An improved model with 11 factors and
42 items provided a much better fit to the data. MIMIC modeling indicated that this
factorial structure was sufficiently stable across drugs, settings, questionnaire versions,
and sexes. Compared to the original OAV scales, the new OAV scales differentiated better
among the three drug groups, were more homogeneous, and had better convergent and
discriminant validities.
The aim of the third study was to detect the most important predictors of psilo-
cybin response. The effects of 24 predictor variables were examined in a sample of
409 psilocybin sessions. It was found that drug dose was by far the most important
predictor. However, several non-pharmacological variables also played an important
role in the effects of psilocybin. Specifically, having a high score in the personality trait
“absorption”, being in an emotionally excitable and active state immediately before drug
intake, having experienced few psychological problems in the past weeks, no previous
experience with classical hallucinogens, and moderate THC and alcohol consumption
increased the intensity of pleasurable effects and/or visual alterations, whereas settings
involving PET measurements, emotional excitability, and low age contributed to the
experience of unpleasant and/or anxious reactions.
Taken together, the three studies have demonstrated that psilocybin induced altered
states of consciousness in a carefully monitored research environment are generally
well tolerated, can be reliably and validly assessed by 11 new subscales of the OAV
questionnaire, and are dependent on several non-pharmacological variables.
Z U S A M M E N FA S S U N G
Seit den frühen neunziger Jahren werden halluzinogene Drogen, wie z.B. Psilocybin,
zunehmend zur Erforschung der neuronalen Grundlagen veränderter Bewusstseins-
zustände und Psychosen eingesetzt. Zudem ist ein erneutes Interesse aufgekommen,
diese Substanzen als Hilfsmittel in der Psychotherapie einzusetzen. Dennoch ist der
psychotherapeutische und experimentelle Gebrauch dieser Substanzen immer noch
umstritten, da unter anderem schädliche Wirkungen befürchtet werden. Obwohl die
Erfahrung zahlreicher Forscher gezeigt hat, dass die potentiellen Risiken minimal sind,
wenn die Verabreichung in einem sorgfältig überwachten klinischen oder wissenschaft-
lichen Setting stattfindet, wurde die Verträglichkeit dieser Substanzen unter diesen
Bedingungen bisher nie systematisch in einer grösseren Stichprobe untersucht. Die
Wiederbelebung der Halluzinogenforschung in den letzten zwanzig Jahren hat auch zu
einem erhöhten Bedarf an Instrumenten geführt, die die subjektiven Wirkungen dieser
Substanzen reliabel und valide erfassen können. Mit Adolf Dittrichs Fragebögen zur
Erfassung veränderter Bewusstseinszustände liegen zwar bereits Instrumente vor, die
sich insbesondere in Europa bewährt haben. Die faktorielle Struktur dieser Fragebögen
ist aber nicht eindeutig geklärt, da die bisherigen psychometrischen Studien schwer-
wiegende methodische Mängel aufweisen. Schliesslich besteht bei der Forschung mit
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halluzinogenen Substanzen auch das Problem, dass die Effekte wesentlich durch nicht-
pharmakologische Faktoren, wie z.B. Persönlichkeitseigenschaften, aktuelle Stimmung
oder die Umgebung, moduliert sein können. Welche Einflussfaktoren am wichtigs-
ten sind, ist bisher aber nicht ausreichend geklärt, da frühere Studien oft nur wenige
Variablen auf einmal berücksichtigt haben.
Um die oben genannten Probleme zu lösen, wurden drei empirische Studien durchge-
führt, welche alle auf den gepoolten Daten von Prof. Vollenweiders Forschungsgruppe
an der Psychiatrischen Universitätsklinik Zürich beruhten. Vollenweiders Gruppe hat in
den frühen neunziger Jahren als eine der ersten die Forschung mit halluzinogenen Sub-
stanzen beim Menschen wiederaufgenommen und seither eine Datenmenge gesammelt,
die weltweit einzigartig ist.
In der ersten Studie wurden akute, subakute und langfristige Wirkungen von Psilocy-
bin untersucht, indem acht doppelblinde placebo-kontrollierte Studien gepoolt wurden.
Die Stichprobe bestand aus 110 Versuchspersonen, die 1-4 orale Dosen Psilocybin in
einer Dosierung von 45-315 μg/kg Körpergewicht verabreicht bekamen. Es zeigt sich,
dass die Probanden die Psilocybinwirkung im Allgemeinen gut tolerierten. Die meisten
Probanden erlebten die Wirkung als angenehm, bereichernd, und nicht bedrohlich.
Starke Angstzustände und/oder negative Gestimmtheit traten nur in den höchsten
zwei Dosierungen in einem relativ kleinen Prozentsatz der Leute auf und liessen sich
in allen Fällen durch emotionale Unterstützung und ohne medikamentöse Interven-
tion beheben. Beschwerden 24 h nach Drogeneinnahme waren mild und betrafen am
ehesten Kopfschmerzen und Müdigkeit. Follow-up Befragungen 8-16 Monate nach der
letzten Psilocybin-Sitzung zeigten, dass alle Probanden gesund waren und dass die
am meisten gefürchteten negativen Konsequenzen der Verabreichung von halluzino-
genen Drogen (Flashbacks, andauernde psychotische Zustände und Induzierung von
Drogenmissbrauch) bei niemandem aufgetreten war.
In der zweiten Studie wurden die psychometrischen Eigenschaften des OAV-Frage-
bogens in einer Stichprobe von Psilocybin- (n = 327), Ketamin- (n = 162), und MDMA- (n
= 102) induzierten veränderten Bewusstseinszuständen untersucht. Die faktorielle Struk-
tur wurde mittels explorativer Faktorenanalyse, hierarchischem Item-Clustering, sowie
mehreren Techniken der Strukturgleichungsmodellierung, inkl. konfirmatorischer Fak-
torenanalyse, explorativer Strukturgleichungsmodellierung und multiple indicators and
multiple causes (MIMIC)-Modellierung, analysiert. Es zeigte sich, dass die ursprünglich
angenommene Faktorenstruktur nicht gut zu den Daten passte. Ein neu entwickeltes
Modell mit 11 Faktoren und 42 Items liess sich wesentlich besser mit den Daten in
Einklang bringen. Eine MIMIC-Modellierung bestätigte, dass die neu gefundene Struktur
eine genügend hohe Stabilität über die drei Substanzgruppen, Umgebung der Drogen-
einnahme, Geschlechter und Fragebogenversionen hinweg aufwies. Im Vergleich zu
den ursprünglichen OAV-Skalen, differenzierten die neuen OAV-Skalen besser zwischen
den drei Substanzgruppen, waren homogener und hatten eine bessere konvergente und
diskriminante Validität.
Ziel der dritten Studie war es, die wichtigsten Prädiktoren Psilocybin-induzierter
veränderter Bewusstseinszustände zu eruieren. Hierzu wurden die Effekte von 24
Prädiktorvariablen in einer Stichprobe von 409 Psilocybin-Sitzungen untersucht. Es
stellt sich heraus, dass die Drogendosierung bei weitem der wichtigste Prädiktor war.
Mehrere nicht-pharmakologische Variablen spielten aber ebenfalls eine wichtige Rolle.
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Namentlich erhöhten eine hohe Ausprägung der Persönlichkeitseigenschaft “Absorpti-
on”, hohe emotionale Erregbarkeit und Aktivität unmittelbar vor der Substanzeinnahme,
eine geringes Erleben von psychischen Problemen in den letzten Wochen, keine Vor-
erfahrung mit halluzinogenen Substanzen und ein moderater Konsum von Alkohol
die Intensität von angenehmen Wirkungen und/oder visuellen Veränderungen, wäh-
rend die Drogeneinnahme in Experimenten mit PET-Messungen, eine hohe emotionale
Erregbarkeit und ein niedriges Alter die Erfahrung von unangenehmen Wirkungen
und/oder angstvolle Reaktionen förderten.
Zusammenfassend haben die drei Studien gezeigt, dass Psilocybin-induzierte verän-
derte Bewusstseinszustände in einer sorgfältig überwachten Forschungsumgebung im
Allgemeinen gut toleriert werden, reliabel und valide mittels 11 neuer Subskalen des
OAV-Fragebogens gemessen werden können, sowie von mehreren nicht-pharmakologi-
schen Faktoren abhängen.
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Himmel und Hölle sind im Menschen.
Und es ist so, dass man mit diesem Stoff nun Einblick
bekommt in die eigene Hölle oder den eigenen Himmel.
— Albert Hofmann (2003)
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G E N E R A L I N T R O D U C T I O N
1.1 a brief history of psilocybin research
The indolealkylamine psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the
main psychoactive principle of a group of hallucinogenic fungi, commonly known
as magic mushrooms. Psilocybin containing mushrooms naturally occur throughout
the world and have been used by indigenous people, particularly of Mesoamerica,
but possibly also of Papua New Guinea and other regions, in shamanistic rituals and
religious ceremonies for centuries, if not millennia (Stamets, 1996; Guzmán, Allen, &
Gartz, 2000). Scientific research with psilocybin began with the rediscovery of still active
psilocybin mushroom cults by Wasson 1955 (Wasson, 1958), first successful cultivation of
psilocybin mushrooms by Heim, and isolation and synthetic reproduction of their pure
psychoactive compound by Hoffman (Hofmann, Heim, Brack, & Kobel, 1958). Early
human trials in the late 1950s and early 1960s soon discovered that psilocybin exerts
similar psychopharmacological actions as other classical serotonergic hallucinogens,
such as the semi-synthetic ergoline D-lysergic acid diethylamide (LSD) and the naturally
occurring phenethylamine mescaline (e.g., Isbell, 1959; Malitz, Esecover, Wilkens, &
Hoch, 1960; Hollister & Hartman, 1962; Wolbach, Miner, & Isbel, 1962).
When Psilocybin was first synthesized, LSD had already been marketed by Sandoz
under the name Delysid® for almost a decade and used internationally as a research
tool to investigate the neurobiological basis of altered states of consciousness (ASCs)
and psychosis and as an adjunct to psychotherapy. However, because psilocybin had a
shorter duration of action and seemed to produce less vegetative side-effects, affective
disturbances, anxiety and panic reactions (Nieto, 1962; Heimann, 1962; A. E. David
& J. M. David, 1961; Clark, 1968; Leuner, 1968; Passie, 1995), it was soon considered
by many investigators as a valuable substitute for the earlier discovered LSD. During
a short, but fruitful, period from the late 1950s to the late 1960s, at least three dozen
research groups in at least two dozen countries have conducted human studies on the
effects of psilocybin. Psilocybin was readily accepted in the research community not
only due to its favorable action profile, but also because it was marketed by Sandoz
under the name Indocybin® for experimental and psychotherapeutic purposes in the
early 1960s (Passie, 1995; Passie, Seifert, Schneider, & Emrich, 2002).
However, scientific interest in human experiments with psilocybin and other hallu-
cinogens rapidly declined during the 1960s because an increasing number of people
started to believe that many hallucinogenic drug experiments were conducted in an
irresponsible manner and that a large amount of the early research was flawed by the
lack of controls and inadequate follow-up (Grob, 1994; Hobbs, 2007). Additionally, hal-
lucinogens, particularly LSD, were increasingly used and abused in non-medical settings
and associated with the counter culture movement of the 1960s, which claimed to draw
inspiration from their use and which was perceived as a threat to society because it
promoted social disobedience and anti-authoritarian attitudes (Hobbs, 2007; Wark &
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Galliher, 2010). The increased uncontrolled use also led to more adverse drug reactions,
such as flashbacks, self-destructive psychotic behavior, and persisting psychosis, which
in turn became increasingly the object of sensationalistic media coverage (Grob, 1994;
Mangini, 1998; Johnson, Richards, & Griffiths, 2008). Consequently, the public opinion
regarding the risks and benefits of hallucinogens dramatically shifted, and by about
1970, hallucinogens were placed into the most restrictive categories of drug prohibition
laws in most countries. This meant that these substances were legally defined as having
a high potential for abuse, a lack of demonstrated safety, and no accepted medical use.
Accordingly, human research with hallucinogens became so difficult and unattractive
that it virtually ceased by the early 1970s.
After a near worldwide moratorium of human hallucinogen research for two decades,
a growing number of investigators have again started to conduct studies involving
hallucinogen administration to human subjects (Langlitz, 2007; Vollenweider & Kometer,
2010). Many of these studies used psilocybin to investigate the neural basis of psychotic
symptom formation including ego-disorders and hallucinations (Vollenweider, 1992;
Vollenweider, Leenders, Scharfetter, P. Maguire, et al., 1997; Vollenweider, Vollenweider-
Scherpenhuyzen, Bäbler, Vogel, & Hell, 1998; Gouzoulis-Mayfrank, Schreckenberger, et
al., 1999; Gouzoulis-Mayfrank, Thelen, et al., 1999; Vollenweider & Geyer, 2001; Hasler,
Grimberg, Benz, Huber, & Vollenweider, 2004) or to explore the effect of psilocybin on
cognitive, visual, and emotional processes (Spitzer, Thimm, et al., 1996; Carter, Petti-
grew, Burr, et al., 2004; Carter, Burr, et al., 2005; Carter, Pettigrew, Hasler, et al., 2005;
Carter, Hasler, et al., 2007; Kometer, Cahn, Andel, Carter, & Vollenweider, 2011; Schmidt,
Csomor, Bachmann, Kometer, & Vollenweider, 2010; Carhart-Harris, Leech, et al., 2012),
including mismatch-negativity (Umbricht, Koller, Vollenweider, & Schmid, 2002; Um-
bricht, Vollenweider, et al., 2003; Heekeren et al., 2008; Schmidt, Bachmann, et al.,
2011), sensory gating (Gouzoulis-Mayfrank, Heekeren, Thelen, et al., 1998; Vollenweider,
Csomor, Knappe, Geyer, & Quednow, 2007; Quednow, Kometer, Geyer, & Vollenweider,
2012), and time perception (Wackermann, Wittmann, Hasler, & Vollenweider, 2008;
Wittmann et al., 2007). Several studies also focused on the pharmacokinetics (Hasler,
Bourquin, Brenneisen, Bär, & Vollenweider, 1997), metabolism (Hasler, Bourquin, Bren-
neisen, & Vollenweider, 2002), dose-response-relationship (Hasler, Grimberg, et al.,
2004), tolerability (Carhart-Harris, Williams, et al., 2011), side-effects (Johnson, Andrew
Sewell, & Griffiths, 2011) and receptor profile of psilocybin (Ametamey et al., 1998;
Vollenweider, Vollenweider-Scherpenhuyzen, et al., 1998; Vollenweider, Vontobel, Hell,
& Leenders, 1999; Hasler, Quednow, et al., 2009; Quednow, Treyer, et al., 2011; Quednow,
Kometer, et al., 2012).
More recently, some researchers have begun to reevaluate the therapeutic potential of
psilocybin (Sessa, 2008; Vollenweider & Kometer, 2010). Conditions that are currently
explored and that have responded positively to psilocybin treatment in recent studies
include obsessive-compulsive disorder (Moreno, Wiegand, Taitano, & Delgado, 2006),
anxiety in patients with advanced-stage cancer (Grob et al., 2011), and cluster headache
(Sewell, Halpern, & Pope, 2006). Other researchers have started to evaluate the potential
of psilocybin to induce mystical-type experiences and long-lasting positive changes in
attitudes, mood, and behavior in healthy volunteers (Griffiths, Richards, McCann, &
Jesse, 2006; Griffiths, Richards, Johnson, McCann, & Jesse, 2008; Griffiths, Johnson, et al.,
2011; Maclean, Johnson, & Griffiths, 2011). They have found that 72% of subjects had a
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“complete” mystical experience, when psilocybin was administered in a very high dose
(429 μg/kg) under supportive conditions (Griffiths, Johnson, et al., 2011). Furthermore,
at the 14 month follow up, experiences were still rated as having substantial personal
and spiritual significance and attributed to positive changes in attitudes, mood, and
behavior (Griffiths, Richards, Johnson, et al., 2008; Griffiths, Johnson, et al., 2011).
The research group of Franz X. Vollenweider at the University Hospital of Psychiatry
in Zurich has been at the forefront in the revival of human research with hallucinogens.
Since the 1990s, this group has conducted 23 psilocybin studies (including pilot studies)
using methodology that has not been available in the early phase of hallucinogen
research, including modern neuroimaging and electrophysiological protocols. In total,
the group has administered psilocybin to more than 260 healthy volunteers in more than
410 individual sessions. Additionally, Vollenweider’s group has conducted a relatively
large number of studies on the effects of ketamine and MDMA. The amount of data that
this group has collected during the past 20 years, particularly with regard to psilocybin,
is unrivaled in the world. Fortunately, most of Vollenweider’s studies have used similar
study designs and rating scales. Thus, they could be easily pooled and served as an
ideal basis for the three empirical studies of the present thesis.
1.2 acute psychological effects
Since psilocybin is usually termed a hallucinogen, one might think that the primary
action of psilocybin is to induce hallucinations. However, the effects of psilocybin
go far beyond visual alterations; they include altered perception of reality and self,
intensification of mood, distorted sense of time and space, activation of vivid memories,
enhanced profundity and meaningfulness, and a ubiquitous sense of novelty (Hasler,
Grimberg, et al., 2004; Nichols & Chemel, 2006). Furthermore, the visual “hallucinations”
induced by psilocybin – at least at moderate doses – are rarely true hallucinations in the
sense that they can not be distinguished from real perceptions. Because the deceptive
character of the hallucinations is usually noticed, they are more accurately described as
non-psychotic or pseudo-hallucinations, although the latter term is problematic because
it can be clinically ambiguous (cf. van der Zwaard & Polak, 2001). Thus, many authors
have argued that the term “hallucinogen” is actually a misnomer (e.g., Cohen & Ditman,
1963) and have – depending on their specific orientation – introduced alternative descrip-
tions for psilocybin-type drugs (Strassman, 1984). For instance, those who have been
struck by the usefulness of these drugs to model aspects of psychosis have introduced
the terms psychotomimetics (mimicking psychosis), psychotogens (psychosis inducing),
and psychodysleptic (mind disrupting). Others who have used these drugs primarily for
psychotherapy and personal growth have called them psycholytic (psyche-loosening),
entheogenic (generating the god within), and psychedelic (mind manifesting).
It is clear from the above descriptions that psilocybin and related drugs can induce a
variety of very profound alterations of consciousness. These alterations are often highly
enjoyable and at high doses can even lead to mystical or so called peak experiences
(Pahnke, 1969; Nichols & Chemel, 2006; Griffiths, Richards, McCann, & Jesse, 2006).
However, higher doses can also induce terrifying experiences, such as paranoid ideation
and cognitive fragmentation (e.g., Malitz, Esecover, et al., 1960; Griffiths, Johnson,
et al., 2011). Accordingly, the British writer Aldous Huxley (Huxley, 1959) reported
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that these drugs could take one to heaven or hell. Because such powerful alterations
of consciousness rarely occur in everyday life, people often have great difficulties
to describe them (Nichols & Chemel, 2006). They are also often highly personally
meaningful. For instance, in a recent study of Griffiths, Johnson, et al. (2011), in
which subjects received five different doses of psilocybin, it was found that 38.9% of
subjects rated at least one of the two high-dose psilocybin sessions as as the single
most meaningful experience of their life and 77.9% as among the five most meaningful
experiences of their life at the 14 month follow-up.
Although several studies have previously investigated acute psychological effects
of psilocybin (e.g., Gouzoulis-Mayfrank, Thelen, et al., 1999; Hasler, Grimberg, et
al., 2004), there were still many unanswered questions regarding the dose-response-
relationships, the cumulative distributions, and time-courses of subjective psilocybin
effects. Furthermore, previous studies were often low in sample size. Thus, one aim of
this thesis was to investigate acute psychological effects in a larger sample. To this end,
psychometric data of eight recent psilocybin studies were pooled and analyzed with a
special focus on dose-response-relationships, cumulative distributions, and time-courses
of psilocybin effects. The results were published as part of a study that also investigated
subacute and long-term psilocybin effects (Studerus, Kometer, et al., 2011). It is included
in this thesis as Chapter 3.
1.3 tolerability of psilocybin administration
Classical hallucinogens in general, and psilocybin containing mushrooms in particular,
are considered to have a lower harm potential than most other abused drugs (Nutt,
King, Saulsbury, & Blakemore, 2007; Carhart-Harris & Nutt, 2010; van Amsterdam,
Opperhuizen, & van den Brink, 2011). For instance, they neither cause any damage
to human body organs at regular doses nor engender drug dependence or addiction
(Nichols, 2004). Nevertheless, their powerful effects on consciousness can pose serious
risks, particularly when higher doses are used recreationally in unsupervised settings.
Probably the biggest danger is that acute psychotic reactions might occur, which
can lead to dangerous and self-destructive behavior during the time of drug action.
Other potential risks of hallucinogen exposure are precipitation or exacerbation of
enduring psychiatric conditions, long-lasting perceptual disturbances, commonly known
as flashbacks, and development of an abusive pattern of hallucinogen use (El-Mallakh,
Halpern, & Abraham, 2008; Hermle, Kovar, Hewer, & Ruchsow, 2008; Johnson, Richards,
& Griffiths, 2008).
However, it makes a big difference whether these drugs are used recreationally or
administered in controlled research settings where subjects are carefully screened and
monitored and judicious doses of pharmaceutical quality drugs are given (Frecska &
Luna, 2006). Complications were remarkably rare, when hallucinogenic drugs were
used extensively in controlled research settings during the 1950s and 1960s (Cohen, 1960;
Strassman, 1984). For instance, flashbacks were virtually never reported in therapeutic
or research settings (Halpern & Pope, 2003)
Recently, Johnson, Richards, and Griffiths (2008) have published safety guidelines
for human hallucinogen research. The safeguards they propose include the exclusion
of volunteers with a personal or family history of psychotic disorders or other severe
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psychiatric disorders, establishing trust and rapport between session monitors and
volunteers before the session, careful volunteer preparation, a safe physical session
environment, and interpersonal support from at least two study monitors during
the session. Modern human hallucinogen research has, independently of Johnson’s
publication, largely adopted these advices, and there is currently no indication that
mistakes of early research (i.e., the irresponsible use of some investigators) would be
repeated.
Nevertheless, safety and tolerability concerns remain major issues of modern human
hallucinogen research. As has been pointed out by Frecska and Luna (2006), many health
care providers and legislation makers continue to judge the safety of hallucinogens by
their illicit abuse rather than by their responsible clinical use and apply these judgments
to make decisions regarding its clinical use. One reason for this is that relatively few
information is available to evaluate the safety and tolerability of psilocybin and other
classical hallucinogens when administered to healthy human volunteers in controlled
settings. Unfortunately, many of the older studies on adverse reactions are case reports
or used small and unrepresentative samples. Furthermore, these studies were often
poorly standardized and lacked adequate control groups and follow-up measures (Grob,
1994).
Thus, one further aim of the study presented in Chapter 3 was to improve knowledge
about the risk-benefit ratio of psilocybin use in experimental psychopharmacology and
to lay the foundations for future studies. To achieve this goal, the study reported about
the proportions of subjects experiencing acute adverse reactions (so called “bad trips”)
under different dose conditions, various somatic and psychological complaints 24 h after
drug administration, as well as longer lasting negative effects, such as Hallucinogen
Persisting Perception Disorder (HPPD), prolonged psychosis, and negative changes in
drug consumption habits. The latter effects were evaluated by analyzing a follow-up
questionnaire that was completed 8-16 months after the last psilocybin session by 90 of
110 included subjects (82%).
1.4 assessment of acute subjective effects
Despite considerable methodological advances in the area of neuroimaging, the neuronal
correlates of consciousness can not be identified without data from the first person
perspective. Consequently, investigators who use hallucinogens as tools to study the
neural basis of ASCs must rely on well-validated rating scales to assess the subjective
effects of these drugs. The revival of human hallucinogen research during the past 20
years has therefore greatly increased the demand for such ratings scales. Perhaps the
currently most widely used instruments for assessing subjective effects of hallucinogens
are the Hallucinogen Rating Scale (HRS) developed by Strassman, Qualls, Uhlenhuth,
and Kellner (1994) and later validated by Riba, Rodríguez-Fornells, Strassman, and
Barbanoj (2001) and the three versions of ASC rating scales (i.e., APZ, OAV, and 5D-ASC)
developed by Dittrich and his colleagues (Dittrich, 1975b, 1985; Bodmer, 1989; Braun,
1997; Dittrich, 1998; Dittrich, Lamparter, & Maurer, 2010). The HRS and the three
different versions of Dittrich’s questionnaire have been administered in approximately
30 and 70 published experimental studies, respectively. Although both questionnaires
have been translated into different languages, the HRS has been used predominantly
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in the US and in Spain, while Dittrich’s scales were most popular in Switzerland and
in Germany. Vollenweider’s research group has used Dittrich’s rating scales in all its
studies, and this probably has largely contributed to their popularity.
Compared to the HRS, Dittrich’s questionnaires have the advantages that their primary
factors were derived empirically by performing multivariate statistical analyses and
that they were designed to be applicable to a wide range of ASCs, not just those induced
by hallucinogenic drugs. The flexibility of Dittrich’s questionnaires is not only reflected
in their item content, but also in the fact that some of their scales are supposed to be
measurement invariant across ASCs induction methods. Thus, they are probably more
helpful to integrate research on ASCs than the HRS.
Because Dittrich’s rating scales continue to be widely used and because many de-
tails of the most important psychometric investigations on these scales have not been
published in English before, the historical development and validation of the three
questionnaire versions APZ, OAV, and 5D-ASC is first summarized and then critically
reviewed in Chapter 2 of this introduction. The review demonstrates that – from a
modern methodological perspective – the existing psychometric studies have many
methodological shortcomings and that some of these seriously weaken the conclusions
drawn by Dittrich and his colleagues.
The review presented in Chapter 2 paves the way for the empirical study in Chapter 4,
which analyzed the psychometric properties of the OAV in a relatively large sample of
experimentally induced ASCs by implementing most of the suggestions for improvement
made in Chapter 2. For instance, the study for the first time applied methods of the
structural equation modeling (SEM) framework to one of Dittrich’s questionnaire. These
methods are associated with many of the methodological and statistical advances in
quantitative psychology in the last two decades (Marsh, Lüdtke, et al., 2010) and are
more appropriate for testing specific hypotheses on latent variable structures than the
previously used exploratory methods.
1.5 prediction of psilocybin response
Acute subjective experiences induced by hallucinogenic drugs differ considerably from
person to person and even in the same individual on different occasions (Nichols, 2004).
It is widely accepted that these differences largely result from differences in set (i.e. the
preparation of the subject, his personality structure, and current mood state) and setting
(i.e. the physical, social, and cultural environment in which the drug is taken) – terms
that were originally coined by Timothy Leary (Leary, Litwin, & Metzner, 1963) and that
soon after became a permanent part of the psychedelic idiom (Stafford & Golightly,
1967; Eisner, 1997).
The effects of hallucinogens are believed to be more strongly dependent on set and
setting than those of other classes of drug (Nichols, 2004). Some authors have even gone
so far as to claim that set and setting are by far the most important determinants of
hallucinogenic drug effects. For instance, Leary (1964) wrote:
Set and suggestive contexts account for ninety-nine percent of the specific
response to the drug. Thus, you cannot sensibly talk about the effects of
psilocybin. It’s always the set and suggestive context triggered off by the
drug. A fascinating tension between these two factors – set and context –
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inevitably develops. If both are positive and holy then a shatteringly sacred
experience results. If both are negative then a hellish encounter ensues.
There is, of course, the tendency for people to impose their familiar games
on to the psilocybin experience. The more rigidly committed to the game,
the stronger this tendency. If the drug-giving person is secure, flexible,
supportive, then the experience is almost guaranteed to be pleasant and
therapeutic. (p. 115)
Accordingly, Leary and others have considered set and setting as essential for the
successful use of these drugs in psychotherapy and for personal growth. Moreover, they
have put forward the ignorance of set and setting, particularly by people who use these
drugs recreationally but also by some professionals, as one of the main explanations
for the troubles that ultimately led to the banning of hallucinogens (Walsh & Grob,
2005). The importance of set and setting was recently reinforced by Griffiths, Richards,
McCann, and Jesse (2006).
However, just like Leary and others have admonished the ignorance of set and setting,
others have warned about their over-emphasis because it had led to a false sense of
security. For instance Ungerleider, Fisher, Fuller, and Caldwell (1968) wrote:
There is an ever-growing LSD mythology, too, much of it having to do with
set and setting. For example, one commonly hears that a bad LSD experience
will not result if:
– One is in a calm frame of mind (no fights that day with spouse or em-
ployer);
– One takes the LSD with one or two good friends or with an experienced
sitter or guide present;
– The room has soft lighting and a thick carpet or mattress to sit on;
– One is listening to the Indian music of Ravi Shankar and reading reassur-
ing phrases from the Tibetan Book of the Dead;
– and perhaps if one has a “downer” or chlorpromazine pill at hand.
But we have hospitalized many persons who had taken these precautions
and who also had had up to 100 previous good LSD experiences. (p. 1489)
The above quotes clearly demonstrate that the evaluation of set and setting was strongly
tied to questions about the safety and therapeutic usefulness of these drugs. Further-
more, it seems that those who were convinced of the benefits and safety of these drugs
for political reasons tended to over-emphasize the importance of set and setting, while
those who wanted the prohibit them tended to ignore or downplay these influencing
factors. However, the incompatibility of the concepts of set and setting with the emerg-
ing orthodoxy that hallucinogenic drug effects were unpredictable and dangerous was
probably not the only reason why influences of set and setting tended to be ignored.
Langlitz (in press) points out:
For scientific, disciplinary, economic, and political reasons, biological psychi-
atry and psychopharmacology had an interest in attributing the effects of
drugs to the drugs alone. This ideology of “pharmacologicalism” helped
psychiatry to be acknowledged as part of scientific medicine, enabled phar-
maceutical companies to fulfill the Food and Drug Administration’s regula-
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tory requirement to demonstrate specificity of drug action, and legitimized
the War on Drugs (DeGrandpre, 2006). (p. 259)
To escape these ideological traps, it is decisive to evaluate the importance of set and
setting on strictly empirical grounds. Unfortunately, only few empirical studies have
investigated the determination of hallucinogen response by set and setting and most of
these were conducted in the 1950s and 1960s when methodological standards were lower
than today. For instance, many of the these studies used poorly validated measures
and relied on small sample sizes. Furthermore, except for one newer study conducted
by Dittrich and his colleagues (Dittrich, 1994; Dittrich & Lamparter, 1994), they only
obtained a few predictor variables at a time and/or did not adjust for confounding
variables. Hence, they could not provide information on the order of importance of
different predictor variables from a wide range of different domains. The lack of high
quality studies in this area is unfortunate because knowledge about set and setting could
improve the safety and standardization of controlled experiments and significantly
advance our understanding of the neurobiological systems involved in the actions of
hallucinogens.
Thus, the study presented in Chapter 5 aimed to predict various dimensions of
psilocybin response by analyzing 24 potentially important predictor variables and by
using a much larger sample size (n = 409) and more sophisticated statistical methods
than in previous studies. The analyzed predictors covered a wide range of domains
and captured both inter- (i.e., stable personality traits, demographic variables, drug
use and pre-experiences) and intraindividual differences (i.e., mood state immediately
before drug intake and psychological problems during the last four weeks before drug
intake), as well as external influences (i.e. whether the experimental session involved
PET measurements or not, time of measuring drug response, and drug dose).
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O N T H E A S S E S S M E N T O F A LT E R E D S TAT E S O F
C O N S C I O U S N E S S B Y D I T T R I C H ’ S A P Z , O AV, A N D 5D - A S C
Q U E S T I O N N A I R E S : A C R I T I C A L R E V I E W
2.1 introduction
Dittrich’s APZ questionnaire and its revised versions, OAV and 5D-ASC, are among
the most widely used self-report questionnaires for assessing subjective experiences
of altered states of consciousness (ASCs). The use of these questionnaires has been
most popular in psychopharmacological research. However, despite their widespread
application, few studies have investigated the psychometric properties of these rating
scales.
This chapter is divided into two parts. In the first part, the available literature on
the development and validation of the APZ, OAV, and 5D-ASC questionnaires is critically
reviewed. Although the validation studies of the APZ have been summarized elsewhere
(Dittrich, von Arx, & Staub, 1985; Dittrich, 1998), detailed information on the OAV and
5D-ASC questionnaires has only appeared in unpublished master and doctoral theses
(Bodmer, 1989; Braun, 1997; Habermeyer, 1999) or in hard to come by book chapters
(Bodmer, Dittrich, & Lamparter, 1994), all of which are written in German. Thus, a
great deal of the information presented in this chapter has not been available to the
English-speaking world before.
The second part of this chapter discusses methodological shortcomings of the existing
APZ, OAV, and 5D-ASC validation studies from a modern methodological perspective.
Due to substantial methodological advances in the past 20 years, particularly in the
area of latent variable modeling, many of the methodological problems highlighted in
this article have not been recognized previously. I will discuss the implications of these
methodological shortcomings with respect to the interpretation of previously obtained
results. Furthermore, I will propose alternative statistical procedures that should be
used in future validation studies and that may lead to a revision of the scales.
2.2 questionnaire development and validation
2.2.1 The APZ Questionnaire
2.2.1.1 Scale construction
Many authors have described strong similarities between different deliberately induced
ASCs (e.g., by hallucinogenic drugs, hypnosis, meditation, sensory deprivation) and
disease-induced ASCs (e.g., schizophrenic psychosis) leading them to hypothesize that
ASCs, independent of their means of induction, have a common core (Dittrich, 1985,
1996). In the western literature, the hypothesis of a common core of ASCs was put
forward more than 165 years ago by Moreau de Tours (1845), but more or less explicit
formulations of this hypothesis can also be found in the works of Masters and Houston
11
12 dittrich’s altered states of consciousness rating scales
(1967), Huxley (1959), Weil (1972), and especially of Ludwig (1966). Dittrich (1985, 1996)
was the first to formulate this hypothesis in such a way that it can be tested empirically:
Irrespective of their mode of induction, ASCs have invariant features in common,
which at the same time differentiate them from normal waking consciousness. These
etiology-independent characteristics form a structure of mutual similarities, which
is maintained when ASCs are induced by different means. On the dimensional
level (i.e., methodologically adopting an approach similar to that of dimensional
theories of personality) this means that ASCs have certain major dimensions in
common, irrespective of their induction means and intensity. Of course, this does
not exclude that etiology-specific dimensions exist, such as probably, “clouding
of consciousness” or “vigilance reduction” for hallucinogens of the second order.
(Dittrich, 1998, p. 81)
Dittrich (1985, 1996) reasoned that, if the above hypotheses could not be falsified for a
broad range of ASC induction methods, integration of phenomenological, psychophysi-
ological, and neurobiological research on ASCs would be greatly enhanced. Not only
would it lay the foundation for a more coherent definition of the term ASC, but the
common features of ASCs could also be reduced to common latent dimensions and thus
described more parsimoniously. Furthermore, because these common latent dimensions
would be invariant across ASC induction methods, different ASCs could be directly
compared by their scores on these dimensions. This, in turn, would eventually lead to
an empirical taxonomy of ASCs.
Dittrich (1985, 1996) tested the above hypotheses in a series of experimental studies,
in which ASCs were induced in healthy subjects by eleven different induction methods
(n = 259) or control condition procedures (n = 134). The studied induction methods
were divided into four groups:
1. Hallucinogens of the first order (N,N-dimethyltryptamine [DMT], psilocybin, and
Δ9-tetrahydrocannabinol [THC]; n = 82)
2. Hallucinogens of the second order (nitrous oxide; n = 38)
3. Sensory deprivation in a broader sense (perceptual deprivation, hypnagogic states,
autogenic training, and hypnosis; n = 79)
4. Sensory overload (stimuli of high variety; n = 60)
The APZ questionnaire, which was originally constructed by Dittrich (1975b) to assess
deliberately-induced as well as disease-induced ASCs, served as the primary outcome
measure in these experiments. The items of the APZ were derived from previously
existing questionnaires on ASCs, narrative reports, psychiatric rating scales, and the
author’s personal experience with ASCs. They were chosen to cover a broad range
of phenomena potentially occurring during ASCs. Each item consists of a statement
describing a specific experience of ASC in the first person singular and past tense. By
responding with “yes” or “no”, subjects are forced to either confirm or negate these
experiences.
From the 158 items of the APZ questionnaire, Dittrich (1985, 1996) identified 72
items meeting his criteria of etiology-independency. That is, the lower bounds of
the 95% confidence intervals of proportions of subjects answering these items with
“yes” were bigger than 0.01 in each of the four main groups of stimuli, and the items
were also significantly differentiating ASC from normal waking consciousness (p <
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0.05, comparisons with control groups and the pre-experimental level in the combined
groups).
By analyzing the correlation matrices of the 72 etiology-independent items using
exploratory factor and cluster analysis and based on considerations of stability, re-
liability, and interpretability, Dittrich determined three primary and one secondary
etiology-independent dimensions. The three primary dimensions were termed Oceanic
Boundlessness (OBN), Dread of Ego Dissolution (DED), and Visionary Restructuraliza-
tion (VRS) and, according to Dittrich (1985, 1996), operationally define what the writer
Aldous Huxley (1959) has described as heaven, hell, and visions. The name of the
OBN scale was derived from a psychological term that was originally coined 1927 in a
letter from Romain Rolland to Sigmund Freud (Rolland, 1967) and later popularized by
Sigmund Freud in his book Civilization and Its Discontents (1930/1961). The OBN scale
includes items measuring positively experienced depersonalization and derealization,
ecstatic experiences of bliss, and feelings of eternity and unity. High scores on the
OBN scale therefore indicate a state similar to mystical experiences as described in
the scientific literature on the psychology of religion (e.g. Stace, 1961). The DED scale
includes items measuring negatively experienced derealization and depersonalization,
cognitive disturbances, catatonic symptoms, paranoia, and loss of thought and body
control. High scores on the DED scale therefore indicate a very unpleasant state, similar
to so called bad or horror trips described by drug-users. The VRS scale contains items
measuring visual (pseudo)-hallucinations, illusions, auditory-visual synesthesiae, and
changes in the meaning of percepts. The secondary scale Global Altered States of Con-
sciouness (G-ASC) consists of the 72 etiology-independent items and can be interpreted
as a general measure of consciousness alteration.
2.2.1.2 Re-examinations of the factorial structure
In order to test the external validity of the experimental results in the field and to
construct psychometrically equivalent scales in several languages, the International
Study on Altered States of Consciousness (ISASC) was carried out (Dittrich, von Arx, &
Staub, 1985). In this study, 1133 subjects from six different countries (i.e., Switzerland,
Germany, Italy, Great Britain, Portugal, and USA) and four different languages (i.e.,
German, Italian, English, and Portuguese) described the most recent ASC they had
experienced within the past 12 months using different language versions of the APZ. The
described ASCs were most frequently induced by cannabis (44%), LSD (8.5%), meditation
(7.6%), hypnagogia (5.6%), listening to music (4.5%), solitude and isolation (4.0%),
autogenic training (2.6%), and hypnosis (1.3%). In 70% of the cases, ASCs were induced
by a drug, which is a significantly higher percentage than in the experimental studies
(46.3%). An analysis of the similarity of the correlations matrices and factor solutions
formed from seven different data sets (experiments and field data from six different
countries) yielded results that corresponded well to those of the experimental studies.
The authors concluded that the external validity of the experiments was demonstrated
in spite of important differences between the two studies and that the four studied
language versions of the APZ are psychometrically equivalent (Dittrich, von Arx, &
Staub, 1985; Dittrich, 1998). The APZ was also translated into Dutch, Finnish, French,
Greek, Spanish, and Russian, but the psychometrical equivalence of these versions has
not yet been tested (Dittrich, 1998).
14 dittrich’s altered states of consciousness rating scales
Two additional studies analyzing the factorial structure of the APZ have been pub-
lished. In the first study (Gouzoulis-Mayfrank, Habermeyer, et al., 1998), 93 hospitalized
schizophrenic patients were asked to describe the acute phase of their last psychotic
episode using the APZ. The 72 etiology-independent items of the completed APZ ques-
tionnaires were analyzed by a principal component analysis (PCA) with three factors
and varimax rotation. The authors reported that only 56.3% of items were correctly
distributed to their hypothesized factor. The proportion of correctly distributed items
was higher for the DED factor (61.9%) than for the OBN (53.8%) and VRS factors (50.0%).
Although the hypothesized factorial structure was poorly reproduced in this study,
it should be noted that the definition of ASC underlying the APZ scale construction
did not include ASCs induced by psychiatric diseases (e.g. see Dittrich, 1998). Hence,
it might be argued that the studied sample was not suitable to falsify the factorial
structure of the APZ. Further shortcomings of the study are the low sample size and
the use of PCA instead of principal factor analysis. In the second study (Bodmer, 1999),
the re-examination of the factorial structure of the APZ was based on a sample of 135
subjects in which ASCs were experimentally induced by either DMT, nitrous oxide, or
sensory deprivation. After performing a principal factor analysis with three factors and
orthogonally rotating the loading matrix to maximal similarity with the hypothesized
factorial structure, 74% of items were correctly distributed to their hypothesized factor.
The disagreement of the empirically derived and hypothesized factorial solutions in this
study mainly resulted from a number of undifferentiated items having salient loadings
on the OBN factor and DED items having no salient loadings on any factor.
2.2.1.3 Reliability assessments
The reliabilities of the APZ scales have been estimated by the Kruder-Richardson for-
mulas KR-8 and KR-20. The KR-20 formula gives identical reliability estimates as
Cronbach’s α when applied to dichotomous variables (Thompson, 2003). In the experi-
mental studies (Dittrich, 1985, 1996), the OBN, DED, and VRS scales showed satisfactory
reliabilities, while the reliability of the G-ASC scale was excellent. In the field studies
(Dittrich, von Arx, & Staub, 1985), the reliability of the OBN scale was substantially re-
duced, while all other scales showed similar reliabilities. The reliability of the OBN scale
was unsatisfactory (r < 0.8) in four of six countries. Test-retest reliabilities calculated
on the basis of repeated measurements approximately one year apart were reported
for a small sample of pharmacologically induced ASCs (n = 61 Dittrich, 1985, 1996). The
estimated retest-reliabilities in this sample ranged from 0.56 for the DED scale to 0.71 for
the OBN scale.
2.2.1.4 Validity assessments
Convergent validities of the APZ scales have been assessed by correlating them with
the scales of the DAE, a questionnaire measuring subjective effects of cannabis (Dittrich,
Baettig, Woggon, & Zeppelin, 1972), and with five scores of cognitive performance tests.
As predicted, most correlations were statistically significant and of at least medium
effect sizes (Dittrich, 1985, 1996).
Discriminant validities of the APZ scales have been assessed in two ways. First,
because the APZ was designed to assess specific states, but not traits, the APZ scales
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were correlated with the scales of the AUPI personality questionnaire (U. Baumann &
Dittrich, 1975; U. Baumann & Dittrich, 1976). As predicted, most correlations were low.
The highest correlations were found between DED and Psychoticism (r = 0.19) and DED
and Neuroticism (r = 0.19; Dittrich, 1985, 1996). Second, because the APZ was supposed
to measure dimensions of ASCs, but not mood changes in general, a double-blind study
was performed in which the effects of ethyl alcohol, chlorpromazine, and placebo on
the scale scores of the APZ were compared. As predicted, the APZ scales did not differ-
entiate between the three experimental conditions (Dittrich, 1985, 1996). To the author’s
knowledge, only one further study has reported correlations between the APZ scales
and other psychological constructs. Specifically, Gouzoulis-Mayfrank, Habermeyer,
et al. (1998) computed correlations between the APZ and the Brief Psychiatric Rating
Scale (BPRS) in a sample of 93 endogenously psychotic patients. They found statistical
significant correlations of medium to large effect sizes between OBN and BPRS Thought
Disorder (r = 0.33) and between DED and BPRS Anxiety/Depression (r = 0.42).
2.2.1.5 Applications
According to Dittrich (1998, pp. 84), “the APZ questionnaire has become the standard
instrument when assessing the common denominator of ASCs.” A literature search
reveals that approximately 25 studies using the APZ have been published. Although
the APZ was developed to measure a broad spectrum of ASCs, the APZ has been used
predominantly in psychopharmacological research. Pharmacological inducers of ASCs
that have been investigated by the APZ include psilocybin (Dittrich, 1985; Vollenweider,
Leenders, Scharfetter, P. Maguire, et al., 1997; Gouzoulis-Mayfrank, Thelen, et al., 1999;
Griffiths, Richards, McCann, & Jesse, 2006; Griffiths, Johnson, et al., 2011; Maclean et al.,
2011), ketamine (Bolle, 1988; Vollenweider, Leenders, Scharfetter, Antonini, et al., 1997),
DMT (Bickel, Dittrich, & Schöpf, 1976; Dittrich, 1985, 1994), ayahuasca (Riba, Rodríguez-
Fornells, & Barbanoj, 2002), Salvia divinorum (González, Riba, Bouso, Gómez-Jarabo, &
Barbanoj, 2006), Salvinorin A (Mendelson et al., 2011), mescaline (Hermle, Fünfgeld,
et al., 1992), THC (Dittrich, Bickel, & Zimmer, 1975; Dittrich, 1975a; Dittrich, Bickel,
Schöpf, & Zimmer, 1976; Koukkou & Lehmann, 1976, 1978; Dittrich, 1985), nitrous
oxide (Dittrich, 1985, 1994), ethanol (Dittrich, 1985), chlorpromazine (Dittrich, 1985),
methylphenidate (Griffiths, Richards, McCann, & Jesse, 2006), 3,4-methylenedioxy-
N-ethylamphetamine (MDE; Hermle, Spitzer, Borchardt, Kovar, & Gouzoulis, 1993;
Gouzoulis-Mayfrank, Thelen, et al., 1999), d-amphetamine (Vollenweider, R. P. Maguire,
Leenders, Mathys, & Angst, 1998), and d-methamphetamine (Gouzoulis-Mayfrank,
Schreckenberger, et al., 1999). Non-pharmacological means of induction investigated
by APZ include sensory deprivation (Dittrich, 1975a, 1985, 1994), hypnagogic states
(Dittrich, 1985), autogenic training (Würmle, 1977; Dittrich, 1985), hypnosis (Dittrich,
1985), sensory overload (Dittrich, 1985), mind machines (Walach & Käseberg, 1998),
endogenous psychosis (Gouzoulis-Mayfrank, Habermeyer, et al., 1998), and sweat
lodges (Polito, Langdon, & Brown, 2010). A shortened version of the APZ was also used
to assess ASCs induced by childbirth (Gruzdev & Spivak, 2006).
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2.2.2 The OAV Questionnaire
2.2.2.1 Scale construction
Although reliabilities and validities of the APZ scales were deemed to be acceptable in
the experimental as well as in the field studies, several weaknesses were also recognized.
For example, because the transition from normal waking consciousness to ASCs is
continuous rather than abrupt, the binary item response format of the APZ was too crude
to measure subtle alterations of consciousness. Consequently, several APZ items showed
very low endorsement rates when measuring experiences of ASCs of low intensity, which
in turn attenuated the item discriminations and scale reliabilities. Other recognized
shortcomings of the APZ concerned the relatively low number of items assigned to
the OBN and VRS dimensions, the low conceptual breadth of the VRS dimension, as
well as problematic wordings of several items. A psychometrically improved version,
named OAV, was therefore developed by Bodmer (1989) in the context a of diploma
thesis carried out at the Department of Psychology at the University of Zürich. Its
name is derived from the first letters of the German names of the primary three
dimensions of the APZ (i.e., Angstvolle Ichauflösung, Ozeanische Selbstentgrenzung,
Visionäre Umstrukturierung). Because the OAV was supposed to measure the primary
three dimensions of the APZ only, its item pool is primarily based on the 72 etiology-
independent items of the APZ. However, the wordings of several items were changed,
some new items were introduced, and some items were completely dropped. The
reformulation of items aimed not only at reducing cross-loadings, decreasing ambiguity,
and enhancing ease of understanding, but also at widening the conceptual breadth of
the OBN and VRS dimensions.
Because the analyses of the APZ had indicated that the VRS dimension describes not
only changes in visual perceptions and their associated meanings, but also a general
increase in the perception of internally produced stimuli, Bodmer (1989) hypothesized
that the VRS dimension could be conceptually extended by incorporating items that
measure an increase of imaginations, associations, and memory retrieval. The proposed
re-conceptualization of the VRS dimension was mainly based on theoretical consid-
erations of Leuner (1962, 1981), who had speculated that hallucinogenic drugs elicit
visual hallucinations by intensifying internal imagery such that the distinction between
internally produced images and external perceptions becomes blurred. Furthermore,
because previous analyses of the APZ had indicated that high scores on the OBN dimen-
sion describe a state similar to mystical experiences, new items for the OBN scale were
formulated on the basis of six of the nine categories of mystical experiences proposed
by Stace (1961). Hence, it was aimed to shift the conceptualization of the OBN scale
toward a more focused and complete assessment of mystical experiences.
In order to allow a more fine-grained assessment of subjective experiences of ASCs
and to reduce item difficulties, the item response format was changed from binary to
visual analogue. Unlike the APZ items, which allowed only “yes” and “no” answers
and thus, according to the response format typology of Russell and J. M. Carroll (1999),
were “ambiguous unipolar”, the visual analogue scales of the OAV were defined in a
“strictly unipolar” manner. That is, the intensity of subjective experiences of ASCs were
measured along a continuum that goes from no, not more than usual on the left to yes,
very much more than usual on the right. By repeating these new descriptions of item
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end poles for every item, the author aimed to ensure that only non-ordinary states of
consciousness were assessed by the questionnaire.
The first draft of the OAV questionnaire contained 70 items and was validated in field
study, in which 177 subjects retrospectively rated an ASC they had experienced in the
past 12 months. Similar to the field studies using the APZ, the majority of the described
ASCs (74.6%) were induced by psychotropic substances. The factorial structure of the
OAV in the collected data set was examined by conducting a principal factor analysis
and orthogonally rotating the factor matrix to maximal similarity with the hypothesized
factor matrix. Taking the highest loadings as decision criterion, it was determined that
only four items were not assigned to their hypothesized factor. After excluding these
four items, the final version of the OAV contained 66 items in total, of which 27, 21, and
18 were assigned to the OBN, DED, and VRS dimension, respectively.
The validation study of Bodmer (1989) indicated that the questionnaire revision
successfully improved several psychometric properties. Specifically, compared to the
original APZ questionnaire, the OAV showed lower item difficulties, higher item dis-
criminations, improved simple structure, and higher scale reliabilities. The improved
scale reliabilities of the OAV could not be explained by the increased scale lengths alone
because a comparison between the APZ and OAV scale reliabilities corrected for different
scale length by the Spearman-Brown formula still showed superior scale reliabilities in
the OAV. Because 49 subjects of the validation study had completed both the APZ and
the OAV questionnaire, similarities of the factors were assessed by simply correlating
the raw summated scales of each of the two questionnaires. As expected, the DED scale,
which had been revised the least, showed the highest correlation (rDED = 0.87) between
the two questionnaires. However, the correlation coefficient for the VRS scales (rVRS
= 0.85) was almost equally high and substantially higher than the correlation of OBN
scales (rOBN = 0.58). Given that the conception of the VRS dimension had been revised
more than the OBN dimension, this finding was rather surprising.
A later study (Bodmer et al., 1994), which used a larger sample (n = 184), corroborated
the finding that the VRS scale correlates higher than the OBN scale across the two
questionnaires. The lower correlation of the OBN scale might be explained by the facts
that the OAV-OBN scale contained the lowest percentage of unchanged items (19%)
and that the length of the scale was increased the most, namely, from 13 items in the
APZ to 27 items in the OAV. However, simple correlations of summated scales must
be interpreted very cautiously because they are biased estimates of the true factor
correlations in at least three ways. First, they are attenuated by the measurement errors
of the two scales. Second, they do not take (non-target) cross-loadings into account.
Unless all the cross-loadings are close to zero, this inflates the correlations of summated
scales (e.g. see Marsh, B. O. Muthén, et al., 2009). Third, because the two questionnaires
were completed by the same subjects, responses to the same items are typically more
positively correlated than can be explained in terms of correlations between the factors
they represent. Unless this type of measurement error is controlled by a confirmatory
factor analysis (CFA) model that includes correlated uniquenesses, the estimated factor
correlations are positively biased (Marsh & Hau, 1996).
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2.2.2.2 Re-examinations of the factorial structure
The hypothesized re-conceptualization of the VRS dimension was not rejected in the
original OAV validation study of Bodmer (1989). That is, the newly constructed items
assessing increased imagination and memory retrieval indeed loaded highest on the
VRS factor. However, in a later study (Bodmer, 1999), in which the factorial structure
of the OAV was re-examined by analyzing a sample of 135 experimentally induced
ASCs (for a description of the sample, see Dittrich, 1994), the VRS factor was poorly
recovered. Specifically, only 5 of the 18 VRS items loaded highest on the VRS factor, while
all remaining VRS items loaded highest on the OBN factor. The correctly assigned VRS
items exclusively measured aspects of elementary visual hallucinations and auditory-
visual synesthesiae. Hence, the distribution of items in this sample did not support the
hypothesis that a single latent construct accounts for the correlations between alterations
in visual perception, changed meaning of percepts, increased imagination, and memory
retrieval.
The hypothesized structure of the VRS dimension introduced by Bodmer (1989) also
poorly fitted the data in a sample of 93 schizophrenic patients who described their last
acute psychotic episode by the OAV questionnaire (Gouzoulis-Mayfrank, Habermeyer,
et al., 1998; Habermeyer, 1999). Although a principal component analysis with three
factors and subsequent varimax rotation correctly assigned 88.9% of OBN and 95.2% of
DED items to their hypothesized factors, this was only true for 44.4% of the VRS items.
As in the sample of experimentally induced ASCs (Bodmer, 1999), the VRS dimension
was reduced to a core of items measuring aspects of elementary visual hallucinations
and auditory-visual synesthesiae, whereas VRS items measuring changed meaning of
visual percepts, increased imagination, and memory retrieval loaded highest on the OBN
factor. Despite these similar patterns of misassignments, the authors of both studies
concluded that the configurations of item loadings were in sufficient agreement with
the original hypotheses.
2.2.2.3 Reliability assessments
The reliabilities of the OBN scales have been estimated by the variance analytic approach
of Hoyt (1941), which produces identical results as Cronbach’s α (Thompson, 2003).
All four scales of the OAV demonstrated high to excellent reliabilities in the field (n =
177; Bodmer, 1989) and in the experiments (n = 135; Bodmer, 1999). With the exception
of the VRS scale in the field data set having a reliability of 0.89, all reported OAV scale
reliabilities were above 0.9.
Test-retest reliabilities were calculated on the basis of 112 subjects completing the OAV
twice (i.e., immediately after the experiments and after one year). The values ranged
from 0.77 for the VRS scale to 0.83 for the OBN scale (Bodmer, 1989).
2.2.2.4 Validity assessments
The validity of the OAV has been deduced from its high correlation with the APZ and
from its proved value in discriminating the effects of different ASC inducing agents.
To the author’s knowledge, correlations between OAV scales and other psychologi-
cal constructs have been reported in only one study. Specifically, in a sample of 93
schizophrenic patients who described their last acute psychotic episode by the OAV
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questionnaire (Gouzoulis-Mayfrank, Habermeyer, et al., 1998), OBN and G-ASC were
significantly correlated with the BPRS Thought Disturbance scale (r = 0.41 and r = 0.33,
respectively) and DED was significantly correlated with the BPRS Anxiety-Depression
scale (r = 0.5).
2.2.2.5 Applications
Similar to the APZ, the OAV has been used predominantly in psychopharmacological
research. At least 25 studies using the OAV have been published. A large proportion
of these studies involved the administration of 3,4-methylenedioxy-methamphetamine
(MDMA; Vollenweider, Gamma, Liechti, & Huber, 1998; Vollenweider, Remensberger,
Hell, & Geyer, 1999; Gamma et al., 2000; Liechti & Vollenweider, 2000; Liechti, C.
Baumann, Gamma, & Vollenweider, 2000; Liechti, Saur, Gamma, Hell, & Vollenweider,
2000; Frei et al., 2001; Liechti, Geyer, Hell, & Vollenweider, 2001; Liechti, Gamma, &
Vollenweider, 2001; Liechti & Vollenweider, 2001; Vollenweider, Liechti, & Paulus, 2005),
psilocybin (Vollenweider, Vollenweider-Scherpenhuyzen, et al., 1998; Vollenweider,
Vontobel, Hell, & Leenders, 1999; Hasler, Bourquin, Brenneisen, & Vollenweider, 2002;
Quednow, Kometer, et al., 2012), and ketamine (Vollenweider, Vontobel, Oye, Hell, &
Leenders, 2000; Umbricht, Koller, et al., 2002; Gouzoulis-Mayfrank, Heekeren, Neukirch,
et al., 2005; Daumann, Heekeren, et al., 2008; Daumann, Wagner, et al., 2010), but
some studies also used the OAV to measure the subjective effects of DMT (Gouzoulis-
Mayfrank, Heekeren, Neukirch, et al., 2005; Daumann, Heekeren, et al., 2008; Daumann,
Wagner, et al., 2010), MDE (Spitzer, B. Franke, et al., 2001), and 3,4-methylenedioxy-
amphetamine (MDA; Baggott et al., 2010). To the author’s knowledge, only one study has
used the OAV to measure non-pharmacologically induced ASCs, namely, ASCs induced
by schizophrenia (Gouzoulis-Mayfrank, Habermeyer, et al., 1998).
2.2.3 The 5D-ASC Questionnaire
2.2.3.1 Scale construction
Although the dimensional analyses of the APZ and OAV questionnaires had revealed
three “etiology-independent” dimensions of ASCs, Dittrich’s own investigations as well
as the scientific literature on ASCs (e.g. Vaitl et al., 2005) pointed to the existence
of further dimensions that are specific to certain ASC-inducing agents. For example,
acoustic alterations and hallucinations are a common feature of non-ordinary states
of consciousness induced by certain psychiatric diseases, such as schizophrenia and
alcohol withdrawal psychoses, and have been described under conditions of sensory
deprivation and hypnagogic states (Mavromatis, 1987), but seem to be less common
in hallucinogen-induced ASCs (Malitz, Wilkens, & Esecover, 1962). In accordance with
these findings, only 2 of the 11 APZ items measuring acoustic alterations met criteria
of etiology-independency in the experimental studies described above (Dittrich, 1985;
Schneiter, 1991). Furthermore, clouding of consciousness and reduction of vigilance are
characteristic features of hallucinogens of the second order and of sedative drugs, but
not of hallucinogens of the first order (Leuner, 1981). Dittrich therefore hypothesized
that “auditory alterations” and “reduction of vigilance” were two etiology-dependent
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dimensions, which, in addition to the three primary etiology-independent dimensions,
could be reliably and validly measured.
In order to test these hypotheses, Dittrich and co-workers constructed the Bewusst-
seinstrübung und Akustische Halluzinationen (BETA) questionnaire (Dittrich, Lamparter,
& Maurer, 1989; Schneiter, 1991), which contains 17 items measuring Vigilance Reduc-
tion (VIR) and 22 items measuring Auditory Alterations (AUA). The AUA dimension was
conceptualized analogously to the VRS dimension. That is, the dimension was not only
supposed to measure auditory (pseudo-)hallucinations, but also changes in the meaning
of auditory perceptions and a general increase of internally produced auditory stimuli.
To reduce item difficulty, items measuring auditory hallucinations were formulated
such that they basically characterized non-psychotic hallucinations. That is, in addition
to a description of a specific auditory hallucination, every item also stated that the
deceptive character of the auditory percept was noticed or at least suspected. Analogous
to the VRS dimension, the AUA dimension was conceptualized to cover hallucinations of
a broad range of vividness and complexity. Specifically, five items were constructed to
measure amorphic hallucinations (e.g., buzzes, drones and soughs), three items were
constructed to measure low-structured hallucinations (e.g., rattles, ticks, rings) and
six items were constructed to measure high-structured hallucinations (e.g., sounds,
melodies, words, sentences). The VIR dimension was designed to cover experiences of
sleepiness, clouding of consciousness and perceptions, and slowing down of thoughts
and actions. Similarly to the OAV questionnaire, the BETA contained a strictly unipolar
visual analogue item response format.
In the context of a diploma thesis carried out at the Department of Psychology at
the University of Zürich, Braun (1997) investigated whether the two hypothesized
dimensions of the BETA questionnaire could be reliably and validly measured and
whether they could be differentiated from the primary three dimensions of the APZ
questionnaire. Braun (1997) pooled APZ and BETA questionnaire data from a study in
which ASCs were experimentally induced (n = 135) and from two field studies (n =
118). She then performed a dimensional analysis on the Pearson correlation matrix of
the 39 BETA items and the 49 APZ items comprising OBN, DED, and VRS scales. Because
the BETA items were measured on a visual analogue scale and the APZ items on a
binary scale, BETA items were dichotomized at their median prior to the computation of
the Pearson correlation matrix. After conducting a principal axis factor analysis with
five factors and a varimax rotation, a factorial solution emerged that was deemed to
be in good agreement with the hypothesized structure. Taking the highest loadings
as decision criterion, 80.7% of items were correctly distributed to their hypothesized
factor. However, an item cluster analysis using the k-means algorithm and the Euclidian
distance metric only recovered the DED, VIR, and VRS factors, whereas the OBN and AUA
factors were merged into the fourth cluster, and a very small cluster containing two VRS
and one OBN items emerged as a fifth cluster. Although, only 69% of all items were
correctly assigned to their hypothesized factor in the cluster analysis, an assessment
of the item distribution similarities by Cohen’s κ indicated that the hypothetical and
empirically derived solutions corresponded to a sufficient degree. Braun (1997) therefore
concluded that the hypothesized five-dimensional structure was not falsified.
Based on the results of the exploratory factor analysis (EFA), eleven items were
excluded from the AUA and VIR scales because they either loaded highest on the wrong
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factor or violated criteria of simple structure. The combination of the original OBN (13
items), DED (22 items), and VRS (14 items) scales from the APZ with the revised AUA (16
items) and VIR (12 items) scales from the BETA resulted in a new questionnaire containing
77 items that measure five dimensions of ASCs. The new questionnaire demonstrated
satisfactory scale reliabilities and item discriminations in the sample of the validation
study. By comparing the means of the scale scores of six ASC-induction techniques
(sensory deprivation, DMT, N2O, LSD, Cannabis, and Opiates) using univariate analyses
of variance, Braun (1997) also demonstrated that the five scales differentiated well
between stimulus conditions.
The validation study of Braun (1997) eventually led to the publication of the Five
Dimensions of Altered States of Consciousness (5D-ASC) questionnaire (Dittrich, Lam-
parter, & Maurer, 1999), which combines all items of the OAV with the revised AUA
and VIR scales of the BETA. The 5D-ASC thus contains 94 items of which 27, 21, 18, 16,
and 12 items are assigned to the OBN, DED, VRS, AUA, and VIR dimensions, respectively.
The 5D-ASC uses the same item response format as the OAV questionnaire. Because the
description of item end poles in the BETA is slightly different from that of the OAV, this
means that the item response format of the AUA and VIR items slightly changed, when
they were incorporated into the 5D-ASC. The historical development of Dittrich’s ASC
questionnaires is summarized in Figure 1.
2.2.3.2 Reliability and validity assessment
Because the OBN, DED, VRS, G-ASC scales of the 5D-ASC contain the same items as those
of the OAV, the reliabilities and validities of these scales have been derived from the
OAV validation studies described above. The reliabilities of the AUA and VIR scales of
the 5D-ASC have been derived from studies using the BETA questionnaire. In a pooled
data set derived from these studies (n = 253), both scales demonstrated reasonably high
reliabilities when estimated by Cronbach’s α, that is, 0.93 and 0.86 for the AUA and VIR
scales, respectively (Braun, 1997). To the author’s knowledge, correlations between the
5D-ASC scales and other psychological constructs have not yet been reported.
2.2.3.3 Applications
The 5D-ASC questionnaires has been used in at least 18 published studies. Similar to its
predecessors, the 5D-ASC has been most popular in psychopharmacological research.
Among the drugs most often studied by the 5D-ASC are psilocybin (Hasler, Grimberg,
et al., 2004; Carter, Burr, et al., 2005; Carter, Pettigrew, Hasler, et al., 2005; Vollenweider,
Csomor, et al., 2007; Wittmann et al., 2007; Wackermann et al., 2008; Kometer et al.,
2011; Carhart-Harris, Williams, et al., 2011; Grob et al., 2011; Schmidt, Bachmann, et al.,
2011), ketamine (Passie, Karst, et al., 2003; Northoff et al., 2005; Sprenger et al., 2006;
Musso et al., 2011; Schmidt, Bachmann, et al., 2011), and MDMA (Hasler, Studerus,
Lindner, Ludewig, & Vollenweider, 2009; Hysek, Simmler, et al., 2011; Hysek, Brugger,
et al., 2012). Non-pharmacologically induced ASCs investigated by the 5D-ASC include
sound-induced trance states (Fachner & Rittner, 2004; Hübner, 2007). A shortened and
modified version of the 5D-ASC, called Experience of Deviation from Normal state (EDN),
was used to assess states of relaxation induced by sensory deprivation in flotation tanks
(Kjellgren, Sundequist, Norlander, & Archer, 2001; Kjellgren, Sundequist, Sundholm,
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APZ
First publication (Dittrich, 1975b)
Item number 158
Response format dichotomous
Item anchors ambiguous unipolar
Primary scales OBN, DED, VRS
Secondary scale G-ASC
OAV
First publication (Bodmer, 1989)
Item number 66
Response format visual-analogue
Item anchors strictly unipolar
Primary scales OBN, DED, VRS
Secondary scale G-ASC
BETA
First publication (Dittrich et al. 1989)
Item number 39
Response format visual-analogue
Item anchors strictly unipolar
Primary scales AUA & VIR
Secondary scale –
5D-ASC
First publication (Dittrich et al. 1999)
Item number 94
Response format visual-analogue
Item anchors strictly unipolar
Primary scales OBN, DED, VRS, AUA, VIR
Secondary scale G-ASC
Figure 1: Dittrich’s Altered States of Consciousness Rating Scales
Norlander, & Archer, 2004), Yogic breathing (Kjellgren, Bood, Axelsson, Norlander, &
Saatcioglu, 2007), natural and simulated natural environments (Kjellgren & Buhrkall,
2010), and spike mats (Kjellgren, Erdefelt, Werngren, & Norlander, 2011).
2.3 methodological issues
Although Dittrich (1998) concluded that his original hypotheses on ASCs have survived
considerable falsification testing not only in experimental but also in field studies and
that the APZ questionnaire has become a psychometrically well-validated instrument for
the assessment of “etiology-independent” features of ASCs in a “etiology-independent”
three-dimensional space, I will demonstrate in this section that the methodological
problems of the existing studies are severe enough to cast doubt on such conclusions.
I will particularly address problems associated with the item selection, dimensional
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analyses, measurement invariance evaluations, binary items, and reliability analyses, as
these – in my opinion – are the biggest cause of concern.
2.3.1 Item Selection
According to Goldberg and Velicer (2006, pp. 212), the item selection “is by far the
single most important decision to be made in any investigation, and it should be
guided by theory and/or the findings from past research". This is because the item
selection will strongly determine the resulting factor structure (e.g. see Velicer & Fava,
1998). Unfortunately, because little empirical research existed on the dimensionality
of ASCs at the time of the APZ questionnaire development, the selection of APZ items
was not guided by strong theory. Hence, it could not be assured that all important
dimensions and/or facets of ASCs were covered by an equal number of items and by an
equal conceptual breadth. Although the 158 items of the APZ have been formulated on
the basis of previously existing questionnaires on ASCs, narrative reports, psychiatric
rating scales, and the author’s personal experience with ASCs, it remains questionable,
whether the selected APZ items and, consequently, the resulting factorial structure were
representative for the domain of interest. The confidence in the proposed factorial
structure could have been improved by repeating the original dimensional analyses
with other sets of items that are independently sampled from the domain of interest.
However, this has not yet been attempted. The confirmation of the three-dimensional
structure with the items sets of the OAV and 5D-ASC questionnaires can not serve as a
real cross-validation because the items sets of these questionnaires were not sampled
independently. In fact, these items were specifically selected to be in accordance with
the dimensional structure originally discovered with the APZ items.
Because Dittrich has adopted a methodological approach that was originally devel-
oped to discover broad dimensions of personality, his approach also rests – at least in
part – on the “lexical hypothesis”, which assumes that the most important variables in a
domain are those used frequently in human communication, thus eventually becoming
part of our natural language (Goldberg, 1981). Although the lexical hypothesis has been
useful in the development of models of personality structure, it may have limitations
with regard to research on ASCs because the western language may not be well equipped
for the expression of rarely occurring ASCs, such as deep mystical experiences.
2.3.2 Factorial Invariance
2.3.2.1 Similarity of correlation matrices
Because sample sizes of the experimental studies were too small to test the hypotheses
in each of the eleven stimulus conditions, the etiology-independency of items could only
be evaluated in the following four groups of ASCs induction techniques: Hallucinogens
of the first order (DMT, psilocybin, and THC; n = 82), hallucinogens of the second order
(nitrous oxide; n = 38), sensory deprivation in a broader sense (perceptual deprivation,
hypnagogic states, autogenic training, and hypnosis; n = 79), and sensory overload
(stimuli of high variety; n = 60). Furthermore, because these groups were still too small
to perform multivariate statistical analysis on each of them, the total data set (N =
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259) had to be used for the dimensional analyses. Pooling the data over all stimulus
conditions was justified on the grounds that similarity tests of the correlation matrices
between all possible pairs of the four stimulus groups reached statistical significance.
However, none of the 5 different similarity tests applied by Dittrich can formally test the
hypothesis that the correlation matrices are equal. Hence, they provide little evidence
that the correlation matrices from different groups could be reduced to exactly the same
latent factor model.
Even if the equality of covariance matrices had been formally tested by a more
stringent structural equation modeling approach (Jöreskog, 1971), it would not prove
factorial invariance between groups because it is possible that the omnibus test of
equality of covariance matrices indicates no group difference while hypothesis tests
of the invariance of specific measurement or structural parameters of the latent factor
model must be rejected (Byrne, 2009). Accordingly, many methodologists have con-
cluded that the omnibus test of equal covariance matrices provides little guidance for
testing the factorial invariance between groups (Brown, 2006). Instead, most authors
recommend evaluating factorial invariance within a multiple groups CFA framework
only. A major advantage of multiple groups CFA is that all potential aspects of invari-
ance across groups can be examined by formal statistical hypothesis tests (Jöreskog,
1971). For instance, by setting increasingly restrictive constraints on the simultaneous
parameter estimation of two CFA models, it can be assessed whether the number of
factors and pattern of indicator-factor loadings is identical across groups (commonly
referred to as configural invariance) and whether there is equality between groups
with respect to factor loadings (weak factorial invariance), indicator intercepts (strong
factorial invariance), and indicator residuals (strict factorial invariance; Meredith, 1993).
Strict factorial invariance (cross-group equality in the loadings, intercepts, and residual
variances) ensures that any systematic group differences in the means, variance or
covariances for the measured variables are due to the common factors, rather than
group differences in the factor structure. The establishment of strict factorial invariance
is therefore a necessary condition for the correct interpretation of differences in the
factor means (Brown, 2006; Millsap & Meredith, 2007). Unfortunately, neither the APZ
nor the OAV and 5D-ASC questionnaires have ever been examined by multiple groups
CFAs. Assessments of the factorial invariance of these questionnaires across different
groups of ASC induction techniques and languages have entirely relied on descriptive
measures of similarity derived from the comparison of EFA models.
2.3.2.2 Item aggregates
In the experimental studies, sample sizes were too small to compute EFAs on the whole
set of 72 etiology-independent items in each of the four groups of stimulus conditions.
Consequently, comparisons across stimulus groups had to be made on the basis of
EFAs and cluster analyses computed on a set of nine item aggregates (so called item
parcels) formed from the 49 variables having salient loadings in the EFA of the pooled
data set. However, aggregating items to parcels is a highly dubious practice when the
investigator’s goal is to represent the dimensionality of the measurement space at the
level of individual items (Little, Cunningham, Shahar, & Widaman, 2002). The use of
item parcels can seriously distort the latent factor model when the item parcels are
not unidimensional or when the uniquenesses (measurement error variances) of items
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within a given parcel correlate with the unique or common factors of items in other
parcels (Brown, 2006). Accordingly, numerous writers have suggested that only under
conditions of unidimensionality should parceling be considered. Unfortunately, Dittrich
has not assessed the dimensionalities of the items parcels for each stimulus conditions.
Hence, the results of the EFA and cluster analysis comparisons of the four stimulus
groups must be interpreted very cautiously.
2.3.2.3 Tucker’s coefficient of congruence
Even if comparisons between stimulus groups had been made on the basis of EFAs and
cluster analyses computed on the whole set of individual items, Dittrich’s approach
of investigating factorial invariance could be criticized for several other reasons. For
instance, in order to assess the comparability of each latent dimension across different
stimulus groups, Dittrich (1985, 1996) computed a similarity index commonly known as
Tucker’s coefficient of congruence (Burt, 1948; Tucker, 1951). Similar to the Pearson’s
product-moment correlation, the value of this statistic varies between +1 (perfect con-
gruence) and -1 (perfect negative congruence), with zero indicating no linear association
between the two factors. Its value is calculated by using only information from the
two factor pattern (loading) matrices across the two groups. Although the coefficient
of congruence has many desirable properties (see Lorenzo-Seva & ten Berge, 2006), it
tends to overestimate similarity when the sign of all loadings is predominantly the
same and the level of the loadings is approximately the same (Pinneau & Newhouse,
1964). In fact, the scale sensitivity problem of this similarity index is so severe that some
researchers have discouraged it’s usage entirely (e.g. Barrett, 2006).
The coefficient of congruence has also been criticized for being a mere descriptive
measure of similarity for which no statistical estimation theory has been developed to
test its significance (Zumbo, Sireci, & Hambleton, 2003). Although a solution to this
problem has recently been proposed (Chan, Ho, Leung, Chan, & Yiu-Fai, 1999), it is still
widely debated how large this coefficient should be to conclude that congruence holds
to a reasonable approximation. In practice, the size of the coefficient of congruence
is usually evaluated by applying some rule of thumb (e.g. see Lorenzo-Seva & ten
Berge, 2006). However, it is unlikely that one decision rule would be appropriate for
all situations because its size is affected by several variables. One such variable is the
factor rotation of each solution under comparison. Because factor rotations are to a
certain degree arbitrary, that is, two independent factor solutions may occupy markedly
different orientations even though they are quite similar, Dittrich (1985, 1996) computed
the coefficient of congruence after rotating one factor structure (the predictor matrix) to
maximal agreement with the other (the criterion matrix) using orthogonal Procrustean
rotation. Although widely applied in the old days of psychometric research and still
recommended by some investigators for specific situations (McCrae, Zonderman, Bond,
Costa, & Paunonen, 1996; Zumbo et al., 2003; Lorenzo-Seva & ten Berge, 2006), this
procedure has many known weaknesses compared to the modern standard approach
of measurement invariance evaluation, that is, multiple group confirmatory factor
analysis (MG-CFA). One of the biggest problems is that Procrustean rotations have a
tendency to capitalize on sample-specific subtleties, which – depending on the properties
of the data being evaluated – may result in spuriously high and misleading coefficients
of congruence (Nesselroade & Baltes, 1970; Korth & Tucker, 1975; Paunonen, 1997). By
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using a Monte Carlo approach, Paunonen (1997) has demonstrated that capitalizing on
chance and thus inflating the coefficients of congruence is dependent on the number
of variables and the number of salient variables per factor (both having an inverse
relation), the size of the salient variables’ pattern coefficients (having a direct relation),
and the number of factors (having a joint relation with the size of salients).
Unfortunately, Dittrich’s comparisons of stimulus groups were made under conditions
that increase the tendency to capitalize on chance the most, that is, a low number of
variables, factors, and salient variables per factor and high loadings of salients. In fact,
using the regression equation proposed by Paunonen (1997), it can be estimated that
under Dittrich’s conditions the upper 95% confidence limit of the random distribution
of the coefficient of congruence is 0.89. Given that some coefficients of congruence
reported by Dittrich (1985, 1996) were lower than that value, the evidence for an
etiology-independent factor structure is actually quite weak. Furthermore, even if all
reported coefficients of congruence had been higher than what might be expected by
chance, it would only indicate statistically significant similarity. Significant similarity,
however, does not imply factorial invariance. It only means that the factor patterns
are not statistically independent. In other words, to demonstrate replicated factors in
two samples, it is not sufficient to reject the null hypothesis of zero factor congruence.
Instead, one has to show that the coefficient of congruence is not statistically different
from one (Paunonen, 1997). In order to test the latter hypothesis, Chan et al. (1999)
have proposed a bootstrap-procedure. Using this procedure in a Monte Carlo study,
they estimated the minimum sizes of the coefficient of congruence that were needed
to not reject the null hypotheses of equal factor loadings under eight different model
conditions. Interestingly, the average critical values determined in that study are
generally much higher than what commonly applied rules of thumb suggest and
thus further call into question that the congruence coefficients reported by Dittrich
(1985, 1996) are high enough to demonstrate factorial invariance. Moreover, even
if all coefficients of congruence indicated equality of factor loadings, it would still
not satisfy the criteria of measurement invariance. As mentioned above, in order to
establish measurement invariance between groups, it is also necessary to show that the
models under comparison are invariant with respect to unique variances and indicator
intercepts. The only possible way of addressing these issues is by carrying out CFAs
involving the analysis of mean in addition to covariance structures (Millsap & Meredith,
2007).
2.3.2.4 Cohen’s Kappa
Previous studies examining the replicability of the factorial structures of the APZ,
OAV, and 5D-ASC questionnaires in different populations (Dittrich, von Arx, & Staub,
1985; Dittrich, 1985; Bodmer, 1989; Bodmer et al., 1994; Dittrich, 1994; Braun, 1997;
Bodmer, 1999) have also relied on Cohen’s κ (Cohen, 1960) as a descriptive measure
of latent structure similarity. The coefficient κ estimates the similarity of two factors
from different solutions by comparing the patterns of salient and non-salient loadings
(Guadagnoli & Velicer, 1991). It has also been used to compare two factorial solutions
as a whole by comparing the distributions of the highest loadings of each item. The
latter approach has been used exclusively in the existing literature on the APZ, OAV,
and 5D-ASC questionnaires. Similar to the coefficient of congruence, the computation
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of κ is entirely based on information of the two factor loading matrices across the two
groups. However, because the factor loadings are treated as binary values, that is,
they are either salient or not, some information is lost in the computation of the index.
Furthermore, the size of κ is dependent on an arbitrarily defined cut-off value above
which variables are determined to be salient. Because κ does only reflect differences in
the distribution of salient items across two groups, it is merely a descriptive measure of
configural invariance, which is the weakest form of factorial invariance. As mentioned
above, configural invariance is a necessary but not sufficient condition for measurement
invariance. Furthermore, κ seems to be a very lenient indicator of configural invariance.
For instance, even if all 18 VRS items of the OAV questionnaire were wrongly assigned to
the OBN factor in one sample, an overall comparison of that factorial solution with the
hypothetically correct solution would result in a κ coefficient of 0.56, which according
to the guidelines of Landis and Koch (1977) would still be interpreted as indicating
fair to good agreement. Obviously, testing the factorial invariance across two samples
by the κ coefficient is so insensitive to large differences in the loading patterns that
a falsification of the hypothesis of similar loading matrices is almost impossible to
achieve. Stronger falsification testing would have been possible by computing κ for each
factor. However, this has not been attempted in any previous APZ, OAV, and 5D-ASC
questionnaire validation study.
2.3.3 Binary Items
Another methodological shortcoming of Dittrich’s dimensional analyses is that binary
items were treated as if they were continuous. This potentially biased not only the
dimensional analyses of the APZ questionnaire, which has a dichotomous response
format, but also the validation of the 5D-ASC, for which a set of dichotomized BETA and
APZ items were analyzed (see Braun, 1997). The main problem is that Dittrich and his
colleagues estimated associations between binary items with the Pearson correlation
coefficient, which in the case of binary variables is called φ coefficient. It has long been
known that the φ coefficient can be severely attenuated if the items differ markedly by
their difficulties (J. B. Carroll, 1945). In fact, the correlation between two binary items can
reach 1.0 only when the items have exactly the same endorsement probabilities. Factor
analyses on the basis of φ coefficients therefore usually lead to an underestimation of
factor loadings (Woods, 2002). Furthermore, because items cluster together according to
threshold, in addition to content, “pseudofactors” that are artifacts of item difficulty
or extremeness can emerge (Reise, Waller, & Comrey, 2000; Kubinger, 2003). Indeed,
an analysis of variance applied to the item difficulties obtained from the total sample
of Dittrich’s experimental studies reveals highly significant differences between the
primary three dimensions (F(2, 46) = 6.48, p = 0.003). It is therefore quite likely that the
dimensional analysis of the APZ has been distorted to some degree by the unequal item
difficulties.
Future studies analyzing the factorial structure of the APZ should be based on
tetrachoric correlations. Unlike Pearson correlations, tetrachoric correlations of binary
items are not attenuated if the items differ by their difficulties (J. B. Carroll, 1945). Hence,
factor analyses based on tetrachoric correlations are much better suited to reveal the
underlying factorial structure of a set of binary items (Kubinger, 2003; Reise et al., 2000).
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Although factor analyzing tetrachoric correlations would be a big improvement, it can
still lead to vastly inflated chi-square values of model fit and underestimated standard
errors of estimates when the factor model is estimated by the ordinary maximum
likelihood estimator (B. O. Muthén, 1989). In recent years, several estimators have been
developed that are better suited for analyzing categorical items; for example, weighted
least squares (WLS), weighted least squares mean and variance adjusted (WLSMV), and
unweighted least squares (ULS). Simulation studies (e.g., Flora & Curran, 2004) have
shown that the WLSMV estimator gives the most accurate results, especially with small
to moderate sample sizes. It is therefore strongly recommended to use this estimator in
future factor analyses of the APZ.
2.3.4 Reliability
In all APZ, OAV, and 5D-ASC questionnaire validation studies, Dittrich and his colleagues
have relied on Cronbach’s α to demonstrate scale reliabilities. However, the use of
Cronbach’s α as a reliability estimate is problematic because it rests on two statistical
assumptions that are rarely met in practice, namely, unidimensionality and essential
tau equivalence (Revelle & Zinbarg, 2009). Unidimensionality means that the common
variance between the items of a scale can be totally explained by one common general
factor and that the scale contains no group factors. Essential tau-equivalence means
that all items of a given scale are equally strongly related to one common factor. Within
the CFA framework, unidimensionality is demonstrated when there are no residual
correlations and essential tau-equivalence is demonstrated when all factor loadings are
equal (Brown, 2006). If only the condition of essential tau-equivalence is violated, α is a
conservative estimate of scale reliability, that is, it will underestimate scale reliability.
However, if the condition of unidimensionality is violated – and this is very often
the case, especially when the scale contains many items – α can both under- and
overestimate scale reliabilities, depending on the underlying measurement parameters
(Zinbarg, Revelle, Yovel, & Li, 2005; Brown, 2006). The use of Cronbach’s α has therefore
long been criticized by several authors (Revelle, 1979; Huysamen, 2006; Sijtsma, 2009;
Green & Yang, 2009). Recently, criticism has become more widespread because many
alternative reliability estimates are now available that are less biased that can be more
easily interpreted (Raykov, 2001; Zinbarg, Revelle, Yovel, & Li, 2005; Revelle & Zinbarg,
2009).
Because Dittrich and his colleagues have neither assessed essential tau equivalence nor
unidimensionality before calculating Cronbach’s α, the reliabilities of the APZ, OAV, and
5D-ASC scales that have been reported so far must be taken with a grain of salt. Future
studies should either test the necessary assumptions before calculating Cronbach’s α or
assess the reliabilities of the scales by using newly developed reliability estimates that
make less strong assumptions and that can be more easily interpreted. Among the most
promising reliability estimates (at least for continuous items) to date are McDonalds ωh
and ωtot (McDonald, 1999; Zinbarg, Revelle, Yovel, & Li, 2005; Revelle & Zinbarg, 2009).
Whereas ωh estimates the amount of variance in a scale attributable to one common
factor, also referred to as general factor saturation, ωtot estimates the amount of variance
due to all common factors (i.e., group factors and general factor; Zinbarg, Revelle, Yovel,
& Li, 2005).
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In addition to the use of Cronbach’s α, the way Dittrich and his colleagues have as-
sessed retest-reliabilities (i.e. simple correlations of summated scores) is also suboptimal.
Test-retest correlations of summated scores have been shown to be positively biased by
the failure to take into account correlated uniquenesses and negatively biased by the
failure to control measurement error (Marsh & Hau, 2007). A much better approach is
to estimate test-retest correlations within the so called correlated uniquenesses model
(e.g., see Brown, 2006).
2.4 discussion and conclusions
This chapter has critically reviewed the available literature on the development and vali-
dation of Dittrich’s APZ, OAV, and 5D-ASC questionnaires from a modern methodological
perspective. It has demonstrated that the existing studies have many methodologi-
cal shortcomings and that some of them seriously weaken the conclusions drawn by
Dittrich and his colleagues.
To be fair, it should be noted that most of the reviewed studies are relatively old.
Specifically, they were mostly conducted between the early eighties and the mid nineties
of the last century, when many of the statistical methods that I have recommended in
this chapter were not yet implemented in statistical packages. In fact, even today some
of these methods are not widely available. For instance, the calculation of polychoric
correlations are still not supported by the newest version of SPSS, and the WLSMV
estimator is only available in the statistical software Mplus (L. K. Muthén & B. O.
Muthén, 2007), although it should be soon implemented in lavaan (Rosseel, Oberski, &
Byrnes, 2011), which is a freely available add-on package to R (R Development Core
Team, 2011). Some of the weaknesses highlighted in this chapter must also be reconciled
with economic constraints. Conducting experiments in which ASCs are induced by
various means is costly because subjects must be carefully selected and monitored.
Thus, it would have been quite difficult to test Dittrich’s hypotheses with larger samples,
more stimulus conditions, and other item sets.
Nevertheless, many of the methodological problems mentioned in this chapter have
been described in the literature long before Dittrich (1985) conducted his first investiga-
tions on the structure of ASCs. Furthermore, the theoretical foundations for structural
equation modeling, CFA, and MG-CFA, which now have become standard methods of
psychometric investigations and which are associated with many of the methodological
and statistical advances in quantitative psychology in the last two decades (Marsh,
Lüdtke, et al., 2010), were mostly established in the late nineteen-sixties and seventies
(e.g., Jöreskog, 1969, 1971), and the first statistical software that could fit such models
(i.e. Lisrel) also became available at that time. Of course, when Dittrich (1985) wrote his
“opus magnum” in the early eighties, such methods were still quite experimental, but
they were already quite established in the mid nineties, when the OAV and 5D-ASC ques-
tionnaires were developed and/or validated. Thus, the inappropriate use of exploratory
methods (EFA) for hypothesis testing and the omission of confirmatory methods (CFA
and MG-CFA) – especially in the newer studies – cannot solely be excused for historical
reasons.
As a proponent of critical rationalism (Popper, 1959), Dittrich has repeatedly exposed
his hypotheses to refutation through falsification tests. Since none of his falsification
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tests have proved his hypotheses wrong, he concluded that his hypotheses have survived
falsification. Thus, even though, as a critical rationalist, he would never claim that
this hypotheses were true, he has concluded that there is considerable evidence that
they are not wrong. However, as I have shown above, Dittrich’s criteria for falsification
were often so lenient that a refutation of his hypotheses was almost impossible to
achieve. The most striking example is the use of Cohen’s κ, which indicates fair to good
agreement between two factor structures even though the loading matrices strongly
differ.
Thus, I consider it an exaggeration to claim that the hypotheses have survived
considerable falsification testing. Similarly, I regard it as premature to call the OBN,
DED, and VRS constructs “etiology-independent” dimensions of ASCs. Although it is
still possible that Dittrich’s hypotheses are true, stronger falsification tests are clearly
needed to substantiate them. Methods of the structural equation modeling framework,
such as CFA, MG-CFA and ESEM (e.g., see Marsh, B. O. Muthén, et al., 2009), are currently
the most appropriate methods for testing Dittrich’s original hypotheses and have the
potential to overcome many of the methodological shortcomings described in this
chapter. Studies that apply these methods to Dittrich’s ASC questionnaires are therefore
highly warranted.
Part II
E M P I R I C A L S T U D I E S
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A C U T E , S U B A C U T E A N D L O N G - T E R M S U B J E C T I V E E F F E C T S
O F P S I L O C Y B I N I N H E A LT H Y H U M A N S : A P O O L E D A N A LY S I S
O F E X P E R I M E N TA L S T U D I E S
3.1 abstract
Psilocybin and related hallucinogenic compounds are increasingly used in human re-
search. However, due to limited information about potential subjective side-effects, the
controlled medical use of these compounds has remained controversial. We therefore
analyzed acute, subacute, and long-term subjective effects of psilocybin in healthy
humans by pooling raw data from eight double-blind placebo-controlled experimental
studies conducted between 1999 and 2008. The analysis included 110 healthy subjects
who had received 1-4 oral doses of psilocybin (45-315 μg/kg body weight). Although
psilocybin dose-dependently induced profound changes in mood, perception, thought,
and self-experience; most subjects described the experience as pleasurable, enriching,
and non-threatening. Acute adverse drug reactions, characterized by strong dysphoria
and/or anxiety/panic, occurred only in the two highest dose-conditions in a relatively
small proportion of subjects. All acute adverse drug reactions were successfully man-
aged by providing interpersonal support and did not need psychopharmacological
intervention. Follow-up questionnaires indicated no subsequent drug abuse, persisting
perception disorders, prolonged psychosis, or other long-term impairment of function-
ing in any of our subjects. The results suggest that the administration of moderate doses
of psilocybin to healthy, high-functioning, and well-prepared subjects in context of a
carefully monitored research environment is associated with an acceptable level of risk.
3.2 introduction
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indoleamine or serotonin-
like hallucinogen and the main psychoactive principle of a group of hallucinogenic fungi
of the genus Psilocybe, also often referred to as “magic mushrooms” (Hofmann, 1968).
Psilocybe mushrooms occur throughout the world and their human use in medical and
religious rituals dates back for centuries, if not millennia (Stamets, 1996; Guzmán et al.,
2000).
Modern psychopharmacological research with psilocybin begun with the discovery
of the cultic use of Psilocybe mushrooms by Mesoamerican Mazatec Indians in 1955
(Wasson, 1958). Psilocybin and psilocin were identified at Sandoz Laboratories as the
psychoactive compounds of Psilocybe mushrooms and synthesized by the renowned
Swiss chemist Albert Hofmann (1958), who some 15 years earlier also discovered the
chemically related ergoline hallucinogen LSD. Soon after, synthetic psilocybin was
marketed by Sandoz under the name Indocybin® for basic psychopharmacological and
therapeutic clinical research (Hofmann, Heim, Brack, Kobel, et al., 1959; Passie, 1995;
Passie, Seifert, et al., 2002).
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Early clinical studies in the 1960s and 1970s demonstrated that psilocybin produces
an altered state of consciousness (ASC) similar to LSD that is characterized by marked
alterations in perception, mood, and thought, including changes in the experience of
time, space, and self, that are rarely experienced otherwise except in dreams, religious
exaltation, and acute psychoses (Isbell, 1959; Rümmele & Gnirss, 1961; Leuner, 1962;
Wolbach et al., 1962; Fischer, 1971; Geyer & Vollenweider, 2008). In these states, percep-
tual hypersensitivity, illusions, and pseudohallucinations (i.e., hallucinations with intact
reality testing and insight) are common (Leuner, 1962; Hill, Fischer, & Warshay, 1969;
Fischer, Hill, & Warshay, 1969; Fischer, Hill, Thatcher, & Scheib, 1970).
Intensification of affective responses, enhanced ability for introspection, regression
to primitive and childlike thinking, and activation of vivid memory traces with pro-
nounced emotional undertones can also occur (Leuner, 1971). Psychophysiological and
pharmacological studies revealed that psilocybin had a much shorter duration of action
than LSD (4-6 h instead of 8-12 h; Cerletti, 1959). Although - apart from the duration of
action - the effects of both drugs were found to be highly similar in a controlled study
(Hollister & Hartman, 1962), clinical observations indicated that psilocybin tended
to produce less anxiety, panic reactions, affective disturbances, and milder vegetative
side-effects than LSD (Heimann, 1962; Nieto, 1962; A. E. David & J. M. David, 1961;
Clark, 1968; Leuner, 1968; Passie, 1995). Hence, many hallucinogen researchers valued
psilocybin as a useful substitute for the earlier discovered LSD to explore the neural
basis of ASCs including the basis of hallucinations, religious, spiritual, and psychotic
dimension, while for others it was an attractive adjunct in psychodynamic-oriented
psychotherapy to bring the unconscious into conscious (Leuner, 1971; Nichols, 2004;
Nichols & Chemel, 2006).
Throughout the 1960s, LSD and related drugs became increasingly associated with
cultural rebellion, were widely popularized as drugs of abuse, and depicted as danger-
ous. Consequently, around 1970, LSD and related drugs were scheduled in the most
restrictive category in most countries. Accordingly, human research on psychedelics
became severely restricted, funding became difficult, and interests in therapeutic use of
these drugs faded.
The 1990s witnessed a re-emergence of human hallucinogen research in Europe,
particularly with the development of new brain imaging techniques, sophisticated neu-
ropsychological approaches, and neuropharmacological findings that have supported
hallucinogens as models of at least some aspects of natural occurring psychosis (for a
review, see Geyer & Vollenweider, 2008). Many of these studies conducted in our and
other laboratories used psilocybin as a tool to investigate the neural underpinnings of
psychotic symptom formation including ego-disorders and hallucinations (Vollenwei-
der, 1992; Vollenweider, Leenders, Scharfetter, P. Maguire, et al., 1997; Vollenweider,
Vollenweider-Scherpenhuyzen, et al., 1998; Gouzoulis-Mayfrank, Schreckenberger, et al.,
1999; Gouzoulis-Mayfrank, Thelen, et al., 1999; Vollenweider & Geyer, 2001; Hasler,
Grimberg, et al., 2004) or to explore the effect of psilocybin on cognitive and visual
processes (Spitzer, Thimm, et al., 1996; Umbricht, Koller, et al., 2002; Umbricht, Vollen-
weider, et al., 2003; Carter, Pettigrew, Burr, et al., 2004; Carter, Burr, et al., 2005; Carter,
Pettigrew, Hasler, et al., 2005; Carter, Hasler, et al., 2007; Kometer et al., 2011), time
perception (Wackermann et al., 2008; Wittmann et al., 2007), and on sensory gating and
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its relation to cognitive alterations (Gouzoulis-Mayfrank, Heekeren, Thelen, et al., 1998;
Vollenweider, Csomor, et al., 2007).
Recent work has also explored the acute and long-term subjective effects of psilocybin
in hallucinogen-naïve healthy subjects and found that 14 months after the experiments
about two-third of participants still rated the experience as among the most personally
meaningful and spiritually significant of their lives (Griffiths, Richards, McCann, &
Jesse, 2006; Griffiths, Richards, Johnson, et al., 2008). In addition, several recent stud-
ies have re-investigated the tolerability and efficacy of psilocybin in the treatment of
anxiety related advanced-stage cancer (Grob et al., 2011) and obsessive-compulsive
disorders (Moreno et al., 2006). Other studies have focused on the pharmacokinet-
ics (Hasler, Bourquin, Brenneisen, Bär, & Vollenweider, 1997), metabolism (Hasler,
Bourquin, Brenneisen, & Vollenweider, 2002), dose-dependent effects (Hasler, Grimberg,
et al., 2004), and receptor mechanism of psilocybin (Ametamey et al., 1998; Vollenweider,
Vollenweider-Scherpenhuyzen, et al., 1998; Vollenweider, Vontobel, Hell, & Leenders,
1999; Vollenweider, Hasler, & Kometer, 2008; Hasler, Quednow, et al., 2009). For ex-
ample, we have shown that the selective 5-HT2A receptor antagonist ketanserin blocks
the hallucinogenic effects of psilocybin in human subjects (Vollenweider, Vollenweider-
Scherpenhuyzen, et al., 1998), providing strong evidence for the link between 5-HT 2A
receptor activation and hallucinosis (Sanders-Bush, Burris, & Knoth, 1988). Moreover, a
recent animal study found a novel mechanism of functional interaction between 5-HT2A
and mGluR2 receptors and suggests that specific mGluR2 agonists may block the effect of
hallucinogens such as psilocybin in humans (González-Maeso, Weisstaub, et al., 2007;
González-Maeso, Ang, et al., 2008; González-Maeso & S. C. Sealfon, 2009). Although
molecular and mechanistic studies in animal are pertinent, translational research in
human subjects and particularly the establishing of the links between the mechanism of
action of hallucinogens and the subjective effects in humans is essential (Vollenweider,
2001).
Although serotonergic hallucinogens such as psilocybin are considered relatively safe
physiologically and do not produce dependence (Leuner, 1981; Nichols, 2004; Johnson,
Richards, & Griffiths, 2008), there is limited information on the acute tolerability and
potential long-term psychological effects of psilocybin. Moreover, given that many of
the early human studies with psilocybin were poorly standardized and lacked adequate
control groups or follow-up measures, or often had small and unrepresentative sample
sizes, it is difficult to draw inferences with this work, e.g., on dose-response effects and
the incidence of acute and subacute distress and side effects.
The purpose of this paper is to provide further information about the acute, subacute,
and potential long-term subjective effects of psilocybin administration in healthy human
subjects in a controlled experimental setting. The present analysis is based on data
of 8 double-blind placebo-controlled psilocybin studies that were conducted in our
laboratory during the past 10 years. The data report on acute, subacute, and long-term
effects of 227 individual psilocybin sessions obtained in 110 subjects using validated in-
struments to assess various aspects of consciousness, mood, psychological and physical
side effects. Whereas parts of the data on the acute effects of psilocybin were previously
published (see Table 1), the data on subacute and long-term effects/side-effects have
not been presented elsewhere before.
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3.3 methods
3.3.1 Study Description
Data from eight experimental studies involving psilocybin administration to healthy
human subjects carried out between 1999 and 2008 at our research facility were pooled
for the present analysis (Table 1). Earlier psilocybin studies were not included because
no long-term follow-up measurements were obtained in those experiments. All eight
studies were approved by the Ethics Committee of the University Hospital of Psychiatry,
Zürich, and the use of psilocybin was authorized by the Swiss Federal Office of Public
Health, Department of Pharmacology and Narcotics, Bern. In each study, a double-blind
placebo-controlled within-subject design was used. Depending on the study, subjects
were tested on 2-5 experimental days, each separated by at least 14 days to avoid carry-
over effects. Each volunteer received placebo and 1-4 different oral doses of psilocybin
in a randomized and counterbalanced order. Additionally, in one study subjects also
received pre-treatments with the 5-HT2A antagonist ketanserin and placebo. Psilocybin
doses ranged from 45 μg/kg to 315 μg/kg body weight (absolute doses: 2-28 mg). For a
detailed description of the administered psilocybin doses in each study, see Table 1.
Experimental sessions of studies 3 and 7 were conducted at the positron emission
tomography center of the University Hospital, Zürich, while all other study sessions
took place at the University Hospital of Psychiatry, Zürich. All subjects were instructed
to have a light breakfast prior to the experiments. Before testing began, blood pres-
sure and heart rate were measured and subsequently monitored at hourly intervals
throughout the day. Subjects finished participation of the study approximately 7 h after
psilocybin administration and were examined by the principal investigator before being
deemed fit for release. Subjects were asked not to engage in demanding work after
the psilocybin session and to contact the research staff if any adverse events occurred.
These procedures are generally similar to those subsequently used and recommended
by Johnson, Richards, and Griffiths (2008).
3.3.2 Subjects
In all studies, psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) was obtained
through the Swiss Federal Office for Public Health, Bern. Psilocybin capsules (1 mg and
5 mg) were prepared at the Pharmacy of the Cantonal Hospital of Aarau, Switzerland.
The psilocybin and lactose placebo were prepared in gelatin capsules of identical
appearance.
3.3.3 Psychometric Ratings of Acute and Post-Acute Effects
All eight studies included in the present analysis used the Five Dimensions of Altered
States of Consciousness rating scale (5D-ASC; Braun, 1997; Dittrich, Lamparter, &
Maurer, 2006) and six studies also used the Eigenschaftswörterliste 60-S (EWL-60-S;
Janke & Debus, 1978, 1986) to assess acute and subacute subjective drug effects.
The 5D-ASC questionnaire is a psychometrically improved and extended version
of the original APZ questionnaire (Dittrich, 1998). The 5D-ASC is a visual analogue
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self-rating scale consisting of 94 items, assessing five primary dimensions and one
global dimension of ASCs. The primary dimensions are comprised of several item
clusters and can be described as follows: (1) Oceanic Boundlessness (OBN) measures
derealization and depersonalization accompanied by changes in affect ranging from
heightened mood to euphoria and/or exaltation, and alterations in the sense of time.
The corresponding item clusters are positively experienced derealization, positive experienced
depersonalization, changed sense of time, positive mood, and mania like experience. (2) Dread
of Ego Dissolution (DED) measures ego-disintegration associated with loss of self-control,
thought disorder, arousal, and anxiety. The item clusters are negatively experienced
derealization, thought disorder, paranoia, loss of thought control, and loss of body control. (3)
Visionary Restructuralization (VRS) measures alterations in perception and meaning. The
Item clusters are elementary hallucinations and illusions, scenery hallucinations, synesthesiae,
changed meaning of percepts, facilitated recollection, and facilitated imagination. (4) Auditory
Alterations (AUA) measures auditory illusions and auditory (pseudo-) hallucinations.
(5) Vigilance Reduction (VIR) relates to states of drowsiness, reduced alertness, and
impaired cognitive function. The OBN, DED, and VRS dimensions have been shown to
be common to a range of altered states of waking consciousness of varying aetiology
and intensity, while the AUA and VIR dimensions are hypothesized to occur only under
certain stimulus conditions (Dittrich, von Arx, & Staub, 1985; Dittrich, 1998). Items
from the OBN, DED, and VRS dimensions are therefore summed to the Global Altered
States of Consciouness (G-ASC) scale. 5D-ASC administration time in the pooled data set
varied between studies from 60 to 270 min after drug intake. In all studies, subjects
were instructed to rate their whole experience by the 5D-ASC retrospectively from the
moment of drug intake to the respective measuring time point.
The EWL-60-S is a self-rating scale that was developed for the multidimensional assess-
ment of mood states and condition (Janke & Debus, 1986). The EWL-60-S consists of a list
of 60 adjectives (e.g., ‘anxious’, ‘tired’, ‘sociable’) that are rated by subjects as to how
well they describe their present state. Subjects must choose from four possible answers
(‘not at all’, ‘somewhat’, ‘quite’, or ‘strongly’). EWL-60-S items can be broken down into
15 mood states and conditions: "Efficiency-activation", "Concentration", "Inactivation",
"Tiredness", "Drowsiness", "Extroversion", "Introversion", "Self-confidence", "Height-
ened mood", "Emotional excitation", "Sensitivity", "Aggression-anger", "Apprehension-
anxiety", "Depressiveness", and "Dreaminess". Depending on the study, the EWL-60-S
was administered at one to four time points during the course of an experimental
session and between 60 min and 24 h after drug administration (see statistical analysis
section for more details on the EWL-60-S administration time points in each study). At
each time of assessment, subjects were instructed to rate their present state.
3.3.4 Psychometric Rating of Subacute Side-Effects
Subacute side effects were assessed in six studies (study # 1, 2, 4, 5, 6, 8) by the List
of Complaints (LC; von Zerssen, 1971). This self-rating scale consists of a list of 65
common somatic and psychological ailments, which can be summed to a global score
of general discomfort. Subjects were asked to rate whether each symptom is present or
not at the time of assessment. In all 6 studies, the LC was administered 24 h after drug
intake.
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3.3.5 Long-Term Follow-Up
Long-term psilocybin effects were assessed by an investigator-constructed follow-up
questionnaire that covered the following areas of content:
1. Ratings of acute drug experiences in retrospect:
Subjects were asked the following question: “How do you rate the acute drug
experience during the experiment in retrospect?” For each of six adjectives (pleasant,
enriching, frightening, unpleasant, influential, and nothing special), subjects had to
choose one of three possible answers (very much, medium, or not).
2. Changes in values and attitudes:
Subjects were asked the following questions: Did the experiment with psilocybin
cause changes in (a) world view, (b) values, (c) awareness of personal problems, (d) the
relationship to your body, (e) relationships to other people, (f) professional relationships,
(g) the relationship to the environment/nature, (h) aesthetic experiencing, and (i) in
the attitude to ASCs? For each item, subjects had to choose from three possible answers
(positive change, negative change, or no change)
3. Changes in drug consumption habits:
Subjects were asked whether they had changed their consumption habits of any
psychoactive drug after the experiments. For each drug that was consumed either more
or less often than before, subjects were asked to give further details on frequency of use,
dosages, route of administration, and setting of use. Subjects were also asked whether
they considered the described changes as a consequence of their drug experience during
the experiments.
4. Spontaneously occurring ASCs before and after the experiments and flashbacks:
Subjects were asked to describe frequencies, durations, circumstances, and symptoms
of ASCs that spontaneously occurred before and/or after the experiments and whether
they interpreted these ASCs as a flashback-like re-experiencing of acute drug effects.
5. Negative changes in psychological well-being and/or mental functions:
Subjects were asked to report the intensity, duration, and frequency of any experienced
negative change in well-being and/or mental functions after the experiments. Sleeping,
memory, and concentration problems, as well as mood swings, anxiety, and reactivation
of old problems were directly listed in the questionnaire, but further symptoms could
be described by the subjects if necessary. Long-term follow-up questionnaires were
mailed to the study subjects (including drop-outs) 8-16 months after completion of their
last experimental session. All follow-up questionnaires were obtained after subjects had
been paid and therefore were more likely to report adverse effects.
3.3.6 Statistical Analysis
All statistical analysis were performed using the freely available statistical package
R© (Version 2.8.1; R Development Core Team, 2008). Since all analyzed studies used
within-subject designs and since there is considerable heterogeneity between studies
(e.g., differences in setting, study manager, and experimental procedure), our pooled
data of acute and subacute psilocybin effects is structured hierarchically with repeated
measurements nested within subjects and subjects nested within studies. Because drug
dose conditions only partially overlap between studies and some subjects prematurely
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dropped out, our data set is also unbalanced with respect to drug dose condition. To
account for observational heterogeneity and the lack of balance, we used mixed-effects
models, which readily handle unbalanced and missing data and allow all observational
units to contribute information to the analysis (Pinheiro & Bates, 2000). We used the
R add-on package nlme (Pinheiro, Bates, DebRoy, Sarkar, & the R Core team, 2008)
to fit mixed effects models. To minimize a potential bias arising from drop-outs, all
available data of drop-outs were included in the statistical analyses on acute, subacute,
and long-term psilocybin effects.
To investigate the acute effects of drug dose on the five ASC dimensions (OBN, DED,
VRS, AUA, and VRS), 5D-ASC data assessing peak drug effects were pooled over all
eight studies. In studies where the 5D-ASC questionnaire was administered more than
once during an experimental session, data from the measuring time points yielding
the highest mean total score were used. The marginally differing psilocybin dose
conditions 115 and 125 μg/kg, as well as 250 and 260 μg/kg were combined because
t-tests between these pairs of dose conditions did not reveal significant differences
of subjective drug effects measured by the global and primary dimensions of 5D-ASC.
The pooled 5D-ASC data were analyzed by linear mixed effects models with treatment
(placebo, 45, 115-125, 215, 250-260, and 315 μg/kg) as a fixed effects factor and study
and subjects within studies as random effects factors. Random effects were modeled
as random intercepts without random slopes. Akaike’s information criterion (AIC)
values were used to decide on appropriate correlation structures of random effects
in model specifications. In cases of variance heteroscedasticity, we used a weighting
procedure to correct for unequal variances between groups. Statistical assumptions
were checked graphically by plotting residuals against predicted values and by normal
quantile-quantile plots of residuals and random effects. In each fitted mixed-effects
model, the shape of the psilocybin dose-response relationship was evaluated by means
of orthogonal polynomial contrasts. Additionally, when significant treatment effects
were detected, one-tailed Dunnett contrasts were applied using the R add-on package
multcomp (Hothorn, Bretz, & Westfall, 2008) in order to find the minimum effective
dose. To determine the proportions of subjects experiencing strong subjective drug
effects cumulative distributions of the three aetiology-independent dimensions (OBN,
DED, and VRS) were inspected for each dose condition. Scale values above 70 percent of
the maximum possible score were considered as strong subjective drug effects.
The analysis of EWL-60-S data was restricted to the placebo and medium dose psilo-
cybin conditions because these were the only drug conditions that occurred in all six
studies using the EWL-60-S. For the analysis of time dependent effects of psilocybin,
the EWL-60-S administration time, which widely varied across studies, was categorized
as follows: t1 = 60-95 min, t2 = 160-180 min, t3 = 260-400 min, and t4 = 24 h after
drug intake. Five studies (study # 1, 4, 5, 6, and 8) had used the EWL-60-S during t1
and t3. Three studies (study # 3, 4, and 8) administered the EWL-60-S during t2 and
three studies (study # 1, 5, and 8) used the EWL-60-S at t4. The EWL-60-S subscales were
analyzed by mixed effects models using the fixed effects factors treatment (placebo vs.
215-260 μg psilocybin) and time (t1, t2, t3, and t4) and the hierarchically nested random
effects factors study, subject, and subject within treatment. For the assessment of acute
effects of psilocybin, which should occur at t1 and t2 and to a lesser degree at t3 and
t4, the interaction of Drug × Time was considered as the main source of information.
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Longer-lasting psilocybin effects were determined by significant main-effects of drug in
the absence of Drug × Time interactions. P-values were adjusted by Holm’s method in
order to maintain a type I error rate of p < 0.05 over all 30 hypothesis tests arising from
the evaluations of the main effect of drug and the Drug × Time interaction in each of
the 15 subscales.
Subacute side effects measured by the LC were analyzed on the total scale as well
as on the item level. Scores of the total scale were square-root transformed to reduce
positive skew and subsequently analyzed by a linear mixed effects model with the
within-subject factor treatment (placebo, 115-125 , 215, 250, and 315 μg/kg) and the
nested random effects factors study and subject. Differences between all possible pairs
of drug dose conditions were assessed by specifying Tukey’s contrasts and adjusting p-
values by Holm’s method. On the item level, frequency differences of single complaints
between three different doses of psilocybin (125, 215, and 315 μg/kg) were analyzed
by Cochran Q tests using data from studies # 1, 2, and 4. In order to analyze single
complaints in the largest possible sample, we also used McNemar tests to compare
items frequencies on placebo and medium dose psilocybin (215-250 μg/kg) taking data
from 6 studies (study # 1, 2, 4, 5, 6, and 8).
Because all participants had received psilocybin and no control group was available
for comparison on responses to the long-term effects questionnaire, responses were
analyzed with descriptive statistics only. Data of forced-choice items were analyzed
by calculating absolute numbers and proportions of responses, whereas data of free-
response items were either categorized to calculate sum and percentage scores or
summarized in the text.
3.4 results
3.4.1 Sample Characteristics and Drop-Outs
In the studies carried out at our research facility between 1999 and 2008, 227 experi-
mental sessions involving psilocybin administration were conducted. In total, 8 very
low doses (45 μg/kg body weight), 74 low doses (115-125 μg/kg), 104 medium doses
(215-260 μg/kg), and 41 high doses (315 μg/kg) of psilocybin were administered. The
number of subjects who received at least one dose of active psilocybin was 110 (59
males and 51 females). Subjects were between the age of 20 and 47 (M ± SD: 26.9 ±
5.5 years) and exclusively Caucasians. 56% of subjects were university students and
33% were university graduates. 60% of subjects had no prior experience with a classical
hallucinogen (LSD, psilocybin, DMT, or mescaline); 20% had consumed it 1-10 times in a
lifetime; and 20% had consumed it more than 10 times in a lifetime but maximally 6
times per year. 90% of subjects had smoked cannabis at least once in a lifetime.
Of the 110 subjects included in the pooled analysis, seven subjects had prematurely
dropped out after having received at least one dose of active psilocybin. A review
of the study protocols and questionnaire data of these subjects revealed that in two
cases, drop-outs were due to technical reasons and unrelated to drug effects (one
subject moved to another country and another subject had too many EEG-artifacts).
In the remaining five cases, two subjects had an unusually intense reaction to a low
dose of psilocybin and were therefore excluded by the study manager due to safety
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considerations. Another subject experienced a transient hypotonic reaction (systolic
and diastolic blood pressure: 86/63 mm/Hg) with dizziness, fainting, and vomiting
after having received 115 μg/kg of psilocybin and was therefore also excluded from
further psilocybin experiments. The remaining two subjects prematurely terminated the
study of their own accord after the high dose psilocybin session. Both subjects reported
having had experiences of strong anxiety, fear of loss of ego control, emerging negative
memories, and thoughts during acute drug effects and were therefore not willing to
participate in further psilocybin sessions. All five adverse drug reactions leading to a
premature termination of the study were confined to the acute phase of drug effects
and were completely resolved by the end of the experimental day.
3.4.2 Acute Psychological Effects
3.4.2.1 Dimensions of ASCs
Psilocybin significantly increased scores of all 5D-ASC scales [main effects of drug in
order of significance: VRS: F(5, 219) = 100.47, p < 0.001; G-ASC: F(5, 219) = 89.34, p <
0.001; OBN: F(5, 219) = 59.93, p < 0.001; VIR: F(5, 219) = 47.08, p < 0.001; AUA: F(5, 219) =
23.01, p < 0.001; DED: F(5, 219) = 21.53, p < 0.001]. Dose-dependent effects of psilocybin
on the sub-scale level are illustrated in Figure 2. Means and standard deviations of
each 5D-ASC in each dose condition is available in Supplementary Table S1. One-tailed
Dunnett’s contrasts detected significant differences between placebo and all drug dose
conditions in all 5D-ASC scales, except for the 45 μg/kg dose condition, which was not
significantly different from placebo in any of the 5D-ASC scales.
Graphical representations of drug effects by locally weighted scatter plot smoothing
curves indicated dose-response-relationships that were reasonably well approximated
by linear functions in all scales of the 5D-ASC. The notion of linear dose-response
relations was also supported by the results of orthogonal polynomial contrasts, which
showed highly significant effects for the linear trends in all 5D-ASC scales. Furthermore,
when dose was treated as a continuous variable in the linear mixed effects models,
regression slopes for doses were significantly different from zero in all 5D-ASC scales.
The regression slope for dose was highest with the dependent variable VRS (estimate ±
SE; 0.154 ± 0.010) followed by OBN (0.117 ± 0.008), VIR (0.100 ± 0.014), DED (0.079 ±
0.010), and AUA (0.047 ± 0.010). Thus, for an increase of 100 μg/kg of psilocybin, the
regression model predicted an average increase of 15% in the VRS, 12% in the OBN, and
8% in the DED scale.
Cumulative distributions of the three aetiology independent dimensions of ASCs for
each of four doses of psilocybin and placebo are displayed in Figure 3. As can be
seen from the plot, the cumulative distributions for all psilocybin doses were relatively
smooth over the whole ranges of the response variables indicating widely varying
individual responses. The proportions of subjects experiencing strong drug effects
(scores > 70% of the maximum possible score) were clearly dose dependent. In the
highest dose condition, 22% of subjects reached or exceeded the cut-off value for strong
OBN, whereas only 5.7%, 7.8%, and 0% of subjects experienced such a strong effect in the
250-260, 215, and 115-125 μg/kg psilocybin dose conditions, respectively. Experiences of
pronounced DED occurred in relatively few subjects and were only observed in the two
highest dose conditions. Specifically, 7.3% and 5.7% of subjects reached or exceeded the
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Figure 2: Dose-dependent percentage scores of item clusters from the Five Dimensions of Altered
States of Consciousness (5D-ASC) rating scale. Error bars represent standard errors.
Ratings were obtained during peak drug effects (60-270 min after drug administration).
Double click here to extract the data underlying this plot.
cut-off-value for DED in the 315 and 250-260 μg/kg condition, respectively. Finally, the
number of subjects exhibiting high to very high VRS scores amounted to 19.6%, 7.5%,
7.8%, and 1.3% in the 315, 250-260, 215, and 115-125 μg/kg dose conditions, respectively.
3.4.2.2 Eigenschaftswörterliste 60-S (EWL-60-S)
Psilocybin induced changes in affective mood states and conditions over four different
time periods are summarized in Figure 4. Mixed effects models fitted for each of the 15
EWL-60-S subscales revealed significant Drug × Time interactions for emotional excitation
[F(3, 284 = 12.54, p < 0.001], dreaminess [F(3, 284) = 11.62, p < 0.001], heightened mood
[F (3, 284) = 9.23, p < 0.001], dazed state [F(3, 284) = 6.59, p = 0.005], sensitivity [F(3, 284)
= 5.64, p = 0.015], concentration [F(3, 284) = 4.98, p = 0.032], and tiredness [F (3, 284) =
4.74, p = 0.041]. Interaction plots indicated that all significant interaction effects, except
for tiredness, were produced by stronger drug effects on early measuring time points
relative to later time points and hence represent acute drug effects. The interaction
effect for tiredness was produced by stronger drug effects on later measuring time
points relative to earlier time points and hence represents a psilocybin after effect.
Significant main effects of drug in the absence of significant Drug × Time interactions
were detected for introversion [F(3, 284) = 60.96, p < 0.001], inactivation [F(3, 284) =
50.82, p < 0.001], efficiency-activation [F(3, 284) = 38.92, p < 0.001], extroversion [F(3,
284) = 12.40, p = 0.014], and apprehension-anxiety [F(3, 288) = 12.36, p < 0.001]. Since
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Figure 3: Cumulative distributions of the three aetiology-independent dimensions of the Five
Dimensions of Altered States of Consciousness (5D-ASC) rating scale for each of four
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Figure 4: Time-dependent effects of medium-dose psilocybin (215-260 μg/kg) on mood states
and condition measured by the Eigenschaftswörterliste 60-S (EWL-60-S). Paired dif-
ferences between placebo and psilocybin conditions for each time and variable com-
bination were divided by their standard deviations in order to express psilocybin
effects in units of Cohen’s d effect size. By convention, Cohen’s d of 0.2, 0.5, and
0.8 are termed small, medium, and large effect sizes, respectively. Error bars denote
Bonferroni-corrected 95% confidence intervals of mean differences. Thus, mean differ-
ences between placebo and psilocybin are significant, where error bars do not include
zero. Double click here to extract the data underlying this plot.
these drug-effects were independent of measurement time, they represent longer-lasting
psilocybin-effects.
3.4.3 Short-Term Side Effects
Global scores of the List of Complaints measured 24 h after drug intake were dependent
on drug condition [F(5, 159) = 9.64, p < 0.001]. All pair-wise comparisons between
placebo and active psilocybin conditions were statistically significant except for the very
low dose psilocybin condition. No comparison between any of two active psilocybin
dose conditions was statistically significant. Single complaints registered 24 h after
psilocybin administrations are summarized in Table 2. Item-level comparisons between
three different psilocybin doses and placebo by Cochran Q tests revealed significant
46 acute, subacute and long-term subjective effects of psilocybin
Table
2:List
of
C
om
plaints,24
h
A
fter
D
rug
Intake
D
ose
effect
relation
(n
=
40)
M
edium
dose
com
parison
(n
=
72)
Placebo
115
μg/kg
215
μg/kg
315
μg/kg
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p-value
b
Signif
Fatigue
12.5%
(
5)
40.0%
(16)
35.0%
(14)
60.0%
(24)
<
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(
9)
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Fast
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(
1)
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5)
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0.064
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0.371
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0.0%
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differences for the items fatigue, headaches, lack of energy, difficulty concentrating,
“gone feeling”, lack of appetite, and heavy or tired legs.
Item-level comparisons of the List of Complaints responses in the largest possible
sample (i.e., medium dose psilocybin vs. placebo) by McNemar tests indicated increased
fatigue, exhaustion, lack of energy, difficulty concentrating, and “gone feeling” after
psilocybin administration. However, if a Holm-correction for multiple comparisons
is applied, only the items fatigue, headaches, and lack of energy in the dose-effect
comparison remain statistically significant. Serious complications, such as fear of death,
shortness of breath, feelings of suffocation, vomiting, and fainting, which were also
covered by the questionnaire, were not reported by any of the subjects.
3.4.4 Long-Term Follow-Up
Long-term follow-up questionnaires were completed by 90 of 110 subjects (82%). 20
subjects were either unavailable due to address change or unresponsive. Chi-square
and Welch’s t tests indicated that those subjects who completed the follow-up ques-
tionnaire were not statistically different from subjects who did not with respect to age,
gender, education, 5D-ASC, and list of complaints scores. Subjects completed follow-up
assessments between 8 and 16 months after their last experimental day (M ± SD: 330 ±
90 days).
3.4.4.1 Retrospective ratings of acute drug effects and changes in values and attitudes
Retrospective ratings of acute drug effects are summarized in Table 3, whereas
changes in values and attitudes are shown in Table 4.
3.4.4.2 Changes in drug consumption habits
Changes in consumption habits of the most often used psychotropic substances are
summarized in Table 5. Most subjects reported unchanged consumption habits for
all drugs. Those subjects who did report changes more often described decreased
consumption. Even for psilocybin itself, more subjects reported to have consumed it
less often (5.6%) than more often (3.3%). Of the three subjects who described increased
psilocybin consumption, two subjects reported to consume it twice a year and one three
times per year. Except for alcohol, nicotine, and cannabis, no drug was used more
often than once per month on average. From the twenty-nine subjects who reported
changes, seven subjects (24%) considered the change as a direct consequence of their
hallucinogen experience. One of these seven reported decreased substance consumption,
another reported increased, and five reported both increased and decreased.
3.4.4.3 Spontaneous alterations of consciousness and flashbacks
Nine subjects (10%) reported spontaneously occurring ASCs before and eight (9%) after
the experiments. Three of these subjects reported experiencing spontaneous ASCs both
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Table 3: Acute Drug Effects
Adjective Subjects
n = 90
pleasant
very 49% (43)
medium 43% (38)
no 8% ( 7)
enriching
very 61% (53)
medium 29% (25)
no 10% ( 9)
frightening
very 5% ( 4)
medium 28% (24)
no 68% (59)
unpleasant
very 10% ( 9)
medium 24% (21)
no 66% (57)
influential
very 22% (19)
medium 45% (39)
no 33% (29)
nothing special
very 4% ( 3)
medium 11% ( 9)
no 85% (70)
Numbers after percents are frequencies.
before and after the experiments. Spontaneous ASCs before the experiments included
out-of-body-experiences during meditation and sleep, trance-like states while deeply
concentrating, euphoric experiences in nature, perceptual alterations in very dark or
bright environments, lucid dreams, hearing voices under high fever, and hypnagogic
hallucinations. All these alterations lasted a few seconds to no more than one hour,
occurred a few times in a lifetime to no more than once per month, and were limited to
specific triggers. They were not experienced as threatening and they did not interfere
with subjects’ everyday lives. Thus, they cannot be interpreted as psychopathological
symptoms.
Spontaneous ASCs after the experiments could not be distinguished from those before
with respect to frequency, duration, and intensity. Except for one subject who reported
irritability, depressive feelings, anxiety/panic, and dizziness/nausea and who will be
discussed in more detail below, all spontaneous ASCs that occurred after the experiments
were described as non-threatening and without impairment in social, occupational, or
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Table 4: Changes in Attitudes
Change Subjects
n = 90
Changes in world view
positive 18% (16)
unchanged 81% (72)
negative 1% ( 1)
Changes in values
positive 18% (16)
neither 77% (68)
negative 5% ( 4)
Changes in awareness of personal problems
positive 29% (25)
unchanged 66% (57)
negative 5% ( 4)
Change in the relationship to one’s body
positive 30% (26)
unchanged 67% (59)
negative 3% ( 3)
Change in relationhips to other people
positive 25% (22)
unchanged 68% (59)
negative 7% ( 6)
Change in professional relationships
positive 6% ( 5)
unchanged 89% (75)
negative 5% ( 4)
Change in the relationship to the environment
positive 38% (33)
unchanged 58% (51)
negative 5% ( 4)
Change in aesthetic experiencing
positive 37% (32)
unchanged 62% (53)
negative 1% ( 1)
Change in the attitude to ASCs
positive 56% (49)
unchanged 41% (36)
negative 3% ( 3)
Numbers after percents are frequencies.
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Table 5: Change in Drug Consumption
Drug less often more often
Alcohol 6.7% ( 6) 3.3% ( 3)
Nicotine 4.4% ( 4) 2.2% ( 2)
Cannabis 8.9% ( 8) 3.3% ( 3)
MDMA (Ecstasy) 4.4% ( 4) 3.3% ( 3)
Psilocybin 5.6% ( 5) 3.3% ( 3)
Cocaine 4.4% ( 4) 1.1% ( 1)
Amphetamine 2.2% ( 2) 0% ( 0)
Numbers after percents are frequencies.
other important areas of functioning. They were controllable and limited to specific
triggers, such as listening to music, meditating, falling asleep (hypnagogic states),
deeply concentrating, or being in a calm and sensory-deprived environment. In all
subjects, spontaneous ASCs after the experiments were described as lasting a few seconds
to no more than half an hour and occurring infrequently.
Although three subjects reported minor visual alterations, they mostly appeared
after the triggers mentioned above. Moreover, the descriptions of these alterations
were vague and not suggestive of the typical symptoms of Hallucinogen Persisting
Perception Disorder (HPPD) mentioned in DSM-IV (i.e., geometric hallucinations, false
perceptions of movement in the peripheral visual fields, flashes of color, intensified
colors, trails of images of moving objects, after-images of moving objects, macropsia,
and micropsia). Only one subject explicitly mentioned the occurrence of visual illusions
beyond the acute effects of the drug, but they appeared only 5-7 times, lasted no more
than a few seconds at a time, and did not occur after the third day after the drug
session. When asked whether they interpreted their spontaneous ASC as a flashback-like
re-experiencing of drug effects, five subjects (5.5% of those who completed the follow-up
questionnaire and 56% of those who reported spontaneous ASCs after the experiments)
answered affirmatively. However, since we have also obtained detailed descriptions of
these events, including frequency, duration, intensity, and accompanying symptoms
and emotions, there was a clear indication that these five subjects had used the term
flashback in a very broad sense, denoting vague states of intense remembering of drug
effects rather than the criteria described for HPPD in DSM-IV.
3.4.4.4 Negative changes in psychological well-being and/or mental functions
Eleven subjects (12%) reported in the follow-up questionnaire that they had experi-
enced negative changes in psychological well-being and/or mental functions after the
psilocybin experiment. However, four of these eleven reported that the changes were
unrelated to the psilocybin sessions and so they will not be discussed here. Among the
remaining seven subjects (8%), only one reported that his symptoms were alarming
and severe enough for him to contact us and to seek professional help. This was the
same subject who mentioned irritability, anxiety, and depressive feelings in the items
regarding spontaneous ASCs described above. This subject was a 23 year-old medical
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student who presented himself as psychologically stable and with an unremarkable
medical history at screening. There was also no indication of above average emotional
lability according to the FPI questionnaire. During the acute effects of the high psilocy-
bin dose (315 μg/kg), the subject experienced a strong sense of unity, but also intense
feelings of loneliness and fear of losing control of his thoughts and body. 150 min
after drug intake, he reached an DED score of 76% of the theoretical scale maximum,
which is the fourth highest score that we measured in the 227 psilocybin sessions
of the present analysis. After providing strong personal support and reassurance by
the study manager, the subject had calmed down considerably by the second 5D-ASC
measuring time point (300 min after drug intake), reaching only 4% of the maximum
possible score in the DED scale. Nevertheless, the subject was monitored carefully and
not released until 8 h after drug intake when all acute psilocybin effects had fully worn
off. However, since the subject felt uncomfortable over the next couple of weeks, several
appointments were made with the principal investigator. In these meetings, the subject
reported emotional instability, anxiety, and depressive feelings, which he attributed to
suppressed memories, thoughts, and feelings that he had been confronted with during
the psilocybin session. Since the subject was strongly motivated to work through these
issues psychologically, he was referred to an experienced psychotherapist. After a few
sessions of psychotherapy, the subject had completely stabilized and has not relapsed
with the symptoms subsequently.
Among the remaining six subjects who also reported negative changes in well-being
and/or mental functions, the following symptoms were described (with number of
subjects in parenthesis): Concentration problems (2), mood swings (2), reactivation
of old problems (1), memory problems (1), and being pensive and introverted (1).
In all these subjects, symptoms were described to be of low intensity and frequency,
non-interfering with everyday life, and only occurring in the first few weeks subsequent
to the experiments.
3.5 discussion
The present work analyzed acute, short-, and long-term effects of psilocybin in healthy
human subjects by pooling raw data from a large body of well-controlled experimental
studies.
3.5.1 Acute Psychological effects
Consistent with other recent, smaller-scaled studies (Griffiths, Richards, McCann, &
Jesse, 2006; Moreno et al., 2006), the present analysis has shown that psilocybin dose-
dependently induces an ASC, which is characterized by marked alterations in all mental
functions, including perception, mood, volition, cognition, and self-experience. The
most prominent features of the psilocybin-induced ASCs were alterations in visual per-
ception (VRS), followed by positively (OBN) and negatively (DED) experienced alterations
of self-awareness and loosening of ego-boundaries. The changes in visual perception
ranged from increased visual imagery with closed eyes, optical illusions, elementary
hallucinations, and synesthesiae to picture-like scenery hallucinations. However, the
experienced hallucinations were almost always recognized as unreal and therefore are
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more accurately described as pseudo- or nonpsychotic hallucinations. Drug effects
accounting for the substantial increase in the OBN scale, ranged from pleasurable expe-
riences of depersonalization, derealization, and a changed sense of time to phenomena
reminiscent of mystical-type experiences. The modest increase in the DED scale was
primarily due to unpleasant disturbances of cognitive functions and somatesthesia, and
much less so to suspiciousness or paranoid ideation. Reality testing usually remained
intact, and most subjects sustained critical distance (“it is as if”) to their own subjective
experience. The Auditory Alterations (AUA) scale was only moderately affected by
psilocybin, since true auditory hallucinations, such as hearing voices, rarely occurred,
and auditory alterations mostly concerned occasional intensification of music and
sounds or misperceptions of real auditory stimuli. Psilocybin also dose-dependently
increased the Vigilance Reduction (VIR) scale. This observation may come as a surprise,
since lack of sedation and clouding of consciousness is usually considered as one of
the most prominent characteristics of classical hallucinogens. In fact, according to
the classification scheme of Leuner (1981), hallucinogens of the first order (e.g., LSD,
psilocybin, DMT, and mescaline) are differentiated from hallucinogens of the second
order (e.g., ketamine, N2O, and scopolamine) by this very feature. However, it should
be noted that the effect of psilocybin on reduction of vigilance was relatively small and
reflects the psilocybin-induced state of dreaminess, contemplativeness, and reduction
of attentiveness, rather than true sedation or clouding of consciousness.
Cumulative distributions of the 5D-ASC major scales revealed widely varying individ-
ual responses. For instance, whereas one subject experienced strong effects on the low
dose condition (63% of the possible maximum of the global scale), two subjects noticed
almost no effects on the highest dose condition (below 5% of the possible maximum).
The high inter-subject and moderate inter-study variability of the pooled analysis sup-
ports the view that psilocybin effects are poorly predicted by drug dose alone and that
other pharmacological variables, such as plasma levels of the active metabolite psilocin,
as well as non-pharmacological variables - notably expectations, personality structure,
interpersonal support, and environment - likely play a very important role (Rinkel,
DiMascio, Robey, & Atwell, 1961; Metzner, Litwin, & Weil, 1965; Dittrich, 1994; Johnson,
Richards, & Griffiths, 2008). The significance of such potential non-pharmacological
predictors will be analyzed and presented in a separate publication.
Dose-response relationships for all major scales of the 5D-ASC were approximately
linear. Since no ceiling effect has been observed within the administered dose range
(45-315 μg/kg body weight), it is conceivable that psilocybin doses exceeding 315 μg/kg
would have produced even stronger subjective drug effects. This view is supported
by a recent study of Griffiths, Richards, McCann, and Jesse (2006), in which subjective
drug effects were measured by the APZ questionnaire in 36 healthy volunteers who had
received 429 μg/kg psilocybin. By estimating 5D-ASC from APZ scores through linear
equations (Bodmer, 1999), we have found higher OBN and VRS scores in the study of
Griffiths than in the highest dose condition of our studies. Furthermore, in the study
of Griffiths, 61% of subjects fulfilled Pahnke’s criteria for having a ‘complete’ mystical
experience (Pahnke, 1969), which seems to be a considerably larger proportion than
we have observed in the highest dose condition. Although we have used a different
methodology and therefore cannot directly compare results, we have found that only
22% of subjects in the high-dose condition exceeded the cut-off value of the OBN scale
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suggestive of deep mystical or transcendent experiences. However, it should it be noted
that, in addition to the higher drug doses in the study of Griffiths, several other factors
might have contributed to these differences. First, the investigation of transformative
peak experiences has not been the primary goal of our research program. Hence,
our studies have not been designed in a way that the occurrence of such profound
experiences is most likely. Whereas volunteers in the study of Griffiths were instructed
to focus explicitly on the phenomenology of the drug experience and were left essentially
undisturbed during their whole psilocybin session, subjects of our studies were engaged
in performing tasks for a considerable amount of time. Second, none of the subjects in
Griffith’s study had previous experience with a hallucinogenic drug, whereas in our
studies about 40% of subjects had previous experience with a classical hallucinogen
(LSD, psilocybin, DMT, or mescaline) and almost 90% had smoked cannabis at least
once in a lifetime. Third, the subjects in Griffith’s study were middle-aged (46 years
on average) and spiritually active, whereas our subjects were predominantly students,
considerably younger (27 years on average), and not selected for being spiritual.
Despite extremely careful preparation, selection, and interpersonal support of subjects,
there also seems to have occurred more acute adverse reactions in the study of Griffiths
than in our studies. Griffiths reports that 31% of subjects experienced significant fear
and 17% had transient ideas of reference/paranoia, whereas in our studies only 7%
of subjects in the highest dose condition fulfilled the criteria for strong dread of ego
dissolution, which is suggestive of acute psychotic reactions. Although these adverse
reactions were confined to the acute phase and were readily managed by providing
interpersonal support without psychopharmacological intervention in all cases of both
research groups, they provide a cautionary note on high-dose psilocybin studies. Clearly,
careful selection of subjects and environment and thorough preparation and monitoring
of subjects is extremely critical in high-dose psilocybin sessions.
The results of our analysis of the time-course of subjective effects measured by
the EWL-60-S indicate that the effects follow differential time courses, which are not
necessarily paralleled by psilocybin plasma levels (Hasler, Bourquin, Brenneisen, Bär, &
Vollenweider, 1997). Whereas the effects of psilocybin on emotional excitation, sensitivity,
heightened mood, and concentration reached their maximum in an early phase (60-
180 min after drug intake), the effects on dreaminess, dazed state, inactivation, and
introversion were more pronounced in a later phase (260-400 min). The results are
consistent with a study of Heimann (1961), in which expressive phenomena, such
as changes in facial expression, voice, and posture, were analyzed by use of video
recording in 12 healthy volunteers who had received 0.06-0.19 μg/kg psilocybin on
two experimental days. Heimann observed that subjects were more active, emotional,
vivid, extroverted, and cognitively impaired in the early phase of the psilocybin session
relative to the later phase and that derealization and depersonalization phenomena
began to dominate over visual alterations about 90-120 min after drug intake. During
this later phase, subjects also increasingly turned inwards and appeared to be in a state
of absent-mindedness with markedly reduced facial expression.
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3.5.2 Short-Term Side Effects
Our pooled analysis further revealed that the administration of psilocybin caused
only few subacute side-effects, as measured by the LC questionnaire 24 h after drug
intake. Furthermore, those complaints that were reported significantly more often after
psilocybin than after placebo concerned relatively mild conditions. Except for headaches,
all significantly affected items described symptoms of tiredness and exhaustion. Serious
complications were not reported in any of the subjects. The reported after-effects of
the LC questionnaire closely match the changes seen in the EWL-60-S questionnaires
24 h after drug intake, namely, a moderate increase of tiredness and reduction of
activation. The results of our analysis therefore suggest that psilocybin is usually well
tolerated and that normal functioning is almost completely restored within 24 h after
drug administration. These findings are in line with an investigation of Hollister (1961),
which measured after effects of the administration of 36-205 μg/kg psilocybin to 17
subjects in 27 separate trials and also found occasional headaches and fatigue as being
the most frequent complaints. Furthermore, our results are consistent with extensive
tests in animals and humans, which found that psilocybin may be considered to be
physiologically well tolerated (for a review, see Passie, Seifert, et al., 2002).
3.5.3 Long-Term Follow-Up
3.5.3.1 Retrospective ratings of acute drug effects
At the time of the long-term follow-up 8-16 months after the last experimental session,
the majority of subjects were still positively impressed by the psilocybin experience.
When subjects were asked to rate the acute psilocybin effects by six descriptive items,
“enriching” was considered as most applicable. Over 60% of subjects rated the ex-
perience as very enriching and over 90% as enriching to at least a medium degree.
Interestingly, several of our subjects rated the psilocybin experience as very enriching
even though they had experienced significant distress during the acute phase. For
instance, among the sixteen subjects who had an DED score of more than 50% of the
maximum possible score, four subjects (25%) did not respond to the follow-up ques-
tionnaire, nine subjects (75% from those who responded) rated the experience as very
enriching, two (17%) as medium enriching, and only one subject (8%) as not enriching.
The positive long-term resolution of acute distressful experiences by the majority the
subjects might be partially explained by the strong support provided by our monitors,
with whom subjects were able to talk freely about disturbing thoughts, feelings, and
memories that had arisen during the session. A significant number of our subjects
reported not only enriching but also influential drug experiences. Our results are
therefore in support of a recent follow-up study by Griffiths, Richards, Johnson, et al.
(2008), in which psilocybin was found to facilitate experiences having enduring personal
meaning and spiritual significance.
3.5.3.2 Changes in values and attitudes
Anecdotal reports and preliminary evidence from small-scaled experimental studies
suggest that hallucinogenic drugs, when used under carefully controlled and supportive
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conditions, sometimes can lead to sustained positive changes in personality, attitudes,
and values, particularly in those subjects who have experienced profound personal
insights and transcendent or mystical-type experiences. Among the most often reported
subjective changes in attitude and personality are more self-understanding, more
tolerance of others, less egocentricity, a less materialistic and aggressive orientation, and
more appreciation of music, art, and nature (McGlothlin & Arnold, 1971). Subjective
changes in attitudes reported in the long-term follow-up questionnaire of the present
study are consistent with results of earlier follow-up studies (McGlothlin, Cohen, &
McGlothlin, 1967; Doblin, 1991; Griffiths, Richards, Johnson, et al., 2008). We have
found the highest percentages of subjects reporting positive changes in items measuring
the attitude to ASCs (56% of subjects), relations to the environment/nature (38%), and
aesthetic experiencing (37%). The observation that aesthetic experiencing (e.g., enhanced
appreciation of art and music) was amongst the most often reported positive changes is
particularly interesting in light of an earlier placebo-controlled study by McGlothlin,
Cohen, and McGlothlin (1967), which measured long-lasting effects of three high-dose
LSD sessions in 24 healthy volunteers. In this study, greater appreciation of music
(67% of subjects) and art (46%) were the most frequently reported subjective changes
six months after the LSD experiments. Furthermore, these subjective evaluations were
supported by certain behavioral changes, such as increase in number of records bought,
time spent in museums, and number of musical events attended.
Given the positive changes in attitudes and values reported by a relatively large
proportion of subjects, it would be tempting to conclude that hallucinogenic drugs
hold a large and presently unused potential for increasing life-satisfaction and personal
growth and for assisting psychotherapy. However, our results should be considered as
exploratory in nature because possible changes have not been measured by validated
questionnaires and no attempt has been made to correlate subjective changes with
behavioral measures or information provided by close relatives and friends. Therefore,
we cannot rule out the possibility that the reported changes are biased towards precon-
ceived opinions and expectations of subjects. Caution is especially warranted since it
has been demonstrated that positive changes in personality, attitudes, and values are
often attributed to the hallucinogen experience in subjects who have shown a previous
interest in hallucinogenic drugs, but not in subjects whose hallucinogen intake was
initiated by their psychotherapist (McGlothlin & Arnold, 1971).
3.5.3.3 Changes in drug consumption habits
Changes in drug use patterns that were reported in the follow-up questionnaires of
the present study were generally benign and well within expected ranges. Our results
therefore indicate that a carefully-monitored administration of 1-4 doses of psilocybin
to healthy volunteers within an experimental setting does not increase the risk for
subsequent abuse of psilocybin or other illicit drugs. Our results are consistent with
the widely accepted view that classical hallucinogens have a very low abuse potential.
Classical hallucinogens are not typically considered as drugs of addiction because they
neither produce compulsive drug-seeking behavior nor physical withdrawal symptoms
(O’Brian, 2005). They also cannot be considered as reinforcing substances because they
fail to engender reliable self-administration behavior in laboratory animals (Deneau,
Yanagita, & Seevers, 1969; Fantegrossi, Murnane, & Reissig, 2008). The view that
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classical hallucinogens lack addictive qualities is further supported by epidemiological
evidence. Recent general population survey data on lifetime prevalence of use of
hallucinogenic mushrooms in 12 EU Member States indicate that among young people
aged 15 to 24 years old, lifetime use of hallucinogenic mushrooms ranges from less
than 1% to 8% (Hillebrand, Olszewski, & Sedefov, 2006). Although psilocybin has, after
cannabis, one of the highest lifetime prevalence rates of all illicit drugs, the proportion
of recent (last 12 months) or current (last month) users is much lower for the use of
psilocybin than it is for cannabis and ecstasy. This observation suggests that the use of
hallucinogenic mushrooms, like LSD, tends to be occasional, or discontinued after some
time. Regular use of classical hallucinogens is unlikely because tolerance to the effects
rapidly develops after three to four daily doses (O’Brian, 2005). Furthermore, the intake
of classical hallucinogens, especially in higher doses, is unattractive to many recreational
drug users because it does not consistently produce any of the pleasurable effects of
addictive drugs, such as escape, euphoria, anxiety relief, increase of self-esteem etc.
Although our experiments have shown that psilocybin can evoke highly-valued and in
some cases even mystical-type experiences, subjects occasionally are also confronted
with frightening and unpleasant thoughts, memories, and emotions. Moreover, as
we have measured by the LC and EWL-60-S questionnaires, most subjects describe the
psilocybin effects as tiring. This effect is further reflected by the observation that after
3-5 h the ‘coming-down’ from the psilocybin-effects, even if it has been a pleasant
experience, is usually welcomed, and that most subjects are glad to regain their normal
state of consciousness. Subjects often reported they were ‘saturated’ by new impressions
and expressed the need to psychologically integrate their experience before they would
consider repeating it.
Our findings are in line with a 10-year follow-up study by McGlothlin and Arnold
(1971), which examined 247 subjects who had received LSD in either an experimental
or therapeutic setting. As in our study, most subjects reported to have discontinued or
reduced their frequency of hallucinogenic drug use. The most often reported reasons
for discontinuation were concerns about possible harm or illegality followed by a loss
of interest. McGlothlin therefore speculated that in many subjects, hallucinogenic
drugs lose their appeal over time simply because the uniqueness of the new modes of
perception and thought that occur with them being often the primary incentive to take
them in the first place is lost after repeated ingestion.
3.5.3.4 Spontaneous alterations of consciousness and flashbacks
Among the most often reported long-term sequelae of hallucinogenic drug use is a
sudden and unexpected reoccurrence of all or certain aspects of the hallucinogenic
effects, long after the drug should have worn off. The phenomenon has been first
described by (Sandison, 1954) and is often referred to as ‘flashback’. However, since its
first description in the scientific literature (Horowitz, 1969), the term ‘flashback’ has been
defined in so many ways that much confusion exists about its characteristics, prevalence,
and aetiology (cf. Halpern & Pope, 2003). The present study avoided methodological
inconsistencies of earlier follow-up studies and contributes to a better understanding
of flashback phenomena after psilocybin administration by using operational criteria
consistent with those of DSM-IV (‘Hallucinogen Persisting Perception Disorder’ (HPPD),
292.89) and ICD-10 (‘Flashbacks’, F16.70).
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Detailed questions about possible flashback phenomena and spontaneous ASC in
the follow-up questionnaire of the present study indicated that none of our subjects
fulfilled diagnostic criteria for HPPD in DSM-IV or flashbacks in ICD-10. Furthermore,
none of our subjects described visual phenomena reminiscent of the typical symptoms
of HPPD mentioned under criterion A of HPPD in DSM-IV (292.89). Our results support
the view that HPPD and other troubling perceptual abnormalities rarely occur in a
therapeutic or research context, where subjects are carefully screened and monitored
and judicious doses of pharmaceutical quality drugs are given (Strassman, 1984; Halpern
& Pope, 2003). The clinical relevance of flashback phenomena has been a matter of
controversial debate for several decades. Whereas some researchers report virtually no
such phenomena in series of hundreds or thousands of cases (Cohen, 1960; McGlothlin
& Arnold, 1971), others report incidence rates as high 33% (Moskowitz, 1971) and 77%
(Holsten, 1976) among individuals who have taken LSD. A recent review by Halpern
and Pope (2003, pp. 116), which analyzed 20 quantitative studies reporting flashback
phenomena, concludes that “the data do not permit us to estimate, even crudely, the
prevalence of ‘strict’ HPPD”. Halpern and Pope (2003) point out that most of these studies
were published before operational diagnostic criteria for HPPD had been established and
therefore used a wide variety of methodologies. They further criticize that confounding
factors such as recent drug intake, polydrug abuse, preexisting psychiatric disorders,
and comorbidity often have been very poorly controlled in the studies.
It should also be noted that the scientific basis for the classification of HPPD in DSM-IV
appears to be formed almost exclusively by the research of Abraham and his colleagues
(1982; 1983; 1988; 1996; 2001). Since the majority of Abraham’s work was focused solely
on LSD use, we cannot safely infer that the diagnosis of HPPD has equal implications for
all classical hallucinogenic drugs. Interestingly, very few case reports have appeared on
flashback-phenomena experienced by individuals who have used psilocybin, DMT, or
mescaline exclusively. In fact, Hermle, Kovar, et al. (2008) report in a recent review that
there exists only one case report (Espiard, Lecardeur, Abadie, Halbecq, & Dollfus, 2005)
where HPPD occurred after hallucinogenic mushroom use.
3.5.3.5 Prolonged adverse reactions
The present study supports the notion that prolonged adverse reactions, such as
persisting psychosis or depression, are exceedingly rare when psilocybin is administered
to well-adjusted subjects in a controlled experimental setting (Strassman, 1984; Abraham
and Aldridge, 1993; El-Mallakh et al., 2008). We have found no incidences of prolonged
psychotic reactions or precipitations of schizophrenia-spectrum disorders in the 110
subjects studied. However, one of our subjects experienced symptoms of emotional
instability, anxiety, and depression, which lasted several weeks and were severe enough
for him to seek professional help. A few subjects described occasional mood swings,
reactivation of old problems, excessive pensiveness and introversion, and memory
and concentration problems in the first few weeks after the drug session. Although
these adverse after-effects were generally benign and in all cases resolved after a few
weeks, they underline the importance of careful debriefing and follow-up of subjects –
especially in the first few days and weeks after drug administration.
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3.5.4 Limitations
It is important to note that the high degree of safety and tolerability of psilocybin
reported in the present study cannot be generalized to situations in which psilocybin is
used recreationally or administered under less controlled conditions. It is likely that the
careful selection, preparation, and monitoring of subjects as well as the administration
of predominantly moderate drug doses have largely contributed to the relatively low
occurrence of adverse events in our studies. Our sample might be unrepresentative not
only due to exclusion of subjects showing potential risk factors (high emotional lability,
history of drug abuse, psychiatric illness, and hereditary risk factors) at screening, but
also due to the use of a recruitment method that is prone to self-selection bias. The
subjects who volunteered for our studies had prior knowledge that experiments would
involve psilocybin administration. Hence, it is likely that individuals who had a positive
attitude towards hallucinogenic drugs and who had a personal interest in experiencing
drug-induced ASCs were more likely to participate in our experiments. McGlothlin
and Arnold (1971) have shown that subjects who are interested in hallucinogenic drug
use are susceptible to naturally occurring ASCs, seek to encourage them through both
drug and non-drug methods, and have a certain type of personality structure. Indeed,
although our subjects were not selected for previous drug-experience, 40% had used
a classical hallucinogen at least once in a lifetime prior to the experiments, which is a
larger proportion than in the general population.
Although previous experience, positive expectancy, and personality characteristics
might have biased subjective drug effects, it may also have contributed to the low
occurrence of adverse events. Subjects who expect positive psilocybin effects tend to
experience more positive psilocybin effects, whereas anxiety and preoccupation before
drug administration not only increases the likelihood of unpleasant experiences, but also
the number of somatic complaints (Metzner et al., 1965). Moreover, emotional lability
and rigid conventionality – personality traits that tend to be below average in our
sample – are positively correlated with DED (Dittrich, 1994). Since safety and tolerability
considerations, in our opinion, are more important than methodological rigor, we have
not sought to maximize the representativeness of our sample by excluding subjects who
had some experience with hallucinogenic drugs – unless they used them on a regular
basis. In fact, subjects with a few past experiences were considered ideal because they
probably would not have volunteered if they had had significant adverse reactions. This
policy has also been proposed by Gouzoulis-Mayfrank, Schneider, et al. (1998).
Apart from the lack of representativeness, our investigation has further limitations.
First, cut-off values used to measure the proportion of subjects experiencing very strong
subjective drug effects – although similar to specifications used by Pahnke (1969) – are
relatively arbitrary, since they neither have been defined a priori nor validated on clear-
cut criteria. Second, we have used an investigator-constructed follow-up questionnaire
whose reliability and validity is not known.
3.5.5 Conclusion
Taken together, our experimental data from 227 psilocybin administrations have demon-
strated safety and tolerability not only acutely, but also in the long run. We found
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no indication for subsequent drug abuse, persisting perception disorders, prolonged
psychosis, or other long-term impairments of functioning in any of our subjects. Acute
adverse reactions (so called ‘bad’ or ‘horror trips’) occurring in a small proportion of
subjects in the two highest dose conditions as well as transient emotional instability
lasting a few days or weeks in a small number of subjects remain the biggest concerns
in psilocybin administration. However, given that all of these adverse reactions resolved
by providing strong interpersonal support and appeared to be positively integrated
at the long-term follow-up, 8-16 months after the drug experiments, we conclude that
psilocybin administration to healthy, high-functioning, and well-prepared subjects in a
responsible clinical or research setting is generally well-tolerated and that future studies
using this important research tool are justified.

4
P S Y C H O M E T R I C E VA L U AT I O N O F T H E A LT E R E D S TAT E S O F
C O N S C I O U S N E S S R AT I N G S C A L E O AV
4.1 abstract
The OAV questionnaire has been developed to integrate research on altered states of
consciousness ASCs. It measures three primary and one secondary dimensions of
ASCs that are hypothesized to be invariant across ASC induction methods. The OAV
rating scale has been in use for more than 20 years and applied internationally in
a broad range of research fields, yet its factorial structure has never been tested by
structural equation modeling techniques and its psychometric properties have never
been examined in large samples of experimentally induced ASCs. The present study
conducted a psychometric evaluation of the OAV in a sample of psilocybin (n = 327),
ketamine (n = 162), and MDMA (n = 102) induced ASCs that was obtained by pooling data
from 43 experimental studies. The factorial structure was examined by confirmatory
factor analysis, exploratory structural equation modeling (ESEM), hierarchical item
clustering (ICLUST), and multiple indicators and multiple causes (MIMIC) modeling. The
originally proposed model did not fit the data well even if zero-constraints on non-target
factor loadings and residual correlations were relaxed. Furthermore, ICLUST suggested
that the “Oceanic Boundlessness” and “Visionary Restructuralization” factors could be
combined on a high level of the construct hierarchy. However, because these factors
were multidimensional, we extracted and examined 11 new lower order factors. MIMIC
modeling indicated that these factors were highly measurement invariant across drugs,
settings, questionnaire versions, and sexes. The new factors were also demonstrated to
have improved homogeneities, satisfactory reliabilities, discriminant and convergent
validities, and to differentiate well among the three drug groups.
4.2 introduction
Altered states of consciousness (ASCs) represent a marked deviation in the subjective
experience or psychological functioning of a normal individual from her/his usual
waking consciousness (Dittrich, 1998). As opposed to psychiatric diseases, ASCs are
short-lasting. They are usually self-induced (e.g., by hallucinogenic drugs, meditation,
hypnosis), but may also occur spontaneously in everyday life (e.g., hypnagogic states).
Although ASCs are by definition different from psychiatric diseases, the study of ASCs
in healthy volunteers has a long tradition of generating hypotheses for psychiatric
research.
Dittrich’s APZ questionnaire and its revised versions, OAV and 5D-ASC, are among
the most widely used self-report questionnaires for assessing subjective experiences
of ASCs in retrospect. Although originally developed in German, these questionnaires
have been translated into many different languages and applied internationally in
approximately 70 experimental studies. The majority of these studies have used these
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questionnaires to assess ASCs induced by psycho-active drugs, particularly psilocybin
(e.g., Griffiths, Richards, McCann, & Jesse, 2006), ketamine (e.g., Northoff et al., 2005),
MDMA (e.g., Hasler, Studerus, et al., 2009), and N,N-dimethyltryptamine (DMT; e.g.,
Gouzoulis-Mayfrank, Heekeren, Neukirch, et al., 2005), but several studies have also
assessed non-pharmacologically induced ASCs, such as ASCs induced by endogenous
psychosis (e.g., Gouzoulis-Mayfrank, Habermeyer, et al., 1998), sensory deprivation
(Kjellgren, Sundequist, Sundholm, et al., 2004), mind machines (Walach & Käseberg,
1998), and monochrome sounds (Hübner, 2007). The three versions of Dittrich’s ASC
questionnaires have been successfully applied to differentiate the subjective effects
of different ASC induction methods (e.g., Dittrich, von Arx, & Staub, 1985; Dittrich,
1994); to characterize dose-response relationships (Hasler, Grimberg, et al., 2004); and
to map first person accounts of ASCs to various neuronal, psychophysiological, and
behavioral measures of ASCs, including measures of positron emission tomography (PET;
e.g., Vollenweider, Vontobel, Hell, & Leenders, 1999), functional magnetic resonance
imaging (e.g., Northoff et al., 2005), and electroencephalography (EEG; e.g., Umbricht,
Koller, et al., 2002).
The original version, APZ, contains 158 dichotomous items covering a broad range of
phenomena potentially occurring during ASCs. It was originally developed by Dittrich
(1975b, 1985, 1996, 1998) in order to test the hypothesis that ASCs – independent of their
means of induction – have features in common that can be parsimoniously described on
stable (i.e., etiology-independent) major dimensions. Dittrich (1985) reasoned that if this
hypothesis could not be falsified for a broad range of ASC induction methods, integration
of phenomenological, psychophysiological, and neurobiological research on ASCs would
be greatly enhanced. For example, the detection of features that are common/invariant
for all ASCs and at the same time differentiate them from normal waking consciousness
would help to lay the foundation for a more coherent definition of the term ASC.
Furthermore, because these common features of ASCs would remain indicators of the
same underlying constructs across different ASC induction methods, ASCs could be
characterized and compared by their relative standing on stable etiology-independent
latent dimensions. Moreover, establishing such dimensions would eventually lead to an
empirical taxonomy of ASCs.
Dittrich (1985) tested his hypothesis in a series of experimental studies, in which
healthy volunteers were treated with one of eleven different ASC induction methods (n
= 259) or control condition procedures (n = 134). The studied induction methods were
divided into four groups: (a) hallucinogens of the first order (i.e., DMT, Psilocybin, and
Δ9-tetrahydrocannabinol); (b) hallucinogens of the second order (i.e., nitrous oxide);
(c) sensory deprivation in a broader sense (i.e., perceptual deprivation, hypnagogic
states, autogenic training, hypnosis); and (d) sensory overload (i.e., stimuli of high
variety). From the 158 items of the APZ, which served as dependent variables, Dittrich
(1985) identified 72 items meeting his criteria of etiology-independency. That is, these
items had a significant proportion of yes-answers in each group of ASC induction
methods and differentiated significantly between treatment and control conditions.
By analyzing the correlation matrices of the 72 etiology-independent items using
exploratory factor analysis (EFA) and cluster analysis and based on considerations
of stability, reliability, and interpretability, Dittrich (1985) determined three oblique
primary and one secondary etiology-independent dimensions. The three primary
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dimensions were termed Oceanic Boundlessness (OBN), Dread of Ego Dissolution
(DED), and Visionary Restructuralization (VRS). The OBN scale basically includes items
measuring positively experienced depersonalization and derealization, deeply-felt
positive mood, and experiences of unity. High scores on the OBN scale therefore indicate
a state similar to mystical experiences as described in the scientific literature on the
psychology of religion (e.g., Stace, 1961). The DED scale includes items measuring
negatively experienced derealization and depersonalization, cognitive disturbances,
catatonic symptoms, paranoia, and loss of thought and body control. High scores
on the DED scale therefore indicate a very unpleasant state similar to so called “bad
trips” described by drug-users. The VRS scale contains items measuring visual (pseudo)-
hallucinations, illusions, auditory-visual synesthesiae, and changes in the meaning of
percepts. The secondary scale (G-ASC) consists of the 72 etiology-independent items
and can be interpreted as a general measure of consciousness alteration. The validity
of the experimental results in the field and the invariance of the factorial structure
across different language versions of the APZ was examined and confirmed in a large
international study on ASCs (Dittrich, von Arx, & Staub, 1985), in which 1133 subjects
from six different countries and four different languages completed the APZ in reference
to their most recent ASC that they had experienced within the past 12 months.
Although reliabilities and validities of APZ scales were deemed to be acceptable in the
experimental as well as in the field studies, several weaknesses were also recognized.
For example, the binary item response format of the APZ was too crude to measure
subtle alterations of consciousness. Furthermore, the OBN and VRS dimensions contained
a relatively low number of items, and the conceptual breadth of the VRS dimension
was considered too narrow. Bodmer (1989) therefore developed a psychometrically
improved version called OAV. The abbreviation OAV stands for the German names of
the three dimensions OBN, DED, and VRS. Because the OAV was supposed to measure
the primary three dimensions of the APZ only, its item pool was primarily derived
from 72 etiology-independent items of the APZ. However, the response format was
changed from binary to visual analogue, several items were re-worded, some new items
were introduced, and some items were completely dropped. The reformulation of
items aimed not only at reducing cross-loadings, decreasing ambiguity, and enhancing
ease of understanding, but also at widening the conceptual breadth of the OBN and
VRS dimensions. Whereas the OBN dimension was changed toward a more complete
assessment of mystical experiences by incorporating items that were formulated on
the basis of six of the nine categories of mystical experiences proposed by Stace (1961),
the VRS dimension was conceptually widened by incorporating items that measure an
increase of imagination, associations, and memory retrieval. The re-conceptualization
of the VRS dimension was mainly driven by theoretical considerations of Leuner (1962,
1981), who had hypothesized that visual hallucinations are associated with an increased
internal stimulus production. The original OAV validation study of Bodmer (1989),
which was based on 177 subjects retrospectively describing their most recent ASC,
indicated that the questionnaire revision successfully improved several psychometric
properties, including item discriminations, simple structure, and scale reliabilities. High
correlations of OBN, DED, and VRS scales across the two questionnaire versions suggested
that these scales measure similar constructs in both questionnaires. Results obtained by
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the APZ and OAV can therefore be compared by transforming the scales through linear
equations (see Bodmer, 1999).
Although the dimensional analyses of the APZ and OAV questionnaires had revealed
three primary “etiology-independent” dimensions of ASCs, Dittrich’s own investigations
(Dittrich, 1985), as well as the scientific literature on ASCs, pointed to the existence
of further dimensions that are specific to certain ASC-inducing agents. For example,
acoustic alterations and hallucinations are a common feature of ASCs induced by certain
psychiatric diseases, such as schizophrenia and alcohol withdrawal psychoses, and have
been described under conditions of sensory deprivation and hypnagogic states (e.g.,
Mavromatis, 1987), but seem to be less common in hallucinogen-induced ASCs (Malitz,
Wilkens, & Esecover, 1962). In accordance with these findings, only 2 of the 11 APZ
items measuring acoustic alterations met criteria of etiology-independency in Dittrich’s
experimental studies (Dittrich, 1985). Furthermore, clouding of consciousness and
reduction of vigilance are characteristic features of hallucinogens of the second order and
of sedative drugs, but not of hallucinogens of the first order (Leuner, 1981). Dittrich (1994,
1996) therefore hypothesized that Auditory Alterations (AUA) and Vigilance Reduction
(VIR) were two etiology-dependent dimensions, which, in addition to the three primary
etiology-independent dimensions, could be reliably and validly measured. In order
to measure these dimensions, Dittrich and co-workers constructed and validated the
so-called Bewusstseinstrübung und Akustische Halluzinationen (BETA) questionnaire
(Dittrich et al., 1989; Schneiter, 1991). Because a dimensional analysis of the Pearson
correlation matrix formed from the 39 BETA items and the 49 APZ items comprising the
primary three scales indicated that the AUA and VIR dimensions could be differentiated
from the OBN, DED, and VRS dimensions and because the reliabilities and validities of the
AUA and VIR scales were demonstrated to be acceptable (Schneiter, 1991; Braun, 1997),
Dittrich et al. (1999) published an extended version of the OAV, called Five Dimensions
of Altered States of Consciousness (5D-ASC), which includes 16 and 12 BETA items
measuring the AUA and VIR dimensions, respectively. The 5D-ASC is the latest version
of Dittrich’s ASC questionnaires. Psychometrically yet untested versions of the 5D-ASC
exist in U.S. English (Dittrich et al., 2010), French, Brazilian Portuguese, Arabic, Dutch,
and Japanese (A. Dittrich, personal communication, February 14, 2010).
Although Dittrich (1998) concluded that his original hypotheses on ASCs have survived
considerable falsification testing not only in experimental but also in field studies and
that the APZ questionnaire has become a psychometrically well-validated instrument for
the assessment of “etiology-independent” features of ASCs in a “etiology-independent”
three-dimensional space, it should be noted that the studies carried out so far have
serious methodological limitations, from which only few have been recognized in the
existing literature. For instance, the dimensional analyses of the dichotomous APZ
items were based on Pearson correlations among the items, which, unlike tetrachoric
correlations, can be severely attenuated if the items differ markedly by their difficulties
(J. B. Carroll, 1945). This is a serious problem, because it may have led to the extraction
of pseudofactors that reflect similar item difficulty rather than similar item content
(Kubinger, 2003). Another methodological shortcoming of Dittrich’s original investiga-
tion is that the stability of the proposed factorial structure across different ASC induction
methods and languages has only been examined by descriptive measures of factor
pattern similarity derived from the comparison of EFA models, namely, by Tucker’s
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coefficient of congruence and by Cohen’s κ. These measures have many recognized
problems (Reise et al., 2000). For instance, because they only estimate the similarity of
factor loadings, but not the similarity of indicator intercepts and residual variances,
they can only provide evidence for the weakest forms of factorial invariance, namely,
the so-called “metric invariance” or “weak factorial invariance” in the case of Tucker’s
coefficient of congruence and “configural invariance” in the case of Cohen’s κ (for a
description of different levels of factorial invariance, see Meredith, 1993). However,
even for the assessment of these weakest forms of factorial invariance, the use of these
similarity measures is problematic because their size is affected by various properties of
the data (Paunonen, 1997; Barrett, 2006). Thus, it is unclear how large they should be to
conclude that factor pattern similarity holds to a reasonable degree. Commonly applied
rules of thumb, which were also used in the study of Dittrich (1985), are not only
unreliable, they also seem to be much too lenient (Chan et al., 1999). Furthermore, due
to his relatively low sample size, Dittrich (1985) assessed the factor pattern similarity
across different ASC induction methods only on the level of aggregated items and only
across four groups of ASC induction methods. The use of item aggregates, however, is
highly problematic when the goal is to represent the dimensionality of the measurement
space at the level of individual items (Little et al., 2002).
Another potential bias in Dittrich’s original investigation is the use of a specific
set of items. Analogous to the dimensions of personality (e.g., the so-called “Big-
Five”), broad dimensions of ASCs can only be found by analyzing sets of items that are
representative for the domain of interest. Although Dittrich (1985) has originally derived
his three primary dimensions of ASCs from a set of 158 APZ items that were selected to
be representative for the domain of interest, it is unknown whether the sampling of
APZ items was indeed unbiased because his investigation was never repeated in other
independent sets of items.
Unfortunately, studies that have re-examined the psychometric properties of Dittrich’s
ASC rating scales after their first publication are scarce and those that exist were based
on very limited sample sizes. Furthermore, because these rating scales were constructed
and validated during the early 80s to the mid 90s, dimensional analyses have fully relied
on exploratory methods. None of these scales has previously been analyzed by modern
latent-variable approaches, such as confirmatory factor analysis (CFA) and structural
equation modeling (SEM), which now have become standard methods of psychometric
investigations and which are associated with many of the methodological and statistical
advances in quantitative psychology in the last two decades (Marsh, Lüdtke, et al.,
2010). Because these methods can also overcome many weaknesses of Dittrich’s original
investigations and more directly assess the validity of Dittrich’s hypotheses, studies
applying these methods on Dittrich’s ASC questionnaires have long been overdue.
Another shortcoming of previous psychometric investigations is that they analyzed
only major dimensions and did not explore potential lower order factors or so-called
facets, even though applied researchers were not satisfied with the large conceptual
breadth of the proposed major dimensions and have constructed their own subscales
based on considerations of item content e.g., Liechti, Gamma, and Vollenweider (2001).
Addressing these issues is important because Dittrich’s questionnaires continue to
be widely used, and few validated instruments are available that measure similar
subjective experiences. In fact, we are aware of only two instruments that measure
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similar experiences and that have gained similar acceptance in applied research, that
is, the Phenomenology of Consciousness Inventory (Pekala, Steinberg, & Kumar, 1986)
and the Hallucinogen Rating Scale (Strassman et al., 1994).
To overcome the methodological limitations of previous investigations, we performed
a psychometric evaluation of the OAV in a relatively large sample of subjects describing
experiences of ASCs that were experimentally induced by psilocybin, ketamine, or MDMA.
In contrast to previous studies, the factorial structure was explored and tested by using
methods of the SEM-framework, including CFA and exploratory structural equation
modeling (ESEM; Asparouhov & B. O. Muthén, 2009), and by applying a hierarchical
item clustering (ICLUST; Revelle, 1978) procedure that was specifically developed to
display the hierarchical structure of a scale. This allowed us to investigate the factorial
structure of the OAV not only on a dimensional level, but also on the level of lower
order factors or facets. A number of lower order factors were extracted and compared
with the original scales. The measurement invariance and population heterogeneity
of these lower order factors across different drugs, settings, questionnaire versions,
and sexes were examined by MIMIC modeling. The reliabilities were assessed not only
by Cronbach’s α, but also by various non-standard reliability coefficients for both the
original and newly-constructed scales. Furthermore, convergent, discriminant, and
known-group validities of these scales were examined. The advantages of the newly
constructed subscales, as well as the implications of our results with respect to Dittrich’s
original hypothesis, are discussed.
4.3 methods
4.3.1 Samples and Data Collection Procedures
The samples used in the present investigation were obtained by pooling data from
43 experimental studies (including pilot studies) carried out at our research facility
between 1992 and 2008 involving psilocybin (115-350 μg/kg po), ketamine (6-12 μg ·
kg-1 · min-1 iv), or MDMA (1.5-1.7 mg/kg po) administration to healthy volunteers. The
studies were part of a research program in which psilocybin, ketamine, and MDMA
were used as tools for pharmacological modeling of core symptoms of schizophrenia
and for investigating cognitive and perceptual processes (Vollenweider & Geyer, 2001;
Geyer & Vollenweider, 2008). All studies were approved by the Ethics Committee of
the University Hospital of Psychiatry, Zurich, and the use of psilocybin, ketamine, and
MDMA was authorized by the Swiss Federal Office of Public Health, Department of
Pharmacology and Narcotics, Berne.
Participants of all studies were recruited through advertisement from the local uni-
versities and hospital staff. All subjects signed an informed consent sheet and were
carefully screened before admission to the studies. Subjects having personal or family
(first-degree relatives) histories of major psychiatric diseases, neurological or substance
related disorders, high emotional lability scores (more than two standard deviations
above the normative mean in the Freiburg Personality Inventory; Fahrenberg, Hampel,
& Selg, 1984), or physical problems (according to a physical examination, electrocar-
diogram, and clinical-chemical blood test) were excluded. All drug sessions were
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Table 6: Descriptive Statistics
Psilocybin Ketamine MDMA Combined
Characteristic n = 327 n = 162 n = 102 N = 591 Test statistica
Age (M± SD) 28.5 ± 6.1 29.5 ± 5.8 26.6 ± 5.1 28.5 ± 5.9 F(2, 588) = 7.7, p < .001
Gender χ2 = 31.2, p < .001
Male 57% (187) 80% (130) 76% (78) 67% (395)
Female 43% (140) 20% (32) 24% (24) 33% (196)
Education χ2 = 4.5, p = .345
High school diploma 7% (24) 9% (15) 5% (5) 7% (44)
University students 57% (187) 55% (89) 67% (68) 58% (344)
University graduates 35% (116) 36% (58) 28% (29) 34% (203)
Dose χ2 = 211, p < .001
Lowb 22% (72) 0% (0) 0% (0) 12% (72)
Mediumc 65% (214) 43% (70) 100% (102) 65% (386)
Highd 13% (41) 57% (92) 0% (0) 23% (133)
Questionnaire version χ2 = 91.6, p < .001
5D-ASC 69% (227) 26% (42) 38% (39) 52% (308)
OAV 31% (100) 74% (120) 62% (63) 48% (283)
Setting χ2 = 57.7, p < .001
PET 16% (51) 48% (77) 25% (25) 26% (153)
No PET 84% (276) 52% (85) 75% (77) 74% (438)
Note. Numbers in parenthesis indicate absolute frequencies. PET = positron emission tomography.
abased on the comparison between the psilocybin, ketamine and MDMA groups. b115 μg/kg psilocybin.
c215-270 μg/kg psilocybin, 1.5-1.7 mg/kg MDMA, 6 μg · kg-1· min-1 ketamine. d315 μg/kg psilocybin, 12
μg · kg-1· min-1 ketamine.
performed by following safety guidelines that are similar to those recommended by
Johnson, Richards, and Griffiths (2008).
In each study, a placebo-controlled within-subject design was used. Depending on the
study, subjects received placebo and 1-4 different doses or combinations of psychoactive
drugs in 2-5 experimental sessions. Experimental sessions were conducted at least two
weeks apart in order to avoid carry-over effects. In the majority of the studies (n =
22), the order of drug administration was randomized and double-blind, but some of
the earlier studies as well as most pilot studies (n = 21) were open-label trials. For the
present investigation, we only used data from those experimental sessions, in which
psilocybin, ketamine, or MDMA was administered alone. Very low dose psilocybin
sessions (15-45 μg/kg po) were excluded due to statistically non-significant subjective
drug effects (Hasler, Grimberg, et al., 2004). In accordance with these criteria, psilocybin,
ketamine, and MDMA were administered in 327, 162, and 102 experimental sessions,
respectively. Racemic, (R)- and (S)-ketamine were administered in 6, 22, and 134 of the
ketamine sessions respectively. The total sample consisted of 591 drug sessions. For a
detailed description of the sample, see Table 6.
Because some studies involved multiple drug sessions and because some subjects
participated in more than one study, the above samples contain non-independent
observations. Unfortunately, some of the multivariate statistical procedures used in
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the present study rely on the assumption of independency of observations. In order
to control for this potential bias, we also analyzed samples that included only one
experimental session per subject. For each subject we selected the experimental session
that was conducted first. By applying these inclusion criteria, we obtained samples
of the following sizes: psilocybin (n = 186), ketamine (n = 109), MDMA (n = 95), and
combined drug group (n = 344).
4.3.2 Measures
4.3.2.1 Altered states of consciousness rating scales (OAV and 5D-ASC)
In each experimental session, subjects were asked to describe the experiences of drug
induced ASCs by the German versions of the OAV or 5D-ASC questionnaires. The OAV
was used in studies conducted before the year 2000 (n = 27), while the 5D-ASC was used
in all later studies (n = 16). Because the 5D-ASC is an extension of the OAV, all 66 OAV
items are also fully contained in the 5D-ASC. They also appear in the same order in
both questionnaires, but are interspersed by 5D-ASC unique items when presented to the
subjects as part of the 5D-ASC. Because the available samples would have been too small
to investigate the factorial structures of both questionnaires, items from the 5D-ASC data
were combined with the corresponding items of the OAV in the present study. Each OAV
item contains a statement describing a specific experience of ASC in the past tense (e.g.,
“It seemed to me that my environment and I were one”). Subjects were instructed to
respond to the described experiences by placing marks on horizontal visual analogue
scales (VASs) of 100 millimeters length. The VASs of the OAV are anchored as no, not more
than usual on the left and as yes, very much more than usual on the right. The items are
scored by measuring the millimeters from the low end of the scale to the subject’s mark
(integers from 0-100). Because the low end of the scale indicates a neutral response, the
response format of these items can be considered as strictly unipolar according to the
response format typology of Russell and J. M. Carroll (1999).
In most studies, the OAV and 5D-ASC were completed during or shortly after the drug
effects peaked. However, in some studies, these rating scales were completed after
the drug effects had worn off or at multiple time points. In the latter case, we only
included those measures that were obtained during the peak drug effect. Depending
on the study, the pooled OAV and 5D-ASC questionnaires were completed 60-300 min
after psilocybin, 25-120 min after ketamine, and 70-160 min after MDMA administration.
Subjects were instructed to retrospectively rate their whole experience from the moment
of drug intake to the respective measuring time point.
4.3.2.2 Short Version of the Adjective Word List (“Eigenschaftswörterliste”; EWL-60-S)
The EWL-60-S (Janke & Debus, 1986) is a German self-report rating scale for the multidi-
mensional assessment of the mental state. It is composed of a list of 60 adjectives (e.g.,
“anxious”, “tired”, “sociable”), which can be grouped into 15 subscales each comprising
4 adjectives (see Table 11 for the names of these subscales). The subscales can be further
grouped into six domains. Subjects are asked to respond to the adjectives on four-point
Likert scales ranging from 0 (not at all) to 3 (very much). The EWL-60-S is a short version
of the original EWL-N and -K questionnaires (Janke & Debus, 1978), which have a very
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similar factorial structure but use a dichotomous instead of a Likert-type response
format. The EWL-60-S has been found to be well suited to measure short-term changes
of mental states induced by psychoactive drugs (e.g., Hasler, Studerus, et al., 2009),
psychological stress (Weber et al., 2007), and embodying of emotion (Wiswede, Münte,
Krämer, & Rüsseler, 2009). Internal consistencies (Cronbach’s α) for the subscales of the
EWL-60-S were reported to range between 0.40 and 0.86 in a sample of elderly people (n
= 128) and between 0.72 and 0.91 in a student sample (n = 67; Janke & Debus, 1986).
The validity of the EWL-60-S has been mostly inferred from the validity studies of the
EWL-N and -K, from which most of the EWL-60-S items were taken.
In the present investigation, the EWL-60-S was used to assess the convergent and
discriminant validities of the OAV scales. The EWL-60-S was administered in 10 of the 43
pooled studies and in 177 of the 591 analyzed drug sessions. These drug sessions mostly
involved the administration of psilocybin (n = 128) and less frequently of (S)-ketamine
(n = 33) and MDMA (n =16). In cases where the EWL-60-S was administered at multiple
time points during one drug session, we used only those measures that were obtained
during the peak drug effects. The internal consistencies (Cronbach’s α) of the EWL-60-S
subscales in our sample were mostly good to excellent and ranged from 0.76 to 0.91.
4.3.2.3 The State-Trait-Anxiety Inventory – State version (Form X; STAI-S)
The STAI-S (Spielberger, Gorsuch, & Lushene, 1970; Laux, Glanzmann, Schaffner, & Spiel-
berger, 1981) is a very popular self-report rating scale designed to measure transitory
feelings of tension and apprehension, or state anxiety. It contains 10 items describing
symptoms of anxiety (e.g., “I feel nervous”) and 10 items describing the absence of
anxiety (e.g., “I feel calm”). The German translation of the STAI-S has shown excellent
internal consistency (average α ≈ .90) and adequate convergent and discriminant va-
lidities with scales of the original EWL questionnaire (Laux et al., 1981). Furthermore,
the revised English version of the STAI-S (Form Y) has demonstrated high sensitivity for
the detection of stress (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983). However,
despite these generally positive psychometric properties, the STAI-S has been criticized
for its inability to adequately discriminate between symptoms of anxiety and depression
(Endler, Cox, Parker, & Bagby, 1992; Grös, Antony, Simms, & McCabe, 2007) and for
its lack of unidimensionality. Most of the studies investigating the dimensionality of
the STAI reported results indicating that the STAI-S scale could be further divided on
the basis of whether the items were keyed in the direction of the presence or absence
of anxiety (Vigneau & Cormier, 2008). Consistent with the view that state-anxiety is
better accounted for by two unipolar instead of one bipolar construct, the state anxiety
present and state anxiety absent scales have been shown to be differentially affected
by situational (Kvaal, Laake, & Engedal, 2001) and cultural (Iwata & Higuchi, 2000)
variables.
Because the OAV contains subscales tapping symptoms of anxiety as well as the
absence of anxiety/well-being, the three STAI-S scales (total scale, anxiety present, and
anxiety absent/calmness) were used to assess convergent and discriminant validities
of the OAV scales. The STAI-S was concurrently administered with the OAV in 56 of the
pooled experimental drug sessions, 45 of which were MDMA and 11 of which were
psilocybin sessions. All three subscales showed good internal consistencies in our
sample (total scale: α = 0.88, anxiety present: α = 0.82, anxiety absent: α = 0.84).
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4.3.3 Statistical Analysis
The originally hypothesized factorial structure of the OAV was tested by CFA and ESEM
(Asparouhov & B. O. Muthén, 2009; Marsh, B. O. Muthén, et al., 2009) using Mplus
Version 5.2 (L. K. Muthén & B. O. Muthén, 2007). ESEM is a recent statistical development
currently only available in Mplus that integrates many advantages of EFA and CFA by
including an EFA measurement model part into a SEM framework. In the present study,
we complemented the CFA with ESEM because the imposed simple structure of CFA
models, that is, constraining non-target factor loadings to zero, is often inappropriate
when analyses are done at the item level and when there are multiple factors, each
measured with a reasonable number of items (Marsh, Lüdtke, et al., 2010). Furthermore,
ESEM allowed us to perform an EFA while at the same time having full access to all the
usual SEM parameters and also taking method effects into account, which may have
resulted from items sharing similar wording. Whereas in conventional EFA, method
effects can confound the detection of more meaningful factors, they can be controlled in
ESEM by allowing correlated residuals (Asparouhov & B. O. Muthén, 2009).
In order to more fully explore the adequacy of the hypothesized three-dimensional
solution, the appropriate numbers of factors to extract was examined by means of Cat-
tell’s scree test (Cattell, 1966), Horn’s parallel-analysis (Horn, 1965), Velicer’s minimum
average partial (MAP) test (Velicer, 1976), Revelle’s very simple structure (VSS) criterion
(Revelle & Rocklin, 1979), and Revelle’s hierarchical item clustering (ICLUST) algorithm
(Revelle, 1978) using functions provided by the nFactors- (Raiche & Magis, 2009) and
psych-packages (Revelle, 2009) of the statistical software R (R Development Core Team,
2009).
Because a well fitting simple structure CFA model with clearly defined factors, that is,
factors that were measured by at least 3 items and that were conceptually meaningful,
was impossible to achieve by the traditional EFA approach and by retaining all 66 OAV
items in the solution even when the number of factors was greatly increased, we used
cluster analysis as an alternative heuristic for initial CFA model specification. Although
rarely used in applied research, a simulation study by Bacon (2001) suggests that cluster
analytic approaches to initial model specification are valuable alternatives to the more
conventional EFA-related approaches because they may lead to better fitting initial
CFA models, which in turn reduces the need for extensive CFA model refinement and
consequently the dangers of so-called specification searches.
We applied Revelle’s ICLUST procedure, a cluster analytic approach that was specifi-
cally developed to cluster questionnaire items and that was recently implemented in the
freely available psych-package (Revelle, 2009) of the software R. ICLUST hierarchically
clusters items using correlations corrected for attenuation as a proximity measure and
the size of the reliability coefficients Cronbach’s α and Revelle’s β (Revelle, 1979) as
stopping rules. A major advantage of ICLUST is that items are only added to clusters if
they increase the cluster’s internal consistency and factorial homogeneity. Furthermore,
as the sequential item-by-item growth of clusters mapped with an accompanying set
of homogeneity statistics can be displayed in a hierarchical tree diagram, the ICLUST
procedure provides uniquely useful diagnostic and interpretative information not avail-
able in conventional approaches of scale construction, such as EFA (Cooksey & Soutar,
2006). For instance, the internal substructure of scales can be directly visualized, and
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defensible decisions can be made on whether to form scales on a macro level (higher
order scales) and at a more finely grained micro level (lower order scales). Because
problematic items usually get merged in a late step of the ICLUST procedure, they can
be more easily identified, and they do not obscure the factorial structure as much as in
an EFA (for more information, see Cooksey & Soutar, 2006).
An initial simple structure CFA model with correlated latent factors was specified and
evaluated on the basis of ICLUST item clusters meeting the following criteria: Satisfactory
indexes for internal consistency (Cronbach’s α > 0.8) and homogeneity (Revelle’s β > 0.7),
a minimal cluster size of three items, good interpretability, and conceptual importance.
The initial factorial solution was then further refined by dropping items with high
cross-loadings.
After having established a well fitting CFA model in the total sample, we used MIMIC
modeling to examine population heterogeneity and differential item functioning (DIF)
across different drugs, questionnaires, settings, and sexes. Although the multiple-
groups CFA approach is more commonly used to examine structural and measurement
invariance, we decided to use MIMIC modeling because it requires lower sample sizes
and allows the simultaneous evaluation of many different contrast variables (Brown,
2006). Whereas multiple-groups CFA entails the simultaneous analysis of two or more
measurement models, MIMIC involves a single CFA model in which latent factor and
item indicators are regressed on covariates. A significant direct effect of a covariate on a
latent factor indicates that the mean of the latent factors differs across different levels of
the covariate (also referred to as population heterogeneity). A significant direct effect of
a covariate on an observed item indicator is evidence for measurement non-invariance
because it means that the item endorsement is significantly different across different
levels of the covariate even though the latent factor is held constant. The occurrence
of measurement non-invariance (also referred to as DIF) in MIMIC corresponds to the
occurrence of non-invariant item intercepts in multiple-groups CFA and has important
consequences for the interpretation of latent factor means. That is, if DIF is present,
group comparisons of latent factor means are confounded by group differences in
the factor structure and therefore cannot be meaningfully interpreted unless group
comparisons are made within the SEM framework, where DIF can be accounted for
(Brown, 2006). In the present study, we first examined a MIMIC model in which only the
latent factors were regressed on the covariates. Because all direct effects between the
covariates and the items were fixed to zero, this constituted the no-DIF model. The latent
factors were regressed on the three binary variables female (0 = male, 1 = female), PET
(0 = experimental session involved no PET, 1 = experimental session involved PET), and
OAV (0 = 5D-ASC, 1 = OAV) and the three-level nominal variable drug. The variable drug
was represented in the model as two dummy coded contrast variables using the MDMA
group as the reference group. For each of the five binary variables included in the MIMIC
model, the minority or focal group contained at least 100 cases. A recent simulation
study (Woods, 2009) suggests that focal groups of this size are large enough to produce
reasonably powerful and accurate MIMIC results when the sample size is similar to our
study. To detect differential functioning (D-F) items we used the so-called “free baseline
designated anchor approach” (for applied examples, see Fleishman, Spector, & Altman,
2002; Woods, Oltmanns, & Turkheimer, 2009), which is supposed to have a lower false
discovery rate than the more commonly applied stepwise forward procedure (e.g.,
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Brown, 2006) and is most similar to well tested item response theory based methods
(Woods, 2009). The procedure involved two steps. First, anchor items were identified
by regressing one item at a time on the five grouping variables (while constraining all
other direct effects to zero) and testing the five regression parameters for significance.
Items with no significant regression parameters were defined as DIF-free or anchor
items. In the second step, all items not included in the DIF-free subset were tested for
DIF by using likelihood ratio (LR) difference tests for nested models. That is, for each
studied item, a comparison was made between a full model (all items were allowed to
have DIF except for the anchor items) and a more constrained model (all items were
allowed to have DIF except for the anchor items and the studied item). If the model
fit of the constrained model was significantly worse relative to the full model, it was
concluded that the studied item had DIF. As recommended by Woods (2009), p-values
of LR difference tests were adjusted by the Benjamini-Hochberg procedure (Benjamini
& Hochberg, 1995) using the p.adjust function in R to control the false discovery rate.
After all D-F items were identified, a model was fitted in which – in addition to the
latent variables – only D-F items were regressed on the grouping variables. However, to
further increase model parsimony, direct effects that were non-significant at p < 0.05 or
had very low effect sizes (y-standardized regression coefficients < 0.2) were dropped in
the final MIMIC model.
Because most OAV items were positively skewed (mean =1.25, range = -0.56 to 4.32)
and kurtotic (mean = 1.27, range = 1.64 to 19.23) and because our data set contained
non-independent observations, latent factor models (CFA, ESEM, and MIMIC) were fitted
by using the Robust Maximum Likelihood (MLR) estimator in combination with the
“Complex” option in Mplus. This method produces adjusted standard errors and fit
indexes for non-normal and clustered data by means of a sandwich estimator and the
Yuan-Bentler T2* test statistic (Yuan & Bentler, 2000; L. K. Muthén & B. O. Muthén,
2007). Because the χ2 statistic of the MLR estimator cannot be used for difference tests,
the Satorra-Bentler scaled χ2 difference test (Satorra & Bentler, 2001) was used for the
comparison of nested models.
Unfortunately, most OAV items were not only positively skewed and kurtotic, but also
showed a strong piling up of values at the lower end of the scale (39% of zero values on
average and 71.3% at the most) and a modest piling up of values at the upper end of the
scale (6.3% of values on average and 27% at the most; see Supplementary Table S2 for
the distributional characteristics of each item). Because parameter estimates produced
by MLR can be biased to some degree if strong floor- or ceiling-effects are present, we
cross-checked our results by categorizing the OAV items into 5 categories and using the
polychoric correlation matrix calculated from categorized variables as input for the latent
factor models and the ICLUST procedure. Polychoric correlations estimate the linear
associations of latent continuous variables underlying the manifest categorical variables.
Because polychoric correlations rest on the assumption that the underlying continuous
variables are bivariate normal and that the observed responses are determined by the
respondents’ thresholds, which are usually converted to the underlying continuous
variable by a non-linear transformation, items were categorized such that the degree
of normality of the categorized variables was maximized (see Supplementary Table S3
for the distributional characteristics of the categorized items). Although polychoric
correlations seem to be robust to modest violations of underlying bivariate normality
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(Flora & Curran, 2004), it is generally recommended to test this assumption by the
LR-χ2 statistic and to evaluate model fit by the root mean square error of approximation
(RMSEA; Schmukle & Egloff, 2009). According to simulation studies, no serious effects
of non-normality on the polychoric correlation estimate are expected to occur as long as
RMSEA values are below 0.1 (Jöreskog, 2005). The cut-points that we used in the present
study (1, 30, 70, and 90 across all items) produced RMSEA values that slightly exceeded
0.10 in only 2 of 2211 estimated polychoric correlations and therefore should not have
resulted in biased parameter estimates. However, it should be noted that polychoric
correlations can still be unreliable when estimated on the basis of frequency tables with
low expected cell frequencies (Jöreskog, 2005). Because we used 5 categories and equal
cut-points across all items, it was unavoidable that some cells of the frequency tables of
item pairs became empty. Although a lower number of categories would have reduced
the number of empty cells, it would have also increased the information loss resulting
from the item categorization. Hence, for the lack of better alternatives, we had to accept
this small degree of potential bias.
Another reason why we decided to cross-check our results by using categorical
variable methodology was the occurrence of L-shape patterns in bivariate scatter
plots of several OAV item pairs describing experience of opposite affective valence.
L-shaped bivariate distributions are well known to occur between strictly unipolar
items measuring opposite halves of one underlying bipolar continuum because giving
a positive response in one item implies giving a neutral response in the other item
and vice versa (Schmukle & Egloff, 2009). Due to the opposite skew of such items,
the size of their correlation is markedly attenuated when estimated by the product-
moment correlation. In fact, it can be shown that the negative correlation between
two items measuring mutually exclusive parts of one bipolar continuum theoretically
cannot exceed -.47 (Russell & J. M. Carroll, 1999). The only exception to this rule is
when the sample is highly polarized (for more details, see Segura & González-Romá,
2003). In contrast to the product-moment correlation, the polychoric correlation can
correctly estimate a perfect negative correlation when an L-shape pattern is present.
Since most factor analyses in the past have relied on product-moment correlations, the
above issue has often led to biased estimates of correlations between latent variables
or to the unexpected finding of two separate unipolar dimensions when only one
bipolar dimension was hypothesized (see Schmukle & Egloff, 2009). Because the OAV
contains strictly unipolar items and because some OAV item pairs of opposite affective
valence tended to form L-shape patterns, we hypothesized that the association between
these items would become more negative when estimated by polychoric instead of
product-moment-correlations and that this would eventually lead to more negative
correlations between latent factors for which these items were indicators. Furthermore,
we hypothesized that the attenuation of product-moment correlations induced by the
L-shape patterns could explain at least in part the unexpected high positive correlation
between OAV factors covering experiences of opposite affective valence (e.g., OBN with
DED) reported in previous factor analyses (Bodmer, 1989, 1999; Habermeyer, 1999).
In the latent factor models, the polychoric correlation matrix of the categorized
variables was used in combination with the robust weighted least squares estimator
(WLSMV in Mplus). The WLSMV provides weighted least square parameter estimates
using a diagonal weight matrix and robust standard errors and a mean- and variance
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adjusted χ2 (L. K. Muthén & B. O. Muthén, 2007). Due to good performance in Monte
Carlo studies, the WLSMV is currently the method of choice for the analysis of skewed
categorical data in small to moderate samples (Flora & Curran, 2004; Brown, 2006).
Because the χ2 of exact model fit is strongly influenced by sample size, adequacy of
fit of the latent factor models was evaluated by Bentler’s comparative fit index (CFI),
the Tucker-Lewis index (TLI), and the RMSEA. Additionally, the standardized root
mean square residual (SRMR) was used for models with continuous outcomes, and
the weighted root mean square residual (WRMR) was used for models with categorical
outcomes. In line with recommendations of Hu and Bentler (1998), CFI and TLI values
close to .95 or greater, RMSEA values close to .06 or below, and SRMR close to .08 or below
were considered as indicating reasonably good model fit. For the WRMR, a cut-off value
close to 1.0 or below was considered suitable (Yu, 2002).
Because the newly constructed OAV scales did not meet the assumption of essential
tau-equivalence (i.e., equality of factor loadings) and because the original OAV scales
additionally were non-congeneric, that is, they contained several group factors in
addition to a general factor, we did not primarily rely on Cronbach’s α for assessing
scale reliability. Although α is the most commonly used reliability estimate, it has
long been pointed out by several authors that α is not a dependable estimator of scale
reliability when the above assumptions are not met and that several alternative reliability
estimates exist that obviate the difficulties encountered with the use of α and that can
be more easily interpreted (Revelle, 1979; Zinbarg, Revelle, Yovel, & Li, 2005; Green
& Yang, 2009). In the present study, scale reliabilities of the newly constructed scales,
which had been shown to be congeneric in the CFA, were directly derived within the
SEM framework by using an approach described by Raykov (2001, 2009). Point estimates
of these reliability estimates, hereinafter referred to as ρSEM, were supplemented by
confidence intervals found by the so-called delta-method (e.g., Raykov & Marcoulides,
2004) to gain ranges of plausible values for the population scale reliabilities. For the
original scales not meeting the assumption of unidimensionality, scale reliability was
mainly assessed by using McDonalds ωh and ωtot (McDonald, 1999; Zinbarg, Revelle,
Yovel, & Li, 2005). Whereas ωh estimates the amount of variance in a scale attributable
to one common factor, also referred to as general factor saturation, ωtot estimates the
amount of variance due to all common factors (i.e., group factors and general factor).
As we had no clear expectations regarding the number of group factors present in the
original OAV scales as well as regarding the patterns of the loadings on the common
factors, ωh and ωtot were estimated by performing a higher order EFA analysis using
the omega function of the psych-package (Revelle, 2009) in R. This method has shown
good performance in a simulation study (Zinbarg, Revelle, & Yovel, 2007). For each
scale, the number of group factors to extract was determined by parallel analyses (Horn,
1965). As an alternative estimate of the general factor saturation and as an index of
homogeneity, we also computed Revelle’s β (Revelle, 1979) using the ICLUST function
in the psych-package. Furthermore, Cronbach’s α was calculated in order to compare
our results with the standard estimate of scale reliability and with the results of older
studies. Confidence intervals for α were calculated using the method described by
Duhachek and Lacobucci (2004)
Criterion validities of the original and newly constructed OAV scales were evaluated
by assessing convergent and discriminant validities, as well as known-group validities.
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Convergent and discriminant validities were assessed by correlating the OAV scales with
subscales of the EWL-60-S and the STAI-S. Known-group validities were examined by
comparing the mean OAV scale scores of the three drug groups.
4.4 results
In contrast to our hypothesis, associations between items of opposite affective valence
with L-shaped bivariate distributions and between latent constructs measuring opposite
affective valence did not become more negative when estimated by polychoric instead of
product-moment correlations. In fact, polychoric correlations were almost always more
positive than product-moment correlations. The difference between the two estimation
methods was 0.11 on average. However, because the factorial solution resulting from
the analysis of categorized OAV items did not markedly differ from the factorial solution
of the continuous items, except that the correlations between the latent variables were
generally larger, we only report results from those statistical analyses that treated the
OAV items as continuous variables. Results from analyses based on categorized variables
are available upon request from the first author.
4.4.1 Fit of the Originally Hypothesized Model
Table 7 provides fit indexes from a series of latent factor models testing Bodmer’s origi-
nally hypothesized factorial structure of the OAV. When modeled as simple structure
CFA with no correlated residuals and unconstrained latent factor covariances, Bodmer’s
factorial structure did not fit the data well. Although the parsimony-adjusted RMSEA
and the absolute fit index SRMR were only slightly above the recommended cutoffs,
comparative fit indexes (i.e., CFI and TLI) were clearly unacceptable. Large modification
indexes for the residual covariances between the items 8, 13, 20, and 25 and between the
items 14 and 51, as well as similar wordings within these two item clusters, suggested
that item covariances within these two item clusters might be explained in part by
shared method effects. We therefore specified a less constrained CFA model in which
residual covariances between the items 8, 13, 20, and 25 and between the items 14 and
51 were allowed to freely co-vary. Although this model fitted significantly better than
the original model according to the scaled χ2-difference test, comparative fit indexes
were still clearly unacceptable. Because the imposed simple structure of a standard
CFA model is often unnecessarily restrictive (Marsh, Lüdtke, et al., 2010), we next tested
geomin- and quartimin-rotated 3-Factor-ESEMs with and without method effects. As
expected, the free estimation of cross-loadings significantly improved model fit. Be-
cause all available fit indexes, including the parsimony-adjusted RMSEA, improved, the
increase in model fit was not primarily achieved at the expense of increased model
complexity. However, even when method effects were taken into account, overall model
fit was relatively poor as the CFI and TLI values were still far below their recommended
cutoffs. An inspection of the item loadings of the geomin-rotated ESEM without method
effects revealed that 59 of the 66 items (89.4%) had their highest loading on the hy-
pothesized factors. Six VRS items (# 17, 18, 37, 40, 52, and 64) describing experiences
of changed meaning of percepts, facilitated recollection, and insightfulness loaded
highest on the OBN factor and one VRS item (# 58) describing experiences of macropsia
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Table 7: Confirmatory Factor Analysis Model Fit Results
df MLR χ2 CFI TLI RMSEA SRMR AIC Δdf Δχ2 p
Bodmer’s original structure
CFA (simple structure) 2076 6661.7 .709 .699 .061 .094 363480
CFA with method effects 2069 6190.6 .738 .729 .058 .089 362819 7 393 < .001
ESEM 1950 5469.9 .777 .754 .055 .050 150706 119 670 < .001
ESEM with method effects 1943 5235.3 .791 .769 .054 .054 150103 7 37 < .001
Bifactor model 2013 5487.6 .779 .765 .054 .086 150545 −70 −223
Bifactor model with method eff. 2006 5116.9 .803 .789 .051 .095 150061 7 942 < .001
OBN factor alone 324 1643.7 .785 .767 .083 .070 64550
DED factor alone 189 612.5 .834 .815 .062 .070 42944
VRS factor alone 135 1199.5 .689 .648 .116 .090 45175
Model revision
Initial ICLUST solution 979 2016.0 .907 .897 .042 .059 255679
Final model 764 1430.8 .929 .921 .038 .052 94687
MIMIC models
Final model: MIMIC without DIF 919 1780.6 .918 .904 .040 .050 97624
Final model: MIMIC with DIF 910 1668.3 .928 .915 .038 .048 97489 9 120 < .001
Note. MLR = maximum-likelihood-robust estimator; CFI = comparative fit index; TLI = Tucker-Lewis index;
RMSEA = root mean square error of approximation; SRMR = standardized root-mean-square residual;
AIC = Akaike’s information criterion; Δχ2 = Satorra-Bentler scaled χ2 difference; CFA = confirmatory
factor analysis; ESEM = exploratory structural equation model; OBN = oceanic boundlessness; DED =
dread of ego dissolution; VRS = visionary restructuralization; ICLUST = hierarchical item-clustering;
MIMIC = multiple indicators multiple causes; DIF = differential item functioning.
and micropsia loaded highest on the DED factor. Although all items had at least one
significant main factor loading of at least modest size (> 0.3), 28 items demonstrated
also significant cross-loadings. The geomin-rotated ESEM that included method effects
showed a considerably different pattern of factor loadings. In this model, only 54.5% of
the items were correctly distributed to their hypothesized factors. Whereas the OBN and
VRS factors essentially collapsed into one large first factor, the DED factor was divided
into one factor tapping experiences of anxiety and another factor tapping experiences of
impaired control and cognition. Supplementary Table S4 and S5 show the hypothesized
and empirical item distributions resulting from the geomin- rotated 3-Factor-ESEMs with
and without method effects, respectively. Quartimin-rotated ESEMs only marginally
differed from their geomin-rotated counterparts.
Because previous EFAs of the APZ and OAV had revealed large first eigenvalues relative
to later eigenvalues and because the existence of a general factor has been hypothesized
for both the APZ and OAV (Dittrich, 1985; Bodmer, 1989), we also tested a bi-factor
model in which all items were allowed to load on a general factor in addition to
their specific group factor. Although this model fit better than all previously tested
models, comparative fit indexes were still clearly unacceptable. In order to examine
the homogeneity of the hypothesized factors, we also modeled each factor separately.
The results indicated that none of the three hypothesized factors can be considered
unidimensional and that VRS is the most heterogeneous factor.
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4.4.2 The Optimal Number of Factors to Extract
Although the OAV questionnaire was specifically designed to measure three dimensions
of ASCs, none of the methods that we used to determine the optimal number of factors
to extract indicated a three-dimensional solution. Parallel analysis, which is considered
as one of the most effective and accurate methods for determining the number of
factors to retain (Velicer, Eaton, & Fava, 2000), suggested 5 and 13 factors, depending
on whether the analysis was based on principal component (PA-PCA) or principal factor
(PA-PFA) eigenvalues, respectively. In case of the PA-PFA, the number of factors was
reduced to 11, when the observed eigenvalues were compared with the 95th percentiles
instead of the means of the eigenvalues generated from random data. Although in
a recent Monte Carlo study, PA-PFA outperformed PA-PCA under conditions similar to
our study (presence of correlated factors or strong general factor as well as group
factors; Crawford et al., 2010), the scree test supported the results of the PA-PCA by also
suggesting a five-factorial solution. However, the MAP test indicated seven factors to
retain, while the VSS criterion for complexity one and two favored one- and two-factorial
solutions, respectively. Furthermore, the ICLUST algorithm, which clusters scales as
long as the homogeneity and internal consistency of the higher level scale is greater
than that of either subcomponent, did not stop until two clusters were left. One of
these two item clusters comprised all DED items, while the other comprised all OBN
and VRS items. Finally, by testing the fit of ESEMs with a varying number of factors, it
was determined that at least 11 factors were necessary to achieve acceptable overall
model fit. The optimal numbers of factors obtained by the methods discussed above are
summarized in Supplementary Table S6.
4.4.3 Construction of New OAV Scales
Although ESEMs with 11 or more factors fit reasonably well, they did not serve well
as a basis for initial CFA model specification because they contained several poorly
defined factors and a relatively large number of items with significant cross-loadings
(see Supplementary Table S7 for the loading matrices of ESEMs with an increasing
number of factors starting with the originally hypothesized three-factor solution).
Instead of dropping multidimensional items step by step and thereby using CFA in
an exploratory fashion, which is generally not recommended because it can lead
to problematic specification searches (Brown, 2006), we inspected the tree diagram
produced by ICLUST to directly derive homogeneous and reliable subscales. By applying
the criteria defined in the method section, 11 item clusters formed from 47 of the 66
original items were detected and used for initial CFA model specification. The ICLUST
tree diagram and the item clusters that were used for the initial CFA model are shown in
Supplementary Fig. S1 (for the ICLUST tree diagram based on the categorized variables
see Supplementary Fig. S2). As the model fit of this initial CFA model was not sufficient
according to the CFI and TLI indexes (see Table 7), we tried to improve model fit by
dropping items showing large modification indexes for cross-loadings and ambiguous
item wordings. The model revision led to a final model that still contained the same
number of factors, but a slightly lower number of items (42 instead of 47). Because the
dropped items (# 12, 39, 41, 48, and 54) had been mostly assigned to different factors,
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Table 8: Correlations Between Latent Factors and Observed Correlations of the OAV
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New scales
Experience of unity — .82 .72 .78 .74 .50 .28 .61 .41 .54 .65
Spiritual experience .69 — .67 .80 .53 .27 .24 .53 .37 .42 .47
Blissful state .62 .53 — .63 .39 .11 −.07 .45 .25 .34 .46
Insightfulness .63 .61 .49 — .49 .34 .30 .61 .45 .47 .67
Disembodiment .64 .45 .35 .39 — .64 .37 .49 .33 .44 .48
Impaired control and cognition .43 .24 .11 .27 .53 — .70 .43 .36 .35 .62
Anxiety .25 .22 −.06 .24 .32 .63 — .23 .26 .20 .39
Complex imagery .52 .44 .39 .48 .40 .36 .20 — .73 .65 .53
Elementary imagery .37 .34 .25 .36 .29 .33 .27 .62 — .70 .41
Audio-visual synesthesiae .49 .38 .32 .39 .39 .31 .18 .56 .62 — .44
Changed meaning of percepts .55 .39 .40 .53 .38 .50 .32 .42 .35 .38 —
Original scales
Altered state of consciousness .83 .66 .57 .68 .70 .69 .51 .70 .62 .64 .72
Oceanic boundlessness .92 .76 .76 .71 .72 .46 .25 .58 .43 .52 .62
Dread of ego dissolution .39 .26 .03 .30 .50 .91 .86 .34 .35 .29 .48
Visionary restructuralization .62 .50 .46 .61 .47 .49 .32 .82 .79 .78 .69
Note. Correlations between latent factors are above the diagonal. Correlations based on scale sum scores
are below the diagonal. All correlations were statistically significant at p < .001 except for blissful state
with dread of ego dissolution, anxiety, and impaired control and cognition.
the model revision did not lead to a major change in the interpretation of any factor.
Figure 5 shows the factorial structure of this final model, including the names that we
gave to these 11 factors and the fully standardized loadings and error variances. The
correlations between the latent factors, as well as their associations with the original
OAV scales, are shown in Table 8. Although the CFI and TLI of this final CFA model were
still slightly below the recommend cutoffs, the RMSEA and the SRMR indicated excellent
model fit (see Table 7).
To assure that the parameters of the final model were estimated with sufficient
accuracy and that statistical power was high enough to detect significant effects, we
performed a Monte Carlo analysis in Mplus as described by L. K. Muthén and B. O.
Muthén (2002). The parameter values from the final model were used as the population
parameter values, the sample size was set to 591, and the model estimation was repeated
10,000 times. The Monte Carlo analysis demonstrated that model parameters and their
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Experience
of Unity
35. I experienced past, present and future as an oneness. .45 [.38, .53]
.74 [.69, .79] 28. Conflicts and contradictions seemed to dissolve. .35 [.28, .42]
.81 [.76, .85]
27. I experienced a touch of eternity. .36 [.29, .43].80 [.76, .84]
21. It seemed to me that my environment and I were one. .43 [.36, .51]
10. Everything seemed to unify into an oneness. .37 [.30, .43]
.80 [.76, .84]
.75 [.70, .80]
Spiritual
Experience
66. My experience had religious aspects. .38 [.28, .47]
.79 [.73, .85]
56. I experienced a kind of awe. .52 [.41, .62].70 [.62, .77]
6. I had the feeling of being connected to a superior power. .45 [.33, .56].74 [.66, .82]
Blissful State
65. I experienced an all-embracing love. .30 [.22, .37]
.84 [.80, .88]
60. I experienced a profound peace in myself. .40 [.33, .48].77 [.72, .82]
7. I enjoyed boundless pleasure. .49 [.40, .57].72 [.66, .77]
Insightfulness
52. I had very original thoughts. .59 [.49, .70]
.64 [.56, .72]
46. I gained clarity into connections that puzzled me before. .47 [.38, .56].73 [.67, .79]
34. I felt very profound. .49 [.40, .59].71 [.65, .78]
Disembodiment
43. I felt as though I were floating. .52 [.43, .61]
.69 [.62, .76]
42. I had the feeling of being outside of my body. .32 [.24, .40].82 [.78, .87]
15. It seemed to me as though I did not have a body anymore. .32 [.24, .39].83 [.78, .88]
Impaired Control
and Cognition
53. I had the feeling that I no longer had a will of my own. .48 [.38, .57]
45. I was not able to complete a thought, my thought repeatedly [...] .65 [.56, .74]
.59 [.52, .66] 44. I felt isolated from everything and everyone. .55 [.45, .64]
.67 [.60, .74]
33. I felt as though I were paralyzed. .54 [.44, .64].68 [.60, .75]
24. I had difficulty in distinguishing important from unimportant things. .45 [.37, .52]
16. I had difficulty making even the smallest decision. .50 [.40, .59]
5. I felt like a marionette. .60 [.50, .70]
.64 [.56, .71]
.71 [.64, .77]
.74 [.69, .79]
.72 [.66, .79]
Anxiety
63. I had the feeling something horrible would happen. .41 [.28, .54]
.77 [.68, .85] 38. I felt threatened. .34 [.22, .46]
.81 [.74, .89]
32. I experienced my surroundings as strange and weird. .40 [.30, .50].77 [.71, .84]
30. I experienced everything terrifyingly distorted. .46 [.33, .60].73 [.64, .82]
29. I was afraid without being able to say exactly why. .33 [.22, .44]
19. I was afraid that the state I was in would last forever. .50 [.36, .63]
.71 [.61, .80]
.82 [.75, .88]
Complex
Imagery
57. My imagination was extremely vivid. .44 [.34, .54]
.75 [.68, .82]
49. I could see pictures from my past or fantasy extremely clearly. .47 [.38, .55].73 [.67, .79]
25. I saw scenes rolling by in total darkness or with my eyes closed. .38 [.28, .47].79 [.73, .85]
Elemental
Imagery
20. I saw lights or flashes of light in total darkness or with closed eyes. .59 [.50, .68]
.64 [.57, .71]
13. I saw colors before me in total darkness or with closed eyes. .16 [.09, .22].92 [.88, .95]
8. I saw regular patterns in complete darkness or with closed eyes. .29 [.22, .35].84 [.81, .88]
Audio-Visual
Synesthesiae
51. The colors of things seemed to be changed by sounds and noises. .22 [.16, .29]
.88 [.84, .92]
14. The shapes of things seemed to change by sounds and noises. .16 [.11, .22].91 [.88, .94]
11. Noises seemed to influence what I saw. .31 [.23, .38].83 [.79, .88]
Changed Meaning
of Percepts
37. Objects around me engaged me emotionally much more than usual. .56 [.47, .65]
.66 [.60, .73]
18. Things around me had a new strange meaning for me. .34 [.25, .42].81 [.76, .87]
17. Everyday things gained a special meaning. .40 [.31, .50].77 [.71, .83]
Figure 5: Final confirmatory factor analysis model with completely standardized loadings and
error variances. Numbers in brackets are the 95% confidence intervals for the estimates.
Covariances between factors were freely estimated and are shown in Table 8.
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standard errors were relatively stable and powerful. Specifically, all parameter estimates
and their standard errors had bias less than 5%, coverage of all parameter estimates
was within the recommended range of 0.91-0.98, and power was higher than 0.8 for all
parameter estimates, except for two factor covariances of small effect sizes.
4.4.4 MIMIC Modeling
The no-DIF MIMIC model showed only slightly reduced global model fit relative to the
final CFA model (see Table 7). This suggests that the associations between the covariates
and the items were mostly well explained by the indirect effects going through the
latent factors. However, by applying the full baseline designated anchor approach to
DIF detection, as outlined in the method section, six D-F items were identified (item # 18,
25, 27, 30, 32, and 33). The estimation of a MIMIC model that included direct effects from
each covariate to each D-F item (5 × 6 = 30 direct effects) revealed that nine direct effects
were statistically significant at p < 0.05 and of at least small to moderate effect size
(y-standardized regression coefficient > 0.2). The final MIMIC model, which accounted
for DIF by allowing these 9 direct effects to be freely estimated, fitted significantly better
than the no-DIF model (see Table 7), and showed reasonably good global model fit.
As with the final CFA model, we performed a Monte Carlo analysis to assure that the
parameters of the MIMIC model with DIF adjustment were estimated with sufficient
power and accuracy. The analysis confirmed that the parameter estimates and their
standard errors were relatively stable and powerful.
From the nine direct effects, six effects (those on item # 18, 25, 27, 30, 32, and 33)
were due to measurement non-invariance between the MDMA and ketamine groups.
Measurement non-invariance between males and females, between the OAV and 5D-ASC
questionnaires, and between the MDMA and psilocybin groups was each accounted for
by one direct effect (those on item # 18, 30, and 25, respectively). Whereas the direct
effects of the two drug contrasts were well explainable by specific effects of psilocybin
and ketamine, the direct effects of the gender and questionnaire version covariates were
more difficult to interpret. However, since all estimated direct effects were of only small
to moderate effect sizes (all y-standardized regression coefficients were between 0.2
and 0.5), these effects must be interpreted cautiously. Furthermore, because the effects
of the covariates on the latent factors in the final MIMIC model with DIF adjustment
were not substantially different from those of the no-DIF MIMIC model, the impact of
the nine direct effects on the estimated group differences in latent factor means can be
considered low. In fact, none of these estimated group differences changed statistical
significance as a consequence of controlling for DIF.
The effects of the grouping variables on the latent factors in the DIF-adjusted final
MIMIC model are shown in Table 9. Compared to MDMA, psilocybin had the most
pronounced effect on scales measuring visual alterations (i.e., elementary and com-
plex imagery, audio-visual synesthesiae, and changed meaning of percepts), but also
facilitated insights and spiritual experiences and slightly increased anxiety. Ketamine,
on the other hand, most strongly reduced blissfulness, increased disembodiment, and
impaired control and cognition. Although the effects were less pronounced than those of
psilocybin, ketamine also induced visual alterations, most notably elementary imagery,
and facilitated spiritual experiences. Furthermore, ketamine slightly increased anxiety
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Table 9: Y-Standardized Regression Coefficients [and 95% Confidence Intervals] of the Final
MIMIC Model With DIF
Factor PET Female OAV Psilocybin Ketamine
Experience of unity 0.27 0.25 0.12 0.13 0.21
[ 0.06, 0.47] [ 0.03, 0.47] [-0.09, 0.34] [-0.14, 0.39] [-0.07, 0.48]
Spiritual experience 0.26 0.09 0.27 0.43 0.31
[ 0.04, 0.49] [-0.18, 0.36] [ 0.04, 0.50] [ 0.16, 0.70] [ 0.05, 0.58]
Blissful state 0.20 0.06 0.28 -0.27 -0.79
[-0.02, 0.41] [-0.16, 0.27] [ 0.08, 0.48] [-0.54, 0.01] [-1.06, -0.52]
Insightfulness 0.30 -0.17 0.32 0.60 0.24
[ 0.08, 0.52] [-0.40, 0.06] [ 0.07, 0.56] [ 0.33, 0.88] [-0.04, 0.52]
Disembodiment 0.53 0.25 0.03 0.14 0.75
[ 0.33, 0.72] [ 0.04, 0.46] [-0.17, 0.23] [-0.09, 0.37] [ 0.51, 0.99]
Impaired control and cognition 0.31 0.36 -0.13 0.26 0.66
[ 0.10, 0.52] [ 0.11, 0.60] [-0.34, 0.08] [ 0.02, 0.49] [ 0.40, 0.91]
Anxiety 0.31 0.05 0.04 0.28 0.31
[ 0.09, 0.53] [-0.15, 0.25] [-0.15, 0.22] [ 0.10, 0.46] [ 0.08, 0.54]
Complex imagery 0.45 0.15 0.02 0.80 0.41
[ 0.24, 0.66] [-0.08, 0.38] [-0.20, 0.23] [ 0.54, 1.05] [ 0.13, 0.69]
Elementary imagery 0.36 0.03 0.08 1.44 0.73
[ 0.19, 0.53] [-0.15, 0.21] [-0.10, 0.26] [ 1.28, 1.61] [ 0.53, 0.93]
Audio-visual synesthesiae -0.04 0.05 0.19 0.87 0.55
[-0.23, 0.14] [-0.17, 0.27] [-0.02, 0.39] [ 0.68, 1.06] [ 0.34, 0.75]
Changed meaning of percepts 0.28 -0.06 0.33 0.44 -0.17
[ 0.07, 0.49] [-0.32, 0.21] [ 0.11, 0.55] [ 0.17, 0.71] [-0.47, 0.13]
Note. Significant regression coefficients (p < .05) are in boldface. By convention, y-standardized regression
coefficients of dummy coded variables of the sizes 0.2, 0.5, and 0.8 indicate small, medium, and large effect
sizes, respectively. MIMIC = multiple indicators multiple causes; DIF = differential item functioning; PET
= positron emission tomography (0 = no PET, 1 = PET); Female (0 = male, 1 = female); OAV = version of the
altered state of consciousness rating scale (0 = 5D-ASC, 1 = OAV); Psilocybin (0 = 1.5-1.7 mg/kg MDMA or
6-12 μg · kg-1· min-1 ketamine, 1 = 115-315 μg/kg psilocybin); Ketamine (0 = 1.5-1.7 mg/kg MDMA or
115-315 μg/kg psilocybin, 1 = 6-12 μg · kg-1· min-1 ketamine).
compared to MDMA. Averaged over all drugs, females reported more impairment in
control and cognition and slightly more/stronger experiences of disembodiment and
unity than males. Relative to the 5D-ASC, the OAV questionnaire measured increased
changed meaning of percepts, insightfulness, blissful state, and spiritual experiences.
Although the different questionnaire lengths and the way items were embedded might
have contributed to these differences, it is more plausible that the questionnaire effects
were confounded by different drug doses. The average psilocybin doses administered in
experiments using the OAV and 5D-ASC were 212 and 251 μg/kg, respectively, whereas
the average doses of ketamine were 6 and 12 μg · kg-1 · min-1, respectively.
When drug sessions involved PET measurements, subjects generally experienced
stronger subjective drug effects. All scale scores were increased except for the audio-
visual synesthesiae and the blissful state scales. The most pronounced effects were
observed with respect to visual alterations and disembodiment. The effects of the PET
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Table 10: Reliabilities of the OAV Scale Scores
Scale Items Cronbach’s α Revelle’s β ρSEM ωh ωtot
Original scales
Altered state of consciousness 66 .96 [.96, .97] .61 .65 .97
Oceanic boundlessness 27 .95 [.94, .96] .71 .74 .96
Dread of ego dissolution 21 .93 [.92, .94] .74 .74 .94
Visionary restructuralization 18 .91 [.90, .92] .73 .70 .93
New scales
Experience of unity 5 .88 [.87, .90] .86 .88 [.87, .90]
Spiritual experience 3 .77 [.74, .81] .73 .78 [.73, .83]
Blissful state 3 .82 [.79, .84] .79 .82 [.79, .85]
Insightfulness 3 .73 [.69, .77] .69 .74 [.69, .79]
Disembodiment 3 .82 [.80, .85] .77 .82 [.79, .86]
Impaired control and cognition 7 .85 [.84, .87] .80 .86 [.83, .88]
Anxiety 6 .89 [.88, .90] .83 .89 [.87, .92]
Complex imagery 3 .80 [.77, .83] .77 .80 [.77, .83]
Elementary imagery 3 .84 [.81, .86] .73 .86 [.83, .88]
Audio-visual synesthesiae 3 .91 [.89, .92] .89 .91 [.89, .93]
Changed meaning of percepts 3 .79 [.77, .82] .75 .80 [.76, .84]
Note. Numbers in brackets indicate 95% confidence intervals.
setting might be explained in part by the fact that subjects had more time to concentrate
on their experiences when drug sessions took place at the PET center. Specifically,
subjects did not have to perform tasks during PET measurements, they were mostly
lying in a comfortable horizontal position, and they could have their eyes closed most
of the time. However, similar to the questionnaire variable, the setting variable might
have been confounded by the effects of different drug doses. The average psilocybin
doses administered at the PET center and at the laboratory were 219 and 254 μg/kg,
respectively, whereas the average doses of ketamine were 0.79 and 0.87 μg · kg-1 · min-1,
respectively.
Although we have controlled the effects of different drug doses in a separate MIMIC
model in which we included more dummy variables for different drug groups (i.e.,
dummy variables for low dose psilocybin, low medium dose psilocybin, high medium
dose psilocybin, high dose psilocybin, medium dose ketamine, and high dose ketamine
with MDMA as the reference group), we decided to provide the results of this analysis
as supplementary material only (see Supplementary Table S8) because a Monte Carlo
analysis indicated that the complexity of this model was too high for the size of our
sample. Nevertheless, the MIMIC model that included these dose predictors suggested
the effects of the PET setting were only slightly confounded by different drug doses.
Although the effect sizes were slightly reduced, none of the effects of the setting variable
changed statistical significance.
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4.4.5 Reliability Assessment
The results of the reliability assessment of the original and new OAV scales are shown
in Table 10. Because the original scales were demonstrated to be multidimensional
in the CFA, it was expected that Cronbach’s α would be a biased reliability index for
these scales. Indeed, a comparison of α with alternative indexes of reliability revealed
that α grossly overestimated reliability, when reliability is defined as the proportion
of variance in a scale that is due to one common factor (McDonald’s ωh) and slightly
underestimated reliability, when reliability is defined as the proportion of variance due
to all common factors (McDonald’s ωtot). However, even though variance explained by
group factors (i.e., factors that are related to a subset of items within a scale) contributed
considerably to the very high α coefficients in the original scales, it should be noted that
these scales showed relatively large general factor saturations. Specifically, Revelle’s
β and McDonald’s ωh were larger than 0.7 for the OBN, DED, and VRS scales and still
exceeded 0.6 for the total scale (i.e., G-ASC). Thus, although the original scales are
not unidimensional, the general factors (i.e., factors that are common to all items in
a scale) clearly dominated these scales because they explained more than 70% of the
variance in the OBN, DED, and VRS scales and more than 60% in the total scale. Because
these values exceeded the recommended minimum threshold of Revelle (1979), who
suggested that the amount of variance explained by the general factor should be at
least 50%, and in case of the OBN, DED, and VRS scales even exceeded the more stringent
recommendations of Rossiter (2002), who suggested aiming for a coefficient β of 0.7, the
calculation of sum scores from these scales, including the G-ASC scale that includes all
66 items, could be justified.
When applied to the new OAV scales, Cronbach’s α was a less biased estimator of
scale reliability. This was expected, as the new OAV scales had been shown to be
unidimensional in the CFA. However, because α underestimates reliability when the
items of a scale are not tau-equivalent (i.e., have unequal factor loadings) and because
the assumption of tau-equivalence was not met by most of the new OAV scales, ρSEM was
slightly higher than α in these scales. When estimated by ρSEM, most of the new OAV
scales showed good reliabilities. Only two of the 11 scales (insightfulness and spiritual
experience) had reliabilities smaller than 0.8. However, both of these scales consisted
of only three items, and their reliabilities were still above 0.7, which indicates modest
reliability (Nunnally & Bernstein, 1994). By comparing ρSEM of the new scales with ωh
and ωtot of the old scales it can be seen that, although the new OAV scales have lower
reliabilities than the old OAV scales when reliability is defined as the amount of variance
in a scale that is due to all common factors, they contain a larger proportion of variance
attributable to one common factor. Hence, the new scales are more homogeneous than
the old scales. This was also confirmed by the values of coefficient β, which generally
were higher for the new scales than for the old OAV scales.
4.4.6 Validity Assessment
Pearson correlations between the OAV scales and the 15 subscales of the EWL-60-S com-
puted from the raw sum scores are presented in Table 11. The directions and sizes of
the correlations between OAV and EWL-60-S subscales covering similar and dissimilar
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content supported the convergent and discriminant validities of the new OAV scales. For
instance, the new OAV anxiety scale correlated highest with the apprehension-anxiety
scale of the EWL-60-S, impaired control and cognition correlated highest with concen-
tration, audio-visual synesthesiae correlated highest with sensitivity, vivid imagery
correlated highest with dreaminess, and blissful state correlated highest with height-
ened mood. Compared to the old OAV scales, the new OAV scales tended to correlate
higher with scales measuring similar experiences. For example, although the OBN
scale correlated highest with the EWL-60-S subscale that was hypothesized to cover the
most similar content (i.e., the heightened mood scale), this correlation (r = .27) was
considerably lower than the correlation between the more specific blissful state scale
and the heightened mood scale (r = .37).
Pearson correlations between the OAV and the STAI-S scales showed that the STAI-S
total scale was significantly associated with DED (r = .59, p < .001), anxiety (r = .54,
p < .001), and impaired control and cognition (r = .45, p < .001). The STAI-S anxiety
present scale correlated significantly with DED (r = .60, p < .001), G-ASC (r = .38, p <
.001), impaired control and cognition (r = .52, p < .001), anxiety (r = .51, p < .001), and
changed meaning of percepts (r = .33, p = .012), whereas the STAI-S anxiety absent scale
correlated significantly with DED (r = .45, p < .001), anxiety (r = .45, p < .001), blissful
state (r = -.44, p < .001), and impaired control and cognition (r = .30, p = .024). Although
these correlations further support the construct validities of the OAV scales, it should be
noted that these correlations were calculated on the basis of a relatively small sample of
56 experimental sessions, primarily involving MDMA administration, which is known to
rarely induce anxiety or even has anxiolytic effects (Liechti & Vollenweider, 2000).
Figure 6 displays the mean scores of the new and original OAV scales in the three
different drug groups. As can be seen from the plot, the new OAV scales differentiated
well among the three drug groups and provided considerably more information on the
specific effects of MDMA, ketamine, and psilocybin than the original scales.
4.5 discussion
This study examined the factorial structure of the OAV questionnaire in a sample of
drug induced ASCs by using SEM methodology. The results of this study do not support
the three dimensional structure originally proposed by the authors of the OAV (Bodmer,
1989; Dittrich, 1994). The original model provided a poor fit to the data not only
when cross-loadings and residual correlations were fixed to zero (simple structure
CFA), but also when cross-loadings were freely estimated and residuals of items with
similar wording were allowed to freely co-vary (ESEM with method effects) or when an
additional general factor was specified (bifactor model).
Although none of the three originally hypothesized OAV factors met criteria of
unidimensionality, the results of this study suggest that the VRS factor is the biggest
source of misfit. The VRS factor provided not only the worst fit to the data when the
three factors were tested separately by one-factor CFAs, it also contained the highest
number of items having “wrong” salient factor loadings in the ESEM (six of the seven
mis-assigned items were VRS items) and had the lowest general factor saturation. The
finding that VRS is the most heterogeneous factor is in agreement with both of the
two other studies that have re-examined the factorial structure of the OAV after its first
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Figure 6: Known-group validities of the original and new OAV scales. Error bars represent
standard errors. Double click here to extract the data underlying this plot.
publication. Habermeyer (1999), who conducted a principal component analysis with
varimax-rotation on a sample of 93 endogenous psychotic patients who completed
the OAV by referring to their most recent acute psychotic episode, found that 10 of
the 18 VRS items loaded highest on the OBN factor. Similarly, in a study of Bodmer
(1999), in which an EFA with target rotation was conducted using measurements of 135
experimentally induced ASCs, 13 VRS items loaded highest on the OBN factor.
The VRS items that were wrongly assigned to the OBN factor in the studies of Haber-
meyer (1999) and Bodmer (1999), as well as in the present study, are highly congruent.
That is, in all three studies, these items describe experiences of changed meaning
of percepts, facilitated recollection, and insightfulness. Additionally, in the studies
of Habermeyer (1999) and Bodmer (1999), the wrongly assigned VRS items included
items measuring vivid imagery. It should be noted that – except for changed meaning
of percepts – these facets were not part of the original conceptualization of the VRS
dimension (i.e., in the original APZ questionnaire), but were introduced during con-
struction of the OAV. Because analyses of the APZ had indicated that the VRS dimension
describes not only changes in visual perceptions and their associated meanings, but
also a general increase in the perception of internally produced stimuli, Bodmer (1989)
hypothesized that the VRS dimension could be conceptually extended by incorporating
items measuring an increase of imagery thoughts, associations, and memory retrieval.
Bodmer’s re-conceptualization of the VRS dimension was mainly driven by theoretical
considerations of Leuner (1962, 1981), who had speculated that hallucinogenic drugs
elicit visual hallucinations by intensifying internal imagery such that the distinction
between internally produced imaginary images and external perceptions becomes
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blurred. However, given that three studies, including the present study – which has a
much larger sample size than the original validation study – have not supported this
hypothesis, it appears now that the re-conceptualization of VRS has worsened rather
than improved its psychometric properties.
Although reducing the VRS dimension to a set of items tapping only visual alterations
would markedly increase its homogeneity, our results indicate that such a construct
would still be difficult to separate from the OBN dimension on a high level of the
construct hierarchy – especially when potential method effects of similarly worded
VRS items are taken into account. Whereas in the three-factorial ESEM without method
effects, VRS emerged as a separate factor, it completely merged with the OBN factor
when method effects were accounted for by specifying correlated errors. Similarly, the
ICLUST algorithm, which seems to be less sensitive to method effects than EFA (Cooksey
& Soutar, 2006), combined the OBN and VRS factors to one cluster. This suggests that
the VRS factor – at least in part – could be an artifact of method effects. Unfortunately,
previous OAV validation studies did not consider this possibility because they exclusively
relied on EFA, which cannot account for method effects (Brown, 2006).
Before discussing the issue of what would be the most appropriate number of
factors to extract from the OAV, it should be noted that psychological constructs have a
hierarchical structure such that different constructs have different levels of conceptual
breadth. Hence, the number of factors that can be proposed and assessed is infinite
(Reise et al., 2000). The appropriate number of factors to extract depends on the
appropriate conceptual breadth of a factor, which, in turn, depends on its specific use.
For instance, factors on a high level of the construct hierarchy (i.e., broad constructs)
are best suited to predict heterogeneous/complex criteria, whereas narrow-band factors
are most efficacious in predicting a specific criterion (Reise et al., 2000). The authors
of the OAV decided to extract factors only on a high level of the construct hierarchy
because they were primarily interested in the so called etiology-independent dimensions
(Dittrich, 1985; Bodmer, 1989). However, even if only higher order factors are considered,
we have not found evidence for a parsimonious fit of a three-factorial solution. The
ICLUST procedure indicated that only two factors account for the variance between OAV
items on a high level of the construct hierarchy. Whereas one of these two factors was
equal to the original DED factor, the other consisted of OBN and VRS items. This suggests
that, on a high level, the OAV items are best divided on the basis of whether they describe
pleasant (OBN and VRS) or unpleasant (DED) experiences. Revelle’s VSS criterion, as
well as indexes of general factor saturation, such as Revelle’s β and McDonald’s ωh,
indicated that the OAV items could be combined on an even higher level of the construct
hierarchy to form a total scale. This finding is in agreement with the originally proposed
general factor G-ASC, which is supposed to be a general measure of the alteration in
consciousness (Bodmer, 1989). According to ωh, the general factor accounted for as much
as 65% of the common variance between all 66 items of the total scale. Thus, although
the total scale is multidimensional and therefore forms ambiguous correlations with
other psychological constructs, the general factor saturation is high enough to justify its
use for the prediction of complex criteria (Revelle, 1979; Rossiter, 2002). The same is
true for the OBN, DED, and VRS and the “pleasant” and “unpleasant” scales, which also
showed strong general factor saturations despite clear rejection of unidimensionality by
CFA.
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Although the authors of the OAV have considered lower order scales as unreliable
and unstable and therefore refrained from their extraction, this study has demonstrated
that a number of lower order scales can be constructed that are not only reliable, but
also stable (measurement invariant) and valid. Specifically, by using ICLUST, CFA, and
MIMIC, we constructed and evaluated 11 new OAV scales formed on the basis of 42
items. The new OAV scales were demonstrated to have many advantages over the
old OAV scales. Most importantly, the new scales met criteria of unidimensionality
and therefore are more homogeneous than the old scales. Unlike the old scales, the
new scales provided a reasonably good fit to the data when modeled as congeneric
factors in a simple structure CFA. This is important because a well fitting CFA model
is a prerequisite for further analyses within the SEM-framework. For instance, testing
measurement invariance by MIMIC or multiple group CFAs and directly estimating
reliabilities and disattenuated correlations with other constructs is not possible without
a well fitting basic measurement model (Brown, 2006). By using a MIMIC model with five
binary predictors, the new OAV factors were demonstrated to be highly measurement
invariant across three drug groups, two settings, two questionnaire versions and sexes.
Although a small number of items showed DIF, especially when comparing the MDMA
and ketamine groups, the impact of DIF on the comparisons of latent factor means
was small. This is important for the use of these scales in applied research because it
suggests that group mean differences in these scales are hardly confounded by structural
differences when calculated on the basis of raw sum scores and by using methods that
cannot account for DIF, such as ANOVA.
Although the new scales, due to their lower item number, were less reliable than the
old scales when reliability is defined as the proportion of variance that is due to all
common factors present in a scale, they still showed relatively high reliabilities. Nine
scales had reliabilities beyond 0.8 and two scales had reliabilities between 0.7 and 0.8.
Because reliability requirements are weaker when scales are used predominantly to
compare groups and not for making decisions about individuals (as it is the case with
the new OAV scales), reliability indexes of this size can be considered adequate. In fact,
it has been argued that increasing reliabilities much beyond 0.8 in basic research is
not worth the effort because measurement error attenuates correlations very little at
this level (Nunnally & Bernstein, 1994). Indeed, the lower reliabilities of the new OAV
scales did not lead to lower correlations with other psychological constructs, such as
the subscales of the EWL-60-S. Even though these correlations were based on raw scores,
i.e., were not corrected for measurement error, the new OAV scales tended to correlate
more strongly than the old OAV scales. This suggests that the lower reliabilities of new
OAV scales were more than compensated by their higher homogeneities.
The new scales were also shown to have good convergent and discriminant validities
and to differentiate well among the subjective effects of psilocybin, ketamine, and
MDMA. For example, in the MIMIC model, 10 of the 11 new factors were significantly
affected by at least one drug contrast variable. The effects of the drug contrast variables
supported the known group validities of the new OAV scales because the magnitude
and direction of the effects were well in line with what is known about these drugs
from the scientific literature. Overall, the new OAV scales differentiated better among
the three drug groups than the old scales. For example, the very strong effects of MDMA
on blissful state and of ketamine on disembodiment would not have been detected by
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using the original OAV scales alone because these experiences would have been mixed
up with other experiences measured by the OBN scale.
The interpretation of our results with regard to Dittrich’s original hypothesis (i.e., ASCs
– independent of their means of induction – can be parsimoniously described by the three
oblique primary dimensions OBN, DED, and VRS and the secondary dimension G-ASC) is
complicated by the fact that we have analyzed an item set that has been pre-selected
to be in accordance with this hypothesis. Unlike the items of the APZ, the items of the
OAV were selected and worded to maximally load on one of the three hypothesized
primary dimensions (see Bodmer, 1989). Consequently, the factorial structure of the OAV
is most likely reflecting this item selection and cannot provide independent evidence for
the validity of Dittrich’s hypothesis. Unfortunately, as mentioned in the introduction,
Dittrich’s factorial structure of ASCs may not only be specific to the set of items he
selected, it may also be dependent on the data analyzing methods he used. Given
these rather severe limitations of Dittrich’s original investigations and given that the
present study has not confirmed that a three-factorial solution provides a parsimonious
fit to the data on a high level of the construct hierarchy, even though the analysis was
based on a pre-selected set of items, it seems highly premature to postulate three major
dimensions of ASCs, let alone to call them etiology-independent.
4.5.1 Limitations
Because the sample of the present study was too small to split it in two halves and to
perform exploratory and confirmatory analyses on separate data sets, we have not cross-
validated our results. It is therefore possible that we have capitalized on chance at least
to some degree. Furthermore, measurement invariance and population heterogeneity of
the new OAV scales were only examined by MIMIC modeling and not by multiple-group
CFA. This means that we were only able to test the invariance of indicator intercepts
and factor means and that all other measurement and structural parameters (i.e., factor
loadings, error variances/covariances, factor variances/covariances) were assumed to
be equal across the levels of the covariates. Studies that use multiple-groups CFA are
clearly needed to further establish measurement invariance of the new OAV scales. The
invariance of measurement and structural parameters should also be investigated across
additional groups of drugs, dosages, ASC induction methods, settings, and languages.
Although the newest version of Dittrich’s ASC rating scales (i.e., the 5D-ASC) contains
94 items, this study has only analyzed the 66 items that it shares with the second
newest version (i.e., the OAV). Future studies must clarify whether the common variance
between the 28 items that are unique to the 5D-ASC is sufficiently well explained by the
two hypothesized factors Vigilance Reduction (VIR) and Auditory Alterations (AUA).
Since we have shown that the OBN, DED, and VRS scales can be split into many reliable
and valid subscales, it is conceivable that the same could be done with the VIR and AUA
scales.
4.5.2 Conclusions and Recommendations
The present study confirmed that the general factor (G-ASC) accounts for most of the
common variance among OAV items. However, our results only partially supported
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the hypothesized structure of group factors. Most importantly, we demonstrated
that the OBN, DED, and VRS scales are multidimensional constructs that can be split
into many reliable and valid subscales. Although the use of the OBN, DED, and VRS
scales – due to their relatively strong general factor saturations – might be justified for
predicting complex criteria, we believe that our newly constructed subscales should be
preferred for most applications because they are only slightly less reliable but much
more homogeneous. Hence, they form less ambiguous correlations with other measures,
are easier to interpret, and provide important additional information on more specific
experiences of ASCs. We especially caution against the use of the VRS factor in its current
form, because a large number of its items repeatedly loaded higher on the OBN than on
the VRS factor and because its emergence in EFA might be an artifact of method effects.
5
P R E D I C T I O N O F P S I L O C Y B I N R E S P O N S E I N H E A LT H Y
V O L U N T E E R S
5.1 abstract
Responses to hallucinogenic drugs, such as psilocybin, are believed to be critically
dependent on the user’s personality, current mood state, drug pre-experiences, ex-
pectancies, and social and environmental variables. However, little is known about
the order of importance of these variables and their effect sizes in comparison to drug
dose. Hence, this study investigated the effects of 24 predictor variables, including age,
sex, education, personality traits, drug pre-experience, mental state before drug intake,
experimental setting, and drug dose on the acute response to psilocybin. The analysis
was based on the pooled data of 23 controlled experimental studies involving 409 psilo-
cybin administrations to 261 healthy volunteers. Multiple linear mixed effects models
were fitted for each of 15 response variables. Although drug dose was clearly the most
important predictor for all measured response variables, several non-pharmacological
variables significantly contributed to the effects of psilocybin. Specifically, having a
high score in the personality trait of Absorption, being in an emotionally excitable and
active state immediately before drug intake, and having experienced few psychological
problems in past weeks were most strongly associated with pleasant and mystical-type
experiences, whereas high Emotional Excitability, low age, and an experimental setting
involving positron emission tomography most strongly predicted unpleasant and/or
anxious reactions to psilocybin. The results confirm that non-pharmacological variables
play an important role in the effects of psilocybin.
5.2 introduction
Responses to classical hallucinogens, such as psilocybin, strongly vary between and
within subjects, even when the drug dose is kept constant (Nichols, 2004; Studerus,
Kometer, et al., 2011). It has therefore long been postulated that a large proportion of
inter- and intraindividual differences in reactions to hallucinogens is determined by
non-pharmacological variables – also often referred to as set and setting. As originally
defined by Leary et al. (1963), set refers to the preparation of the subject, his personality
structure, and current mood state, whereas setting refers to the the physical, social, and
cultural environment in which the drug is taken. Although set and setting influence
the psychological effects of any psychotropic substance, including alcohol and nicotine
(e.g. see Janke, 1983), the effects of hallucinogens seem to be particularly strongly
determined by these conditions (Eisner, 1997; Nichols, 2004). In fact, they are not only
said to be influenced by an individual subject’s mental state and surroundings, but to
pharmacologically amplify the impact of these non-pharmacological factors on human
experience (Grinspoon & Bakalar, 1979; Langlitz, 2010).
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Since human hallucinogen research has been dormant for almost three decades and
has only come to a revival recently (Vollenweider & Kometer, 2010), most of what
we know today about non-pharmacological predictors of hallucinogen response is
based on a small number of older studies, many of which do not conform to modern
methodological standards. Nevertheless, most of these studies suggest that responses
to classical hallucinogens are dependent at least to some degree on the personality
structure (e.g., Kornetsky & Humphries, 1957; Rinkel et al., 1961; Fischer, Marks, Hill,
& Rockey, 1968; Barr & Langs, 1972; Hemsley & Ward, 1985; Dittrich, 1994; Lienert &
Netter, 1996; Bresnick & Levin, 2006). Further influencing factors include the mood
state immediately before drug intake (e.g., Metzner et al., 1965; Dittrich, 1994), peer-
support (Dunsmore & Kaplan, 1997), estimated emotional support (Leary et al., 1963),
expectations of the subjects (e.g., Leary et al., 1963; Metzner et al., 1965; Dittrich, 1994),
age (Hyde, 1960; Metzner et al., 1965), body morphology (Metzner et al., 1965), size
of the group in which the drug is taken (Leary et al., 1963), and drug pre-experiences
(Leary et al., 1963; Metzner et al., 1965).
However, most of these studies have obtained only a limited number of potential
predictors at a time. Furthermore, almost all of these studies have relied on simple
correlations instead of multiple regression to investigate associations between set
and setting variables and drug response. Thus, they did not adjust for potentially
confounding variables and also could not reveal the order of importance of different
variables. The only exception is a study by Dittrich and his colleagues (Dittrich &
Lamparter, 1994; Dittrich, 1994), which has used multiple regression to predict responses
to N,N-dimethyltryptamine (DMT), nitrous oxide, and sensory deprivation from a large
number of different set and setting variables. Unfortunately, the sample size of the DMT
subgroup was relatively small (n = 45), and the study so far has only been published in
book chapters.
Given these methodological problems and given that a growing number of investiga-
tors are using hallucinogens for experimental and therapeutic purposes (Vollenweider
& Kometer, 2010), new investigations on set and setting are both timely and important.
Beyond basic research, such investigations could serve the following purposes. First,
they can help to improve the safety of controlled experiments using hallucinogens by
providing a basis for deciding which subjects to exclude at screening and how to adjust
the environment and procedures for minimizing the risk of adverse reactions. Second,
they help to better standardize future experiments. For instance, treatment allocation
can be improved by stratifying experimental and control groups on the most important
non-pharmacological predictors and efforts in controlling confounding variables can be
better directed to those that really matter. Furthermore, the most important predictors
can be used for covariate adjustment in randomized controlled trials, which improves
precision and power in the estimation of treatment effects (Steyerberg, 2009). Last but not
least, knowledge about non-pharmacological predictors can significantly advance our
understanding of the neurobiological systems involved in the actions of hallucinogens.
This is because individual differences in personality, demographic characteristics, mood,
etc. on the one hand, and responsiveness to hallucinogens on the other hand, could
be both related to structural and functional differences in specific neurotransmitter
systems. In the case of psilocybin, differences are most likely related to differential func-
tioning and density of cortical 5-HT2A receptors because this is the main site of action of
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classical hallucinogens (González-Maeso, Weisstaub, et al., 2007; Geyer & Vollenweider,
2008). However, other receptors (particularly the 5-HT1, 5-HT4, 5-HT5, 5-HT6, and 5-HT7
receptors) and neurotransmitter systems (particularly the glutamate system), which
are additionally involved in the actions of classical hallucinogens (González-Maeso
& S. Sealfon, 2009; Vollenweider & Kometer, 2010), might also contribute to common
individual differences.
Thus, to further elucidate the dependency of psilocybin response on set and setting,
the present study investigates the relative importance of 24 predictor variables, including
age, sex, years of education, body mass index, personality traits, drug pre-experience,
mental state before drug intake, psychological distress, experimental setting, and drug
dose. The analysis is based on the pooled data of 23 controlled experimental studies.
Most of these have been published before as single studies. Additionally, data from
eight of the 23 pooled studies (i.e., those carried out between 2000 and 2008) were
used in a recent pooled analysis on acute, subacute, and long-term subjective effects of
psilocybin (Studerus, Kometer, et al., 2011) and data from 20 studies (i.e., all but the
three most recent studies) were used in a recent psychometric investigation of the OAV
questionnaire (Studerus, Gamma, & Vollenweider, 2010). However, none of these studies
have yet reported about the dependency of psilocybin effects on non-pharmacological
predictors.
This study improves on previous predictor studies in several ways. First, the sample
size (n = 409) is about four times as large as in the largest previous study (Leary et al.,
1963). Second, the predictor variables that we used covered a wide range of potentially
important domains, and the effects of these predictors were adjusted for the most
important confounders. Third, all outcome variables and most of the predictor variables
were measured by validated instruments. Fourth, psilocybin was administered under
highly standardized research conditions. Finally, by using modern statistical techniques,
such as the bootstrap, more reliable estimates of variable importance were obtained.
5.2.1 Pooled Studies
The sample used in the present investigation was obtained by pooling raw data from
23 experimental studies (including pilot studies) involving psilocybin administration
to healthy volunteers. The studies were conducted at our research facility between
1992 and 2011 as part of a research program in which psilocybin was used as a tool
for pharmacological modeling of core symptoms of schizophrenia and for studying
cognitive, perceptual, and emotional processes (Vollenweider & Geyer, 2001; Geyer
& Vollenweider, 2008). All studies were approved by the Ethics Committee of the
University Hospital of Psychiatry, Zurich, and the use of psilocybin was authorized by
the Swiss Federal Office of Public Health, Department of Pharmacology and Narcotics,
Berne. To minimize potential risks of psilocybin administration, safety guidelines
similar to those recommended by Johnson, Richards, and Griffiths (2008) were followed
in all studies.
All pooled studies used placebo-controlled within-subject designs. Depending on the
study, subjects received placebo and 1-4 different doses of psilocybin in 2-5 experimental
sessions, each separated by at least two weeks to avoid carry-over effects. In six of the
pooled studies, subjects also received a receptor blocker (i.e., buspirone, ketanserin,
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haloperidol, lamotrigine, and risperidone) alone and in combination with psilocybin. In
the majority of the studies (n = 16), the order of drug administration was randomized
and double-blind, but some of the earlier studies as well as most pilot studies (n = 7)
were open-label trials.
For the present analysis, we only used data from experimental sessions in which
psilocybin was administered alone and at a dose of at least 115 μg/kg po. Lower
psilocybin doses were excluded because they failed to produce subjective drug effects
that were statistically different from placebo (Hasler, Grimberg, et al., 2004; Studerus,
Kometer, et al., 2011). The pooled sample included 409 psilocybin administrations and
261 subjects. The administered psilocybin dose ranged from 115 to 315 μg/kg po (M ±
SD: 214 ± 63 μg/kg; see also Table 13 for the frequencies of different dose categories).
5.2.2 Subjects
Participants of all studies were recruited through advertisement from the local universi-
ties and hospital staff and carefully screened before admission to the studies. Exclusion
criteria were as follows: Personal or family history of schizophrenia, major depression,
bipolar, and borderline personality disorder; personal history of alcohol or illicit drug
abuse; neurological disorders; and abnormal blood count, electrocardiogram, or blood
pressure. Additionally, most studies excluded subjects with an Emotional lability score
in the Freiburg Personality Inventory (FPI; Fahrenberg, Hampel, & Selg, 1978) more
than two standard deviations above the mean of a normative sample. All subjects gave
their written consent after having received detailed information about the aims of the
studies, the experimental procedures involved, and the effects and possible risks of
psilocybin administration. Subjects were reimbursed for their time and free to withdraw
from the study at any time. Descriptive statistics of the included subjects are presented
in Table 12.
5.2.3 Predictor Variables
Two groups of predictor variables were used: (1) Predictor variables that only varied
between subjects, i.e., were constant across different drug sessions of the same indi-
vidual, and (2) predictor variables that varied between and within subjects. Predictor
variables of the first group were measured at screening and included age, gender, body
mass index (BMI), years of education, drug use, psychological problems, and stable
personality traits, whereas predictor variables of the second group were either measured
at the beginning of each drug session shortly before drug administration (e.g., measures
of the present mood state) or determined by the design of the experiment (e.g., drug
dose, environment of the drug session, and time of assessment). Predictors of the first
and second group thus describe subject (Table 12) and session characteristics (Table 13),
respectively.
5.2.3.1 Drug use and pre-experience with classical hallucinogens
Depending on the study, information on present and past drug use was obtained by
semi-structured psychiatric interviews or by one of two different versions of investi-
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Table 12: Descriptive Statistics of Subjects (n = 261)
Characteristics Valuesa Missings
Age 27.8±6.0 0%
Body mass index 22.2±2.3 25%
Gender 0%
male 62% (161)
female 38% (100)
Education 0%
High school diploma 9% (23)
University students 56% (147)
University graduates 35% (91)
Hallucinogen-naïve 15%
yesb 59% (131)
no 41% (90)
Daily smoker 24%
yes 30% (59)
no 70% (139)
THC use 16%
never 16% (35)
rarelyc 50% (109)
sometimesd 35% (76)
Alcohol consumption 23%
<= 60 ml per month 55% (110)
>60 ml per month 45% (90)
ZKPQ
Impulsive Sensation Seekinge 0.4±0.8 52%
Neuroticism-Anxietye -0.9±0.7 52%
Aggression-Hostilitye -0.6±0.9 52%
Activitye 0.0±0.9 52%
Sociabilitye -0.1±0.9 52%
TAS
Absorptionf -0.8±1.2 72%
SCL-90-R
Global Severity Indexg -0.3±0.9 31%
Note. THC = Tetrahydrocannabinol; ZKPQ = Zuckerman-Kuhlman Personality Questionnaire;
TAS = Tellegen Absorption Scale; SCL-90-R = Symptom Check-List-90-Revised.
aMeans ± standard deviations and frequencies are shown for continuous and categorical
variables, respectively. Numbers in parenthesis indicate absolute frequencies. bExperience of a
classical hallucinogen at least once in a lifetime previous to the first experimental day. cLess
than once per month. d1-10 times per month. eNormed on the Bielefeld-Jena sample (n = 141)
of Angleitner, Riemann, and Spinath (2004). fNormed on the sample of Ritz and Dahme (1995).
gNormed on a German community sample (n = 1006; G. H. Franke, 1995).
96 prediction of psilocybin response in healthy volunteers
gator constructed questionnaires. The following categorical predictor variables were
constructed by pooling information from all available sources: (1) “Daily-smoker” is
a dichotomous variable that is one if the subject smokes at least one cigarette a day
and zero otherwise. (2) “Alcohol consumption” is a dichotomous variable that is one if
the subject drinks more than 60 ml pure ethanol from alcoholic beverages per month
and zero otherwise. (3) “THC use” is an ordered categorical variable with the three
categories “never” (absolutely no experience with THC), “rarely” (less than once per
month), and “sometimes” (at least once per month). THC use was represented in all
regression models as two dummy coded contrast variables using an ordinal coding
scheme. That is, when both variables were contained in the model, the first dummy
variable represented the difference between “never” and “rarely” and the second be-
tween “rarely” and “sometimes”. (4) “Hallucinogen-naïve” is a dichotomous variable
that is one if the subject has never used classical hallucinogens, such as psilocybin, LSD,
and mescaline and zero otherwise. Hallucinogen-naïve is the only drug use variable
that could change from one session to another within the same individual because
participations on earlier experimental psilocybin sessions were also counted as lifetime
hallucinogen experiences. Distributional characteristics of the four drug use variables
are displayed in Table 12.
5.2.3.2 Zuckerman-Kuhlman Personality Questionnaire (ZKPQ; Zuckerman, 2002)
The ZKPQ contains 99 self-referent true/false statements that cover five major dimensions
of personality (1) Impulsive Sensation Seeking consists of of the two facets Impulsivity
(i.e., a lack of planning and tendency to act quickly on impulse without thinking) and
Sensation Seeking (i.e., a general need for thrills and excitement and preference for
unpredictable situations and friends). (2) Neuroticism-Anxiety describes emotional
upset, worry, fearfulness, obsessive indecision, lack of self confidence, and sensitivity
to criticism. (3) Aggression-Hostility reflects a readiness to express verbal aggression;
rude, thoughtless or antisocial behavior; vengefulness; spitefulness; and a quick temper
and impatience with others. (4) Activity consists of the two facets Need for General
Activity (i.e., impatience and restlessness when there is nothing to do) and Work Activity
(i.e., a preference for challenging and hard work). (5) Sociability comprises the two
components Parties and Friends (i.e., a liking for big parties, interacting with many
people and having many friends) and Isolation Intolerance. There is also a control scale,
the Infrequency scale, that serves to eliminate subjects with possibly invalid records.
The ZKPQ is the standard instrument for the assessment of Zuckerman’s alternative
Five-Factor Model (FFM) of personality. In contrast to the classic FFM (the so called “Big
Five”), which has been identified by lexical analyses of words describing personality, the
development of the alternative FFM was guided by the assumption that basic personality
traits are those with a strong biological-evolutionary basis (Zuckerman, 2002). Conse-
quently, the primary dimensions of the ZKPQ were identified by factor analyzing scores
on a variety of personality and temperament scales with known or suspected biological
determinants. However, despite conceptual and methodological differences, joint factor
analyses of the ZKPQ with the NEO-PI-R (Costa & McCrae, 2008), a well established
measure of the Big Five, suggest a large overlap between the two FFMs (P. Schmitz, 2004).
That is, the ZKPQ factors Sociability and Neuroticism-Anxiety are considered highly
convergent with the Big Five factors Extroversion and Neuroticism, respectively, and
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Table 13: Descriptive Statistics of Psilocybin Sessions (n = 409)
Characteristics Valuesa Missings
Psilocybin dose (μg/kg) 214.1±63.0 0%
Psilocybin dose (categorized) 0%
115-125 μg/kg 23% (93)
170 μg/kg 9% (35)
215-225 μg/kg 20% (83)
250-270 μg/kg 38% (157)
315 μg/kg 10% (41)
Time of assessmentb 0%
60-90 min 23% (96)
110-160 min 39% (158)
195-270 min 23% (94)
6-10 h 13% (53)
24 h 2% (8)
Setting 0%
PETc 12% (51)
no PET 88% (358)
aMeans ± standard deviations and frequencies are shown for continuous and categorical
variables, respectively. Numbers in parenthesis indicate absolute frequencies. bCompletion of
OAV or 5D-ASC questionnaire after drug intake. cDrug sessions involving positron emission
tomography measurements.
the ZKPQ factors Impulsive Sensation Seeking and Aggression Hostility have shown at
least moderate negative correlations with the Big Five factors Conscientiousness and
Agreeableness, respectively.
The authorized German adaptation of the ZKPQ, which has shown good psychometric
properties in two independent German samples (Angleitner, Riemann, & Spinath, 2004),
was used in 11 of the 23 pooled studies and completed by 125 subjects.
5.2.3.3 Freiburg Personality Inventory (FPI; half form B; Fahrenberg et al., 1978)
The FPI half form B contains 105 self-referent true/false statements which – according to
the authors of the instrument – measure nine primary and three secondary dimensions
of personality. It was administered as part of the screening procedure in 16 of the 23
pooled studies and completed by 155 subjects. The FPI measures very similar personality
traits as the ZKPQ. Thus, in order to reduce multicollinearity and to keep the number of
candidate predictors low, we only used the scales of the FPI for imputing missing values
of the ZKPQ, but not for predicting acute drug responses directly (see statistical analysis
section for additional details). Even though the FPI was more completely assessed (40.6
% missings in the FPI vs. 52.1 % missings in the ZKPQ), we decided to use the ZKPQ and
not the FPI for predicting psilocybin responses because the ZKPQ has undergone more
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extensive psychometric testing and is much more widely used internationally than the
FPI half form B.
5.2.3.4 Tellegen Absorption Scale (TAS; Tellegen & Atkinson, 1974)
The TAS is a widely used self-report questionnaire for assessing the personality trait
absorption. As measured by the TAS, absorption refers to an individual’s openness to
a variety of cognitive, perceptual, and imagistic experiences as well as vivid imagery,
synesthesiae, and intense involvement in aesthetics and nature. The TAS has been
reported to be strongly associated with fantasy proneness, and modestly with the Big
Five factor Openness to Experience and hypnotic susceptibility (Roche & McConkey,
1990)
We used the German Version of the TAS (Ritz & Dahme, 1995) with a modified item
response format (i.e., five-point Likert scale ranging from does not apply (0) to does fully
apply (4) instead of the original dichotomous true or false response), which is the same
version as Ott, Reuter, Hennig, and Vaitl (2005) have used. It was administered in 4 of
the 23 pooled studies and completed by 73 subjects. The internal consistency as well as
the general factor saturation of the TAS in our sample were excellent (Cronbach’s α =
0.95; McDonald’s ωh = 0.75).
5.2.3.5 Passive-Spontaneous Imagination (PASI)
The PASI is a subscale of the Hallucination Prediction Inventory (HPI-81; Diezi, Faeh,
& Hermann, 1982), which was constructed to explain individual differences in ex-
periencing visual alterations during ASCs. It consists of 30 four-point Likert scale
items measuring the frequencies of visual phenomena that spontaneously occur during
hypnagogic and hypnopompic states, daydreaming, closed eyes, listening to music,
thinking, and imagining (see Supplementary Table S9, for an English translation of the
PASI items). The PASI was reported to have good psychometric properties in a normative
sample of 442 subjects (Diezi et al., 1982). Furthermore, in a experiment, in which ASCs
were induced by sensory deprivation (n = 35), the PASI was a strong predictor of visual
hallucinatory phenomena as measured by the Visionary Restructuralization scale of the
APZ questionnaire (Dittrich, 1998).
The PASI was administered in 8 of the 23 pooled studies and completed by 107 subjects.
The internal consistency of the PASI in our sample was excellent (Cronbach’s α = 0.93),
and the general factor saturation was satisfactory (McDonald’s ωh = 0.65). There was
also a strong correlation of the PASI with the TAS (r = 0.77, n = 53), suggesting a large
overlap between these two constructs. In order to reduce redundancy, we only used the
PASI to impute missing values of the TAS, but not for predicting psilocybin responses
directly. Similar to the FPI and ZKPQ, the TAS was preferred over the PASI even though
it had more missing values (72 % missings in the TAS vs. 59 % missings in the PASI)
because it is more widely used internationally and has been more extensively validated.
5.2.3.6 The Symptom Check-List-90-Revised (SCL-90-R; Derogatis, 1994; German version by
G. H. Franke, 1995)
The SCL-90-R is a widely used self-report inventory designed to screen for a broad range
of psychological problems present in the past four weeks. Each of the 90 items is rated
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on a five-point Likert scale of distress ranging from not at all (0) to extremely (4). The
items of the SCL-90-R are assigned to 9 different symptom dimensions: Somatization,
Obsessive-Compulsive, Interpersonal Sensitivity, Depression, Anxiety, Anger-Hostility,
Phobic Anxiety, Paranoid Ideation, and Psychoticism. However, because these nine
dimensions are not supported by most exploratory and confirmatory factor analyses
and because many studies have pointed to the presence of a strong general factor (N.
Schmitz et al., 2000), only the Global Severity Index (GSI), which is the total score of all
SCL-90-R items, was used as a predictor variable.
The SCL-90-R was administered as part of the screening procedures in 14 of the 23
pooled studies and completed by 179 subjects. The internal consistency of the GSI in the
pooled sample was excellent (Cronbach’s α = 0.94), and the general factor saturation
was satisfactory (McDonald’s ωh = 0.62).
5.2.3.7 Adjective Word Lists (“Eigenschaftswörterliste”; EWL-60-S and EWL-K)
Two different versions of the Adjective Word List were used to assess the current mental
state shortly before drug administration. The older version EWL-K (Janke & Debus, 1978)
was used in studies before the year 2000 (n = 7), whereas the newer version EWL-60-S
(Janke & Debus, 1986) was used in later studies (n = 5). Both questionnaires contain a
list of adjectives which must be rated on how well they describe the current mental state.
The EWL-K contains 123 adjectives and a dichotomous true or false response format,
whereas the EWL-60-S contains 60 adjectives and a four-point response format ranging
from not at all (0) to strongly (3). In both questionnaires, items are grouped into six main
scales: Performance-Related Activity, General Inactivation, Extroversion-Introversion,
General Well-Being, Emotional Excitability, and Anxiety-Depressiveness. We combined
these scales across questionnaire versions by using only those items that are contained in
both questionnaire versions (see Supplementary Table S10 for a list of the overlapping
items in each scale). To adjust for the different item response format, each EWL scale was
z-transformed within each questionnaire version. By combining EWL-K and EWL-60-S,
measures of the mental state before drug intake were available from 185 of the 409 drug
sessions.
5.2.4 Response Variables
5.2.4.1 Altered States of Consciousness Rating Scales OAV and 5D-ASC)
In each experimental session, subjects were asked to rate drug induced alterations of
consciousness by either the OAV questionnaire (Bodmer et al., 1994) or its extended
version 5D-ASC (Dittrich et al., 2006). The OAV was used in studies conducted before
the year 2000 (n = 10), whereas the 5D-ASC was used in all later studies (n = 13). In
all studies, questionnaires were administered during the acute or post-acute effects of
the drug and subjects were asked to rate their experiences from the moment of drug
intake to the time of assessment. If the questionnaires were completed more than once
during an experimental session, only data from the measuring time points yielding the
highest mean total score were used. The frequencies of different assessment times in
the pooled sample are shown in Table 13. Because the time of assessment could have
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affected subjective drug effects ratings, time (defined as the logarithm of minutes after
drug intake) was included as covariate in all statistical analyses.
There are 66 visual analogue items that occur in both the OAV and 5D-ASC and that can
be used to assess three primary and one global dimension of ASCs. The three primary
dimensions are called Oceanic Boundlessness (OBN), Dread of Ego Dissolution (DED),
Visionary Restructuralization (VRS), and the global dimension is called Global Altered
States of Consciouness (G-ASC). The OBN dimension describes highly enjoyable and
positively valued experiences of ASCs, such as deeply felt positive mood, experiences
of unity, transcendence of time and space, spiritual experiences, and sense of intuitive
understanding. Because many of the OBN items have been directly formulated on the
basis of six of the nine categories of mystical experiences proposed by Stace (1961), high
scores on the OBN scale indicate a state similar to mystical experiences as described in
the scientific literature on the psychology of religion. The DED dimension measures
experiences of cognitive impairment, loss of self-control, feelings of disintegration or
separation from oneself and the world, and anxiety or panic. High scores on the DED
scale therefore indicate a very unpleasant state similar to so called “bad trips” described
by drug users. The VRS dimension assesses elementary and complex visual pseudo-
hallucinations, audio-visual synesthesiae, increased production of vivid imagery from
memory or fantasy, as well as changes in the meaning of percepts. Finally, the secondary
scale G-ASC is the total score of all 66 OAV items and thus can be considered as a general
measure of consciousness alteration.
The OBN, DED, VRS, and G-ASC dimensions have been hypothesized to be fundamental
dimensions of ASCs that are factorially invariant across ASC induction methods (Dittrich,
1998). However, a recent psychometric investigation of the OAV (Studerus, Gamma, &
Vollenweider, 2010) has only partially confirmed this hypothesis. Specifically, it has
been found that the VRS factor contains several items that load more strongly on the
OBN factor and that the VRS factor could be merged with the OBN factor on a high level
of construct hierarchy. Furthermore, all original OAV factors were demonstrated to be
multidimensional. Studerus, Gamma, and Vollenweider (2010) therefore constructed
and validated eleven new lower order factors that are more homogeneous than the
original factors and that can be used to describe more specific aspects of ASCs (see
Studerus, Gamma, & Vollenweider, 2010, for descriptions of these scales). Nevertheless,
because the original factors have shown relatively strong general factor saturations, they
still can be advantageous for capturing complex criteria. To this end and in order to
compare our results with earlier studies, we decided to use both the original and the
recently constructed subscales as dependent variables.
5.2.5 Statistical Analysis
To ensure the validity of the assumptions of linear mixed effects models (i.e., Gaus-
sian distribution of random effects and within-subjects errors, homoscedasticity, and
linearity), an extended method of Box-Cox transformation (Gurka, Edwards, Muller,
& Kupper, 2006) was applied to all response variables. The negative inverse of the
square root was found to be appropriate for the Anxiety factor, and a natural logarithm
transformation worked best for the DED, Spiritual Experience, Insightfulness, Disem-
bodiment, and Audio-Visual-Synesthesiae factors. All other response variables were
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transformed by taking the square root. Predictor variables were not transformed be-
cause partial residual plots indicated that linearity assumptions were already reasonably
well satisfied after transforming the response variables.
As depicted in Supplementary Figure S3, several predictor variables contained con-
siderable proportions of missing values. Because the missing data mostly resulted from
different study designs among the pooled studies, the missing data mechanism can be
assumed to be “missing at random” MAR or “missing completely at random” (MCAR;
Enders, 2010). To minimize potential bias and loss of information arising form missing
data, we used a statistical technique called multiple imputation (MI; Rubin, 1987). MI
is regarded as the method of choice for handling complex incomplete data problems
because it yields unbiased parameter estimates and standard errors under an MAR or
MCAR missing data mechanism and maximizes statistical power by using all available
information (Enders, 2010). We imputed missing values by the Multivariate Imputation
by Chained Equations (MICE) software (van Buuren & Groothuis-Oudshoorn, 2011),
which is freely available as an add-on package to R (R Development Core Team, 2011).
The MICE-package uses fully conditional specification as imputation method, which
means that imputation models can be flexibly specified on a variable-by-variable basis.
We used predictive-mean-matching, proportional odds models, and logistic regressions
to impute continuous, ordered categorical, and binary variables, respectively. The scales
of the the FPI and PASI questionnaires were included in the MI procedure as auxiliary
variables to improve the imputation of the ZKPQ and TAS scales, respectively. For each
variable, the set of predictors was restricted to those that correlated with at least 0.15
with the variable to be imputed. This resulted in a series of imputation models that
contained the best 9-29 predictors of each target variable. Due to the relatively large
fraction of missing information in some variables, we generated 20 multiply imputed
data sets, which is a larger number than what the literature historically recommends
(Enders, 2010). Recent simulation studies (e.g., Graham, Olchowski, & Gilreath, 2007)
show that this has a very beneficial impact on statistical power, especially when the
fraction of missing information is as high as in the present study. Convergence of
the Gibbs sampling algorithm and the quality of imputed values were assessed in
accordance with recommendations of van Buuren and Groothuis-Oudshoorn (2011).
To ensure that no severe multicollinearity existed between predictor variables, variance
inflation factors (VIFs) were computed for each predictor variable within in each of the
imputed data sets. Because no VIF was larger than 3, we did not exclude any predictor
variable due to multicollinearity.
Because some subjects participated in more than one psilocybin study and because
some studies involved multiple psilocybin sessions, our pooled data set contains non-
independent observations. To account for this non-independency, we used linear mixed
models in which the intercepts were allowed to vary per subject. We also considered
more complex mixed effects models with varying slopes for the drug dose effects and
varying intercepts by study. However, model comparisons by Akaike’s information
criterion (AIC) in the full models suggested that the varying intercept per subject model
was sufficient to account for the clustering in our data.
In order to directly compare regression coefficients of binary and continuous pre-
dictors, continuous predictor variables were rescaled within each imputed data set by
dividing them by two times their standard deviations. Because binary variables – except
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when highly skewed – have a standard deviation of roughly 0.5, our rescaling procedure
resulted in regression coefficients that reflected the change of the dependent variable
for a two standard deviation change in both binary and continuous predictors (see also
Gelman, 2008). Outcome variables were z-transformed within each imputed data set
such that regression coefficients were also comparable across models with different
outcomes.
Regression models that contain too many unimportant predictor variables can result
in loss of precision in the estimation of regression coefficients and the predictions of
new responses (Royston & Sauerbrei, 2008). On the other hand, selecting variables by
data-dependent methods (e.g., stepwise approaches) may result in overly optimistic
estimates of predictive ability and model fit and unstable sets of predictor variables,
especially in small data sets (Steyerberg, 2009). To reduce these risks, we built our
models by combining backward elimination with a two step bootstrap approach. A
major advantage of this approach is that it also solves the problem of variable selection
under multiple imputation (e.g., Heymans, van Buuren, Knol, van Mechelen, & de Vet,
2007).
In the first step, 200 bootstrap samples were taken from each of the 20 imputed
data sets. The bootstrap samples were obtained by drawing from individual cases (i.e.,
psilocybin sessions) with replacement and were of equal sample size as the original
sample. Within each bootstrap sample, parsimonious models were searched for by
applying backward elimination. That is, starting from the full models, predictors were
dropped in a stepwise fashion until no predictor was left with a Wald test p-value larger
than 0.157. This significance level corresponds to selecting predictors with 1 df based on
the AIC (Steyerberg, 2009). The random intercept for the subjects was always included
in the models and only fixed effects were considered for elimination. Predictors were
ranked according to their inclusion frequencies in the final models. Those predictors
that were selected in at least 50% of the 20 × 200 bootstrap samples were considered
important and further analyzed in a second modeling step. Thus, the first step primarily
served to reduce model space with a minimal risk of eliminating important predictors
(see also Sauerbrei, Holländer, & Buchholz, 2008).
The second modeling step was very similar to the first step. Again, 200 bootstrap
samples were taken within each imputed data set and backward elimination was applied
with a stopping rule of p = 0.157. However, this time we began from full models that
included only those predictors that were selected in the first step. The model that was
selected most often across all bootstrap samples was considered the most stable model
and further explored for relevant interactions. The two step bootstrap procedure was
repeated for each of the 15 response variables.
In each of the resulting 15 final models, the multivariate associations between the
repeatedly measured outcomes and the fixed effects in the models were estimated by
the R2 statistic proposed by Edwards, Muller, Wolfinger, Qaqish, and Schabenberger
(2008). To obtain reliable standard errors, confidence intervals, and associated p-values
of the fixed effects parameters, Markov Chain Monte Carlo (MCMC) sampling was used.
MCMC sampling is a modern alternative to the conventional significance test of fixed
effects in mixed effects models based on t or F statistics, which is unreliable due to the
lack of a clear definition of the degrees of freedom (Baayen, Davidson, & Bates, 2008).
For each final model and each imputed data set, random draws from the posterior
5.3 results 103
distributions of the parameters were taken and then mixed across data sets. The mixed
draws approximate the posterior distribution of the pooled parameters and thus can
be used for inference after multiple imputation (Gelman, 2004). A simulation study by
Zhou and Reiter (2010) has shown that this approach leads to better results than the
conventional application of Rubins’s rules (Rubin, 1987), especially when the number
of imputed data sets is large.
5.3 results
The selection frequencies of the predictor variables and models as a result of the
bootstrap selection procedures are provided in Supplementary Table S11. Drug dose
was the only predictor variable that reached a selection frequency of 100% and it did so
with all 15 response variables. The number of predictor variables that were selected
in more than 50% of the bootstrap samples ranged from 5 for the dependent variable
DED to 20 for the dependent variable Audio-Visual Synesthesiae. BMI and daily smoker
were the only variables that never reached a selection frequency of 50%. In general, the
number of predictor variables reaching the cutoff of 50% was considerably lower for the
original OAV scales than for OAV subscales (6-7 vs. 16-24). The lower number of selected
variables in the first step also led to more stable models in the second step. Whereas the
most frequently selected model of the dependent variable OBN was selected in 32.1% of
the cases, the most frequently selected model of the dependent variable Anxiety was
selected only in 0.3% of the cases.
Because drug dose was clearly the most important predictor, first order interactions
between drug dose and all other predictors were explored within the most frequently
selected models. Only 12 of the 15 × 23 tested interactions were significant at p <
0.05 and only one interaction, namely, PET × Drug Dose predicting Anxiety, reached
significance at p < 0.01. The interaction indicated that Anxiety increased with increasing
drug dose in the non-PET condition, but decreased with increasing drug dose in the PET
condition. However, it should be noted that the variability of the drug dose variable
within the PET condition was very small. Specifically, only 215 and 250 μg/kg doses of
psilocybin were administered in experiments involving PET measurements. Thus, the
significance of this interaction was considered rather questionable and not included in
the final models.
The variances explained in the full and simplified final models of all 15 outcome
variables are presented in Table 14. As can be seen from the table, the variable selection
procedure only slightly reduced explained variances, suggesting that the most important
predictors were retained in the models, and the excluded variables were mostly noise
variables. The variance explained in the simplified models was highest for the OAV total
scale (R2= 0.31) and lowest for Disembodiment (R2= 0.163). In general, the main scales
tended to have higher explained variances than the subscales even though they were
explained by a lower number of predictors.
The size and statistical significance of the regression coefficients of the most stable
models, as estimated by the MCMC sampling method, are shown in Figure 7. Standard
errors and highest posterior density 95% credibility intervals are additionally provided
in Supplementary Table S11. Overall, drug dose had the strongest effect on psilocybin
response. It was significantly associated with all outcome variables and had the highest
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Table 14: Variance Explained in the Full and Simplified Models
Outcome
Edward’s R2
Full Simplified
models models
Main scales
Altered State of Consciousness 0.337 0.310
Oceanic Boundlessness 0.293 0.266
Dread of Ego Dissolution 0.232 0.182
Visionary Restructuralization 0.333 0.293
Subscales
Experience of Unity 0.221 0.196
Spiritual Experience 0.249 0.220
Blissful State 0.195 0.179
Insightfulness 0.225 0.184
Disembodiment 0.175 0.163
Impaired Control and Cognition 0.202 0.192
Anxiety 0.201 0.187
Complex Imagery 0.237 0.229
Elementary Imagery 0.205 0.194
Audio-Visual Synesthesiae 0.226 0.217
Changed Meaning of Percepts 0.234 0.221
effect size in all models, except in the models predicting Spiritual Experience, Anxiety,
and Changed Meaning of Percepts. The time of assessment was positively associated
with Spiritual Experience and Elementary Imagery and negatively associated with
DED and Impaired Control and Cognition, indicating that disturbances in control
and cognition were less often reported when asked about later in the session. In
experimental sessions involving PET measurements, participants reported much higher
levels of Anxiety. In fact, of all 24 analyzed predictor variables, PET was the strongest
predictor of Anxiety, and its effect size was more than twice as high as the one of drug
dose. Compared to younger subjects, older subjects reported less Impaired Control
and Cognition and also showed a trend for more Blissful State (p = 0.059). Years of
education, gender, and BMI were not significantly associated with any response variable.
Drug use and pre-experiences with hallucinogenic drugs only moderately affected
psilocybin responses. Although hallucinogen-naïve subjects tended to report stronger
effects in most outcome variables, statistical significance was only reached for Dis-
embodiment, VRS, and Changed Meaning of Percepts. Psilocybin responses did not
differ between subjects who never consumed THC and those who rarely consumed
THC. However, subjects who sometimes smoked cannabis (more than once per month)
reported significantly more Blissful State than subjects who rarely consumed cannabis
(less than once per month) and also showed a trend for less Anxiety (p = 0.07). There
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Figure 7: Regression coefficients of the final models pooled across 20 imputed data sets. The
effects are adjusted for the influences of all other variables in the models. One, two,
and three asterisks represent p-values < 0.05, 0.01, and 0.001, respectively.
were also statistically significant positive associations between alcohol consumption and
experience of Audio-Visual Synesthesiae and Complex Imagery.
The mental state immediately before drug intake had a relatively strong influence
on several outcome variables. Specifically, Performance-Related Activity, which was
measured by the adjectives go-getting, avid, active, and energetic, had a major influence
on the overall consciousness alteration (G-ASC) and on several experiences covered by
the OBN and VRS dimensions. Emotional Excitability was strongly positively associated
with Spiritual Experience and Anxiety and moderately with all OAV main scales, as
well as Insightfulness and Audio-Visual Synesthesiae. High Anxiety-Depressiveness
before drug intake did not lead to significantly more unpleasant experiences during the
sessions.
The GSI scale of the SCL-90-R was negatively associated with OBN, Blissful state,
and Complex Imagery, indicating that subjects who experienced more psychological
problems previous to the experiments reported less pronounced effects with these scales.
Except for Absorption, which strongly predicted several experiences measured by the
OBN and VRS dimensions, most personality traits did not have a major influence on
psilocybin responses. Of the personality traits constituting Zuckerman’s alternative five-
factor model, only Sociability was significantly associated with any outcome variable.
Specifically, subjects who were more sociable (i.e., outgoing and extroverted) reported
less Spiritual Experience and more Audio-Visual Synesthesiae.
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The fractions of missing information (FMI) and the relative increases in variance due to
missingness (RIV), which quantify the missing data’s influence on the sampling variance
of the parameter estimates, are shown in Supplementary Table S11. For all imputed
variables, FMI values were lower than their missing data rates, which indicates that
the variables in the imputation model were predictive of the missing values. Because
some of the information loss was mitigated by borrowing information from correlated
variables, increases in sampling errors of the regression coefficients were not completely
commensurate with overall reductions in sample sizes. Not surprisingly, the RIV was
largest for Absorption (0.94 on average), which was also the variable with the highest
missing data rate. This indicates that the confidence interval of the regression coefficient
for Absorption was on average about 0.94 times larger than it would have been if this
scale had no missing values.
5.4 discussion
The present study sought to predict acute responses to psilocybin when administered
in a controlled scientific setting to healthy volunteers. The relative importance of 24
predictor variables from a wide range of domains were investigated.
Drug dose was clearly the most important predictor of psilocybin response. It was the
only predictor that was always retained in automatic variable selection and its effect size
was largest in 12 of the 15 final prediction models. Furthermore, its effect on general
consciousness alteration, as measured by the OAV total scale, was more than twice as
high as that of other predictors. The personality trait of Absorption was found to be
the second most important predictor of psilocybin response. It was highly positively
associated with the overall consciousness alteration and strongly predicted mystical-
type experiences and visual effects induced by psilocybin. Further variables that were
found to be important for predicting psilocybin response were Performance-Related
Activity, Emotional Excitability, psychological distress as measured by the GSI, pre-
experience with classical hallucinogens, frequencies of THC and alcohol consumption,
Sociability, time of assessment, and setting (PET vs. no PET measurement). Being
in an emotionally excitable and active state immediately before drug intake, having
experienced few psychological problems in the past weeks, no previous experience
with classical hallucinogens, and moderate THC and alcohol consumption increased the
intensity of pleasurable effects and/or visual alterations, whereas settings involving
PET measurements, Emotional Excitability, and low age contributed to the experience of
unpleasant and/or anxious reactions.
The finding that Absorption was amongst the most important predictors of psilocybin-
induced ASCs is consistent with a large number of studies showing that Absorption is
associated with differential responsivity to various ASC induction procedures, including
hypnosis, meditation, marijuana intoxication, and electromyograph biofeedback (Pekala,
Wenger, & Levine, 1985; Vaitl et al., 2005). Absorption has also been reported to
be positively associated with the occurrence of synesthesiae after the ingestion of
ayahuasca (Bresnick & Levin, 2006), a hallucinogen with similar modes of action as
psilocybin. This is in agreement with our results, which showed that, of all 15 response
variables, Absorption most strongly predicted Audio-Visual Synesthesiae. A recent
study by Ott et al. (2005) suggests that inter-individual differences in Absorption and
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responsiveness to hallucinogenic drugs could be both related to the binding potential
of the 5-HT2A receptor, which is the main site of action of serotonergic hallucinogens,
such as psilocybin (Vollenweider & Kometer, 2010). Although Ott et al. (2005) have
demonstrated a significant association between T102C polymorphism affecting the
binding potential of the 5-HT2A receptor and the TAS scale, they did not assess the
association between TAS and responsivity to serotonergic hallucinogens. The present
study is filling this gap, as it is, to our knowledge, the first study predicting the effects
of a classical hallucinogen by Absorption in a larger sample.
Apart from a strong influence of Absorption and a relatively minor influence of the
ZKPQ factor Sociability, which is highly convergent with the Big-Five factor Extroversion
(P. Schmitz, 2004), personality traits only marginally contributed to the prediction
of psilocybin responses. This is rather surprising because personality traits have
been postulated by many authors to be among the most important determinants of
hallucinogen response (e.g., Fischer, Marks, et al., 1968; Barr & Langs, 1972). It is also
worth noting that we did not detect any statistically significant relationship between
Neuroticism-Anxiety and negative reactions to psilocybin. This finding contradicts
several earlier, smaller scaled studies (Hemsley & Ward, 1985; Dittrich, 1994; Lienert &
Netter, 1996), which have found moderate to strong correlations between Neuroticism
and anxious reactions to classical hallucinogens and which have led to our policy of
excluding subjects with very high Neuroticism scores (i.e., more than two SD above
the mean) at screening. Although the exclusion of highly neurotic subjects could have
distorted our sample and thus reduced the predictive ability of Neuroticism, it should be
noted that the chosen cutoff affects only the highest 2.3% of the normal distribution and
that there was still substantial variability of Neuroticism in our sample. Nevertheless,
as has been shown in Table 12, both mean and variance of Neuroticism in our sample
where somewhat reduced compared to normative data. Hence, we cannot rule out
the possibility that Neuroticism increases the risk of adverse reactions in the highest
tail of the distribution. A positive relationship between Neuroticism and the effects
of classical hallucinogens would also be biologically plausible because a recent PET
study has demonstrated a positive correlation between Neuroticism and frontolimbic
5-HT2A receptor binding (Frokjaer et al., 2008). Thus, excluding highly neurotic subjects
at screening might still be a sensible approach for increasing the safety of controlled
experiments involving hallucinogen administration.
In contrast to personality factors, current mood state and psychological distress in
the past four weeks before drug intake were generally more important for predicting
psilocybin response in this study. This is in agreement with the existing literature.
For instance, Metzner et al. (1965) have found that the best predictor for mood during
the psilocybin session was mood before the session, and Dittrich (1994) reported
that Emotional Lability, a factor that was predominantly measured by state variables,
most strongly increased the likelihood of experiencing DED after DMT administration.
Interestingly, we have found that Emotional Excitability shortly before drug intake
predicted anxious reactions to psilocybin much better than Anxiety-Depressiveness.
However, this could also be due to statistical reasons. Whereas Emotional Excitability
was measured by 11 items, Anxiety-Depressiveness was measured by only 4 items that
additionally also had relatively high item difficulties. Consequently, the variability –
and possibly also the reliability – of Anxiety-Depressiveness was substantially lower
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than that of Emotional excitability. It should also be noted that these two factors were
relatively highly correlated in our sample (r = 0.5), which frequently might have led
to the inclusion of only one of these two variables in automatic model selection. The
finding that Performance-Related Activity was amongst the most important predictors
of experiences described by the OBN and VRS dimensions has, to our knowledge, not
been described in the literature before. One possible explanation is that the items
assessing Performance-Related Activity (i.e., go-getting, avid, active, and energetic)
not only captured variance associated with fitness and energy, but also variance with
positive mood and general optimism. Correlations with EWL subscales (not reported)
are in support of this hypothesis because they reveal that Performance-related activity
is most strongly associated with the EWL subscale Heightened mood (r = 0.47).
The finding that the PET environment was strongly associated with anxious reactions
could be partially explained by the perceived atmosphere at the PET center. Whereas
non-PET experiments were mostly conducted in laboratory rooms that were furnished
in an aesthetically pleasing way, the environment at the PET center was much more
clinical and “antiseptic” (i.e., lots of technical equipment, white walls, personnel in
white lab coats). Our results are therefore in support of current safety guidelines
(Johnson, Richards, & Griffiths, 2008), which recommend avoiding “cold” and overly
clinical environments in human hallucinogen research in order to reduce the risk of
anxious reactions. Although we have found increased Anxiety in PET experiments, that
does not mean that psilocybin experiments involving PET measurements are unsafe.
The percentage of strong anxious reactions in the PET experiments was still relatively
low, and all of them could be successfully managed by providing interpersonal support.
Furthermore, there are other factors that might have contributed to the increased
Anxiety in the PET environment. For instance, in contrast to non-PET experiments,
subjects could have their eyes closed while lying in the scanner and they were less
distracted by performing tasks. Thus, they could concentrate more on the experience,
which in turn might have increased the confrontation with inner fears.
Our results indicate that, in contrast to MDMA (Liechti, Gamma, & Vollenweider,
2001), the effects of psilocybin were not moderated by gender. This is consistent not
only with earlier studies investigating the subjective effects of classical hallucinogens
in humans (Hyde, 1960; Leary et al., 1963), but also with neuroimaging studies, which
have found no gender differences in 5-HT2A receptor binding in cortical regions (Adams
et al., 2004; Frokjaer et al., 2008). The only demographic variable that was statistically
significantly associated with any psilocybin response in this study was age. Specifically,
older subjects reported less Impaired Control and Cognition and tended to experience
more Blissful state compared to younger subjects. These associations are similar to
those observed by Hyde (1960) and Metzner et al. (1965) and could be explained by
an increased experience with managing occurrent negative emotions in older people
(Blanchard-Fields, 2007). It is also consistent with the fact that 5-HT2A receptors densities
decrease with increasing age (e.g., Adams et al., 2004).
The finding that hallucinogen-naïve subjects reported slightly more VRS, Disembod-
iment, and Changed Meaning of Percepts is consistent with the study of Metzner
et al. (1965), which found that previous experience with classical hallucinogens was
negatively associated with the number of somatic symptoms and visual alterations
induced by psilocybin. However, our results disagree with those of Dittrich (1994),
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who found that familiarity with drug-induced ASCs was not predictive of any acute
effects of DMT, as measured by the OAV questionnaire. One possible explanation of this
discrepancy might be that the predictor variable “familiarity with drug-induced ASCs”
in the study of Dittrich not only included pre-experience with classical hallucinogens,
but also other psychotropic substances.
Although subjects were asked to rate their experiences in retrospect and mostly
during or after the peak effects of the drug, Impaired Control and Cognition induced by
psilocybin was rated as less intense and Spiritual Experience and Elementary Imagery
were rated as more intense when questionnaires were completed later in the sessions
compared to earlier in the sessions. These findings are in agreement with a study of
Linton, Langs, and Paul (1964), which found that subjects tended to forget ego-alien
and threatening aspects of an LSD experience more often than those dealing with affects
or changes in the perceived meaning of events. Although it is tempting to explain these
associations by the well-known phenomenon of “motivated forgetting” (Anderson &
Levy, 2009), they could also have resulted from differential time courses of psilocybin
effects (e.g., see Studerus, Kometer, et al., 2011).
5.4.1 Limitations
The present study has several limitations. First of all, the design of our study does
not allow causal interpretations of predictor effects. Although we analyzed data from
experimental studies, the only variable that was systematically manipulated was drug
dose and only within, not between, studies. Hence, with the exception of drug dose,
associations between predictors and outcomes are purely observational.
Although several statistically significant relationships between non-pharmacological
predictors and outcome variables were detected, there were still relatively large propor-
tions of unexplained variances in the outcome variables. For instance, more than 80%
of the variance of the outcome variable Anxiety was left unexplained, suggesting that
there is considerable unpredictability in anxious reactions to psilocybin – even under
highly standardized conditions.
Generalizations of our results are hindered by the composition of our sample and
the circumstances in which psilocybin was administered. For instance, our subjects
were relatively young, highly educated, and high-functioning. They had more pre-
experiences with classical hallucinogens and cannabis than their corresponding age
group in the general population and also showed low Neuroticism-Anxiety scores (i.e.,
almost one SD below the mean of a normative sample). The distortions in our sample
most likely resulted from our recruitment method, which is prone to self-selection bias
(see also Studerus, Kometer, et al., 2011). The specific composition of our sample and
the fact that psilocybin was administered in a carefully monitored research environment
might have reduced the occurrence of unpleasant reactions (i.e., so called bad or horror
trips). This in turn might have lowered our ability to detect risk factors for unpleasant
reactions.
The individual studies that were pooled for the present analysis were not specifically
designed to investigate predictors of psilocybin response. Consequently, the predictor
variables analyzed herein are not necessarily those that – according to the literature
– would be most promising to investigate. Although the studied predictors cover the
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most important domains, some of them are clearly underrepresented. For instance, the
influence of the setting was only covered by the PET vs. no PET variable. Furthermore,
expectancies of the subjects, which are well known to influence the effects of most
psychoactive drugs, including alcohol and nicotine (Vogel-Sprott & Fillmore, 1999),
could not be studied because no such variables were obtained.
Because the majority of the pooled studies used double-blind placebo-controlled
designs, one might argue that we could have controlled for expectancy effects by
including the response to placebo as a covariate into the analyses. Unfortunately, the
effects of psilocybin were so strong that most subjects could easily differentiate them
from placebo. Moreover, because the items of the OAV questionnaire are visual analogue,
anchored no, not more than usual on the left and yes, much more than usual on the right,
most subjects placed marks at the left end of the scale for all items once they were
convinced that they had received placebo. Consequently, mean and variances of the
OAV scales were essentially zero under placebo, which severely limited the usefulness
of these scales as covariates. While some investigators have used an active placebo to
increase the success of the double blind in experiments involving hallucinogens (e.g.,
Griffiths, Richards, McCann, & Jesse, 2006), an even better approach for separating
pharmacological effects from the cognitive expectations of receiving the drug and its
effect might be the so called balanced-placebo design (BPD; Marlatt & Rohsenow, 1980).
The BPD is a 2 × 2 factorial design that crosses the administered substance (drug
vs. placebo) with an instructional set manipulation (subjects are told they receive the
active drug vs. subjects are told they receive placebo). To our knowledge, the BPD
has not yet been used in experiments with classical hallucinogens, but a recent study
has demonstrated its feasibility with marijuana (Metrik et al., 2009). It is therefore
conceivable that the BPD could also foster our understanding of expectancy effects in
responses to classical hallucinogens.
Another limitation of the present investigation is that responses to psilocybin, as
measured by the OAV, could be confounded by individual differences in the interpre-
tation of the item anchors at the right end of the visual analogue scale. Specifically,
the anchor yes, much more than usual could have had different meanings depending
on whether the subject has experienced profound ASCs before. Future studies should
therefore validate our results by also using behavioral measures and/or external raters
for assessing psilocybin response.
In the present study, we have only predicted single aspects of ASCs. Another ap-
proach, taken by Barr and Langs (1972), is to predict patterns of psilocybin responses.
This could be accomplished by cluster analyzing individual responses using Pearson
correlations as a proximity measure. The response clusters could than be predicted
by multinomial regression models. Because psilocybin, especially with higher doses,
sometimes can elicit responses that are not only quantitatively but also qualitatively
different (Nichols, 2004), it is possible that a categorical approach would be better
suited to detect determinants of profound ASCs, such as mystical-type experiences or
so called “horror trips”. The main reason why we did not follow such an approach
in this investigation is that these experiences only occurred in a small proportion of
our subjects (cf. Studerus, Kometer, et al., 2011). Hence, even with our large sample,
the event-per-variable ratio and statistical power were considered too low for such an
analysis.
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A few further statistical issues are worth noting. Although we used a two-step
bootstrap procedure to protect against the dangers of data-driven model selection,
the stability of some prediction models were relatively low. For instance, the most
frequently selected model of the outcome variable Anxiety was selected in only 0.3%
of the cases, and there were many other models that were only slightly less frequently
selected. Thus, there was considerable uncertainty in some of the final models, which
could have introduced bias in the estimation of regression coefficients and confidence
intervals (Steyerberg, 2009). The natural remedy for this problem would have been to
base inference on a set of competing models using model averaging and the selection
frequencies as model weights (Sauerbrei et al., 2008). However, because our analysis was
already complicated by the fact that we had used mixed effects models in combination
with multiple imputation, we did not want to introduce additional complexity into the
analysis and therefore abstained from performing frequentist model averaging.
The relatively large proportion of imputed values in some predictor variables (up to
70%) might cause distrust in our results. However, it should be noted that the applied
MI procedure completely protects against false inference, as long as the missing data
mechanism is correctly modeled and the MAR or MCAR assumptions are met (Enders,
2010). Even a predictor with 90% missing values could still be estimated with MI,
albeit with relatively large uncertainty (Steyerberg, 2009). There are several reasons
why we believe that the high missing data rate is not a major problem in the present
investigation. First, the MAR assumption is highly plausible because missing data almost
exclusively resulted from different study designs among the pooled studies. Second,
the number of imputed data sets was relatively high, which is recommended with large
proportions of missingness (Enders, 2010). Third, even for the predictor with the highest
missing data rate (i.e., Absorption), the loss of statistical power induced by missingness
was moderate and did not inhibit the detection of statistically significant associations.
5.4.2 Conclusions
Although drug dose was clearly the most important determinant of psilocybin response,
the results of this study confirm that a substantial proportion of the intra- and in-
terindividual differences in acute responses to psilocybin is related to differences in set
and setting. The results suggest that important predictors of psilocybin response can
be found in a wide range of different domains, including personality, current mood,
psychopathology, drug pre-experience, demography, and environment.
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G E N E R A L D I S C U S S I O N
6.1 tolerability
The first empirical study of this thesis investigated acute, subacute, and long-term
subjective effects of psilocybin in a sample of 110 subjects who had received 1-4 oral
doses of psilocybin (45-315 μg/kg body weight) in the context of double-blind, placebo-
controlled experimental studies. The primary aim of this study was to report about
the subjective tolerability of psilocybin when administered to healthy volunteers in a
supervised research environment.
Consistent with recent smaller scale studies (Hasler, Grimberg, et al., 2004; Carhart-
Harris, Williams, et al., 2011), psilocybin dose-dependently induced marked alter-
ations in all mental functions, including perception, mood, volition, cognition, and
self-experience. Furthermore, dose-response relationships were linear within the ad-
ministered dose range for all major dimensions of the 5D-ASC questionnaire. Of all
main scales of the 5D-ASC, psilocybin most strongly increased the Visionary Restruc-
turalization (VRS) scale followed by the Oceanic Boundlessness (OBN) scale. The Dread
of Ego Dissolution (DED) scale, which covers experiences that are characteristic for so
called “bad trips”, was the least affected 5D-ASC main scale. Furthermore, changes in
the DED scale were primarily due to unpleasant disturbances of cognitive functions
and somatesthesia, and much less so to suspiciousness or paranoid ideation. Very
high DED scores (> 70% of the possible maximum) were only measured in the 250-260
μg/kg and 315 μg/kg dose conditions in small percentages of subjects (i.e. 5.7% and
7.3%, respectively). However, all of these acute adverse reactions were successfully
managed by providing interpersonal support and reassurance (e.g. by touching the arm
or shoulder with verbal reminders that the participant is in a research study, has taken
the hallucinogen, and that he or she will return to normal consciousness). Furthermore,
it was never necessary to administer a tranquilizer. In accordance with a study of
Heimann (1961), psilocybin effects as measured by the EWL-60-S subscales differed in
their time-courses. Whereas the effects on emotional excitation, sensitivity, heightened
mood, and concentration reached their maximum in an early phase (60-180 min after
drug intake), the effects on dreaminess, dazed state, inactivation, and introversion were
more pronounced in a later phase (260-400 min).
Measures of mood and somatic and psychological ailments indicated that subacute
side effects of psilocybin were generally mild and that usual functioning was almost
completely restored 24 h after drug administration. The most frequent subacute side
effects of psilocybin were symptoms of fatigue and headache, which occurred in 60%
and 37.5% of subjects, respectively, in the highest dose condition. These findings are
in agreement with an earlier study of Hollister (1961), which also found occasional
headaches and fatigue as being the most frequent after effects of psilocybin, and provide
further evidence that psilocybin is physiologically well tolerated (see also Passie, Seifert,
et al., 2002).
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A follow-up questionnaire that contained items about (1) acute drug experiences in
retrospect, (2) changes in values and attitudes, (3) changes in drug consumption habits,
(4) spontaneously occurring ASCs before and after the experiments and flashbacks,
and (5) negative changes in psychological well-being and/or mental functions was
completed by 90 of the 110 subjects 8-16 months after the last experimental session.
Relatively large numbers of subjects rated the acute drug experience retrospectively as
very enriching and influential and only few subjects as very frightening and unpleasant.
These results are consistent with recent studies of Griffiths and his colleagues (Griffiths,
Richards, Johnson, et al., 2008; Griffiths, Johnson, et al., 2011), which demonstrated that
psilocybin can facilitate experiences having enduring personal meaning and spiritual
significance. Interestingly, almost all subjects who experienced strong DED during
the session evaluated the experience as enriching in retrospect, which suggests that
unpleasant and anxious reactions to psilocybin were mostly positively integrated in the
long run. Similar results have been recently reported by Griffiths, Johnson, et al. (2011).
They found that psychological struggle during the session did neither affect the rate of
mystical experiences nor subsequent ratings of the session as having personal meaning
and spiritual significance.
Significant numbers of subjects reported psilocybin-induced positive changes in
attitudes at the long-term follow-up. The most frequently reported positive changes
concerned attitudes toward ASCs (56% of subjects), environment/nature (38%), and
aesthetic experiencing (37%). However, even though similar changes have been found in
earlier follow up studies (McGlothlin, Cohen, & McGlothlin, 1967; Doblin, 1991; Griffiths,
Richards, Johnson, et al., 2008), these results must be interpreted cautiously because they
have neither been validated on behavioral measures nor on information provided by
close relatives and friends. Hence, they could be biased towards preconceived opinions
and expectations of subjects.
Only few subjects reported changes in drug consumption habits, and those who did
more often described decreased than increased substance consumption. Furthermore,
there was no indication that any subject developed an abusive pattern of drug use.
These results are in accordance with a large number of animal (e.g., Fantegrossi et al.,
2008) and human studies (e.g., McGlothlin & Arnold, 1971), which have consistently
shown that classical hallucinogens are not addictive.
Detailed questions about possible flashback phenomena and spontaneous ASC in
the follow-up questionnaire indicated that no subject had experienced Hallucinogen
Persisting Perception Disorder (HPPD) or flashbacks as defined in the DSM-IV and ICD-10,
respectively, subsequent to the experiments. This supports the view that HPPD and other
troubling perceptual abnormalities rarely occur in a therapeutic or research context,
where judicious doses of pharmaceutical quality drugs are given (Strassman, 1984;
Halpern & Pope, 2003). Apart from the research setting, the use of psilocybin might
also have contributed to absence of HPPD and flashbacks. Psilocybin has a relatively
short duration of action and therefore seems to produce flashbacks less frequently than
LSD (Hermle, Kovar, et al., 2008).
The follow-up questionnaire also provided no indication that any of the subjects
had experienced prolonged psychosis or depression. However, one of the 110 subjects
experienced symptoms of emotional instability, anxiety, and depression in the first
few weeks after drug administration, which were severe enough for him to seek
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professional help. Although the symptoms were relatively benign and completely
resolved after a few psychotherapeutic sessions, this case underlines the importance of
careful debriefing and follow-up of subjects – especially in the first few days and weeks
after drug administration.
Taken together, the study presented in Chapter 3 provided considerable evidence
that psilocybin is well tolerated both acutely and in the long run. It is likely that the
careful selection, preparation, and monitoring of subjects, as well as the administration
of predominantly moderate drug doses, have largely contributed to these results. Hence,
the results could be used to justify controlled experiments with these drugs, but should
not be generalized to unsupervised and recreational drug use.
6.2 assessment
The second empirical study presented in Chapter 4 evaluated the psychometric prop-
erties of the OAV, which is one of the most widely used self-report questionnaires for
assessing hallucinogen-induced ASCs. The development of the OAV was driven by the
hypothesis that ASCs – independent of their means of induction – have features in
common that can be parsimoniously described on three etiology independent dimen-
sions: Oceanic Boundlessness (OBN), Dread of Ego Dissolution (DED), and Visionary
Restructuralization (VRS; Dittrich, 1985; Bodmer, 1989). Hence, an important goal of this
study was to test whether the hypothesized three-dimensional structure was superior
to other solutions and whether this structure was invariant across stimulus conditions.
Unlike in previous studies, these hypotheses were tested by using methods of structural
equation modeling (SEM). SEM methodology is considered more appropriate for testing
specific hypotheses on latent structures than the previously used exploratory methods
(Brown, 2006). The study also used a larger sample than previous studies. Specifically,
it was based on a sample of 591 measures of ASC, 327, 162, and 102 of which were
experimentally induced by psilocybin, ketamine, and MDMA, respectively.
The originally proposed three-dimensional structure provided a poor fit to the
data when modeled with a simple structure CFA. However, because such models
are sometimes unnecessarily restrictive (Marsh, Lüdtke, et al., 2010), several attempts
were made to model it in a less restrictive way: (1) by freeing residual correlations
(i.e. introducing method effects), (2) by freeing cross-loadings (i.e. relaxing the simple
structure assumption), and (3) by introducing an additional general factor (i.e. modeling
it as a bifactor model). Although freeing these restrictions considerably improved model
fit, the overall model fit was still unacceptable even in the least restrictive model. This
was mainly because all three factors were multidimensional and because the VRS factor
contained several items that loaded more strongly on the OBN than on the VRS factor.
Interestingly, the latter was also found in both of the two other studies that have
reexamined the factorial structure of the OAV (Habermeyer, 1999; Bodmer, 1999).
Since the original model could not be rescued by relaxing assumptions, the hierar-
chical structure of the OAV was explored by using Revelle’s ICLUST algorithm (Revelle,
1978). The analysis revealed that the OBN and VRS factors merged on a high level of the
construct hierarchy. However, on a lower level of the hierarchy, the original factors split
into 11 homogenous factors, which were named as follows: (1) Experience of Unity,
(2) Spiritual Experience, (3) Blissful State, (4) Insightfulness, (5) Disembodiment, (6)
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Impaired Control and Cognition, (7) Anxiety, (8) Complex Imagery, (9) Elementary
Imagery, (10) Audio-Visual Synesthesiae, and (11) Changed Meaning of Percepts. A
simple structure CFA with these 11 factors provided an acceptable fit to the data. Fur-
thermore, MIMIC modeling indicated that these 11 factors were measurement invariant
across the three drugs, physical environments of the drug sessions (PET vs. non-PET),
questionnaire versions (OAV vs. 5D-ASC), and sexes. Thus, the summated scales of these
factors can be used to make unbiased comparisons across these conditions.
Because the new scales were unidimensional whereas the old scales were not, the new
scales were more reliable when reliability is defined as the proportion of variance that is
due to one general factor. Nevertheless, the original OAV still showed relatively strong
general factor saturations. Over 60% of the variance in the total scale and over 70% of
the variances in the OBN, DED, and VRS scales were explained by general factors. Thus,
although these scales form ambiguous correlations with other psychological constructs,
they could still be useful for the prediction of complex criteria (cf. Revelle, 1979; Rossiter,
2002).
Correlations with the EWL-60-S and STAI-S scales indicated that the new OAV scales
tended to have better convergent and discriminant validities than the old scales. This is
most likely because the new scales are more homogenous than the old scales. The new
scales also differentiated better among the three drug groups. For example, specific
MDMA and ketamine effects, such as strong positive mood and disembodiment, could
be well differentiated by the new scales, but were mixed up with other effects in the old
scales.
Taken together, the study presented in Chapter 4 demonstrated that the factorial
structure of the OAV items is better represented by 11 lower order factors than by
the original factors. The new factors have the potential to considerably improve the
assessment of psilocybin-, ketamine-, and MDMA-induced ASCs, because they form
less ambiguous correlations with other measures, are easier to interpret, and provide
important additional information on more specific aspects of ASCs.
6.3 prediction
The aim of the third empirical study presented in Chapter 5 was to examine the relative
importance of 24 variables, including age, sex, years of education, body mass index,
personality traits, drug pre-experience, mental state before drug intake, psychological
distress, experimental setting, and drug dose, in the prediction of acute subjective effects
of psilocybin. The new OAV subscales that were constructed and validated in Chapter 4,
as well as the original OAV scales, served as dependent variables in this study. The
statistical analysis was based on the pooled data of 23 studies involving 409 psilocybin
administrations to 261 healthy volunteers.
Drug dose was clearly the most important predictor because it was always retained
in automatic variable selections and because it had by far the largest effect on the
overall consciousness alteration as measured by the OAV total scale (i.e., G-ASC). The
second most important predictor was the personality trait of absorption because it was
highly positively associated with G-ASC, mystical type experiences, and visual effects
induced by psilocybin. This finding is in agreement with large number of studies
showing that Absorption is associated with differential responsivity to various ASC
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induction procedures (Pekala, Wenger, & Levine, 1985; Vaitl et al., 2005). Furthermore,
it is consistent with a recent study of (Ott et al., 2005), which indicated that Absorption
is associated with the T102C polymorphism and, consequently, the binding potential of
the 5-HT2A receptor.
Other personality traits, including Neuroticism, had only a minor influence on the
effects of psilocybin. This is rather surprising because personality traits in general and
Neuroticism in particular have often been associated with hallucinogenic drug effects
(e.g., Kornetsky & Humphries, 1957; Rinkel et al., 1961; Fischer, Marks, et al., 1968; Barr
& Langs, 1972; Hemsley & Ward, 1985; Dittrich, 1994; Lienert & Netter, 1996; Bresnick &
Levin, 2006). Some authors have even claimed that personality traits are among the most
important determinants of drug response (e.g., Fischer, Marks, et al., 1968; Barr & Langs,
1972). One explanation for this discrepancy might be that in this study the regression
coefficients were adjusted for potential confounders, whereas in most other studies
they were not. Other explanations are differences in measurement instruments, sample
characteristics, and setting. For example, due to the nature of the recruitment, the
participants of this study had a mean Neuroticism score that was almost one standard
deviation below the population average. Furthermore, as demonstrated in the first
empirical study of this thesis, acute adverse reactions were relatively rare. Hence, the
association between Neuroticism and acute adverse reactions might have been blurred
in this sample.
The mood state immediately before drug intake and psychological distress in the
past four weeks in general predicted drug effects more strongly than personality traits,
which is in agreement with existing studies (Metzner et al., 1965; Dittrich & Lamparter,
1994). Specifically, Performance-related activity was relatively strongly positively associ-
ated with G-ASC and with various experiences covered by the OBN and VRS dimensions,
whereas Emotional excitability was strongly positively associated with Spiritual Ex-
perience and Anxiety and moderately with all OAV main scales, Insightfulness, and
Audio-Visual Synesthesiae. By contrast, psychological distress as measured by the total
scale of the SCL-90-R was negatively associated with OBN, Blissful State, and Complex
Imagery.
Experiments involving PET measurements were strongly positively associated with
Anxiety. In fact, the effect of PET on Anxiety was even larger than that of drug dose.
One possible explanation for this large effect could be that the atmosphere at the PET
center was perceived as cold and clinical, which is well known to increase the likelihood
of anxious reactions (see, Johnson, Richards, & Griffiths, 2008).
Age was negatively associated with Impaired Control and Cognition, whereas gender
did not significantly predict any outcome. This is consistent with both human hallu-
cinogen studies (Hyde, 1960; Metzner et al., 1965; Leary et al., 1963) and neuroimaging
studies, which have found decreasing 5-HT2A receptors densities with increasing age
(Adams et al., 2004) and no differences in 5-HT2A receptors between genders (Frokjaer
et al., 2008).
There were also moderate associations between drug pre-experience and drug re-
sponse. Specifically, hallucinogen-naïve subjects tended to report more Disembodiment,
VRS, and Changed Meaning of Percepts; subjects who smoked cannabis at least once
per month experienced more Blissful state than those who never smoked cannabis; and
regular alcohol consumption was positively associated with Audio-Visual Synesthesiae
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and Complex Imagery. These results partially confirm those of Metzner et al. (1965),
but are contradicting those of Dittrich and Lamparter (1994).
In conclusion, the results of this study confirmed that a large proportion of inter-
and intraindividual differences in acute responses to psilocybin is explained by non-
pharmacological variables. Moreover, important predictors can be found in a wide
range of domains, including personality, mood, drug pre-experience, psychopathology,
setting, and demography.
7
P E R S P E C T I V E S
The present thesis investigated the tolerability, assessment, and prediction of subjective
psilocybin effects using the pooled the data of controlled experimental studies. All
of the studies on which this thesis is based were carried out by Franz Vollenweider’s
research group at the University Hospital of Psychiatry in Zurich, which was one of
the first to get governmental approval for the use psilocybin in human research after
the nearly worldwide moratorium for many decades. Because Vollenweider’s group
has continuously collected data since the 1990s and because regulatory hurdles in most
countries are bigger than in Switzerland, the data set on which this thesis is based
is unique in the world with respect to its size, recency, and standardization. Hence,
the richness of the data is certainly the biggest strength of this thesis. Since the data
offered an unique opportunity to answer important research questions, I put a lot of
effort to conduct the statistical analyses in accordance with the highest methodological
standards. Consequently, I consider this as another major strength of this thesis.
However, there is still much room for improvement. A major problem that concerns
almost all human hallucinogen studies is that the effects of hallucinogens could be
biased towards expectancies of investigators and participants. The study of McGlothlin
and Arnold (1971) indicates that preconceived opinions and expectancies can have
a serious impact, especially on reported long-term beneficial effects of these drugs.
The standard method for dealing with expectancy effects is to administer the drug in
a double-blind placebo-controlled fashion, and this has also been done in almost all
studies of Vollenweider’s research group. However, means and standard deviations of
most 5D-ASC items obtained under placebo conditions were virtually zero, suggesting
the effects of psilocybin were so powerful that they could easily be distinguished from
placebo by most subjects. Thus, at least with regard to subjective effects, the use of a
placebo control seems to be of limited usefulness. The limited control of expectancy
effects might have biased the results of all three studies of this thesis to some degree,
but the problem was likely most severe in the long-term follow-up measure of the first
study presented in Chapter 3 because the follow-up questionnaire was unvalidated and
there was no placebo control (i.e. all subjects knew that they had received psilocybin at
least once).
To increase the success of the blinding, some investigators have used an active placebo,
such as nicotinic acid (e.g., Pahnke, 1963) or methylphenidate (e.g., Griffiths, Richards,
McCann, & Jesse, 2006). Griffiths, Richards, McCann, and Jesse (2006) additionally
tried to control expectancy effects by studying participants without personal histories
of hallucinogen use; randomly assigning participants into two groups with different
number, order, and blinding of drug administration; and by using instructional sets that
provided the expectation that sessions could involve not only the administration of a
wide range of psilocybin doses but also a range of novel drugs, some of which could
produce effects that overlap with those produced by psilocybin. They reported that in
23% of all drug sessions at least one of the two monitors did not correctly identify the
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administered drug. Furthermore, they observed that in two of the three occasions in
which the primary monitors misclassified a high dose psilocybin session as an active
placebo session, the participants nevertheless rated their experiences as among the
five most meaningful and spiritually significant experiences of their lives, suggesting
that these experiences were not merely artifacts of monitor expectation or suggestion.
Although Griffiths, Richards, McCann, and Jesse (2006) did not directly ask participants
to identify the drug they had received, it seems that subjects were at least partially
blind to the drug because some subjects rated their experience as being among the
most personally meaningful experiences of their lives even though they had received
methylphenidate. On the other hand, this finding could also be taken as an indication
for the powerful effects of suggestion that were at work in this study because it is
hard to believe that methylphenidate alone could induce experiences that are equally
significant as, for example, the birth of a child or a marriage.
Although the methods used by Griffiths, Richards, McCann, and Jesse (2006) seem
to be helpful, expectancy effects might be even more rigorously controlled in human
hallucinogen research by adopting the so called balanced-placebo design (BPD). The
BPD is considered the optimal method for separating pharmacological effects from the
cognitive expectations of receiving the drug (Marlatt & Rohsenow, 1980). It is a 2 ×
2 factorial design that crosses the administered substance (drug vs. placebo) with an
instructional set manipulation (subjects are told they receive the active drug vs. subjects
are told they receive placebo). If the instructional set manipulation is credible, this
allows a determination of expectancy effects independent of pharmacological effects
and vice versa and the “antiplacebo” effect of the pharmacological action of the drug
when expecting no drug (Vogel-Sprott & Fillmore, 1999; Metrik et al., 2009). To ensure
the credibility of the instructional set manipulation, various techniques have been
developed, such as pouring from an unopened liquor bottle and false breath alcohol
feedback in the case of alcohol or simulating the smell and appearance of a cigarette
in the case of nicotine (Metrik et al., 2009). Although the BPD has not yet been used in
experiments with classical hallucinogens, a recent study has demonstrated its feasibility
with marijuana (Metrik et al., 2009). It is therefore likely that it would also work in
experiments with classical hallucinogens. A direct comparison of various techniques
for controlling expectancy effects (e.g., the regular placebo controlled design vs. the
methods of Griffiths described above vs. the BPD) could be very useful not only for
evaluating their feasibility and efficiency, but also for evaluating how much self-reported
psilocybin effects are affected by expectations.
Besides controlling expectancy effects, it would also be helpful to compare self-
reported effects of psilocybin with behavioral measures and judgments of external raters.
Unfortunately, this could not be done in the present thesis because comparable objective
measures were mostly unavailable. By contrast, Griffiths and his colleagues (Griffiths,
Richards, McCann, & Jesse, 2006; Griffiths, Johnson, et al., 2011) have used community
observers to corroborate potential changes in attitudes and behavior. However, because
external raters can be biased by preconceived opinions and expectancies as well, it is
highly important to ensure that the external raters are objective. Unfortunately, the
objectivity of the community raters in Griffiths studies must be questioned because the
community observers were chosen by the participants themselves. Hence, it is likely
that they had very similar opinions about hallucinogens as the participants.
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Although the study presented in Chapter 4 has contributed to an improved assessment
of psilocybin-induced ASCs by constructing and validating 11 new subscales of the OAV
questionnaire, the OAV has still several problems that could not be solved in this thesis.
For example, the items of the OAV and its revised version 5D-ASC do not sufficiently
cover affective states induced by hallucinogens. Thus, in order to assess all important
aspects of classical hallucinogens, they still have to supplemented by other rating scales,
such as the EWL-60-S (Janke & Debus, 1986), the Positive and Negative Affect Schedule
(PANAS; Watson, Clark, & Tellegen, 1988), or the Profile of Mood Scale (POMS; McNair,
Lorr, & Droppleman, 1971).
Another problem of the OAV and 5D-ASC is that their item response format is strictly
unipolar. As a result, hallucinogen-induced changes assessed by these questionnaires
can only occur in one direction. For most of the changes, this is not a problem because
changes in the opposite direction can not occur. However, some changes, such as for
example changes in anxiety, could theoretically occur in both directions and thus are
censored when assessed by unipolar items. Since only changes in the positive direction
are assessed and changes in the negative direction are censored, it has occurred that
psilocybin on average slightly decreased anxiety when assessed by the STAI-S, but clearly
increased anxiety when assessed by the 5D-ASC (M. Kometer, personal communication,
August 19, 2011). The unipolar item response format of the OAV and 5D-ASC also leads
to strongly skewed item distributions with a large piling up of values at the lower end
of the scale. As described in more detail in Chapter 4, such distributions usually can
not be transformed to normality with non-linear transformations and can severely bias
model parameters and goodness of fit of structural equation models.
Because the above problems are difficult to solve by modifying existing questionnaires,
it would be worthwhile to construct a new questionnaire assessing hallucinogen-induced
ASCs. To improve on existing measures, the item selection should be guided by theory
as much as possible, the item response format should be bipolar and result in normally
distributed scores, and the item anchors should be clearly defined such that they are
not subject to individual interpretation.
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